

## 1 **Bacteria-to-human protein networks reveal origins of endogenous DNA** 2 **damage**

3 Jun Xia<sup>1-5,19</sup>, Li-Ya Chiu<sup>6,19</sup>, Ralf B. Nehring<sup>1-4</sup>, María Angélica Bravo Núñez<sup>†1-4</sup>, Qian Mei<sup>1-4,7</sup>,  
4 Mercedes Perez<sup>6</sup>, Yin Zhai<sup>2,4</sup>, Devon M. Fitzgerald<sup>1-4</sup>, John P. Pribis<sup>1-5</sup>, Yumeng Wang<sup>8-10</sup>,  
5 Chenyue W. Hu<sup>11</sup>, Reid T. Powell<sup>12</sup>, Sandra A. LaBonte<sup>13</sup>, Ali Jalali<sup>4,14</sup>, Meztli L. Matadamas  
6 Guzmán<sup>‡1-4</sup>, Alfred M. Lentzsch<sup>6</sup>, Adam T. Szafran<sup>15</sup>, Mohan C. Joshi<sup>1,3,4,8</sup>, Megan Richters<sup>1-4</sup>,  
7 Janet L. Gibson<sup>1-4</sup>, Ryan L. Frisch<sup>¶1-4</sup>, P.J. Hastings<sup>1,4</sup>, David Bates<sup>1,3,4</sup>, Christine Queitsch<sup>16</sup>,  
8 Susan G. Hilsenbeck<sup>4</sup>, Cristian Coarfa<sup>4,15</sup>, James C. Hu<sup>8</sup>, Deborah A. Siegele<sup>8</sup>, Kenneth L.  
9 Scott<sup>1,4,5</sup>, Han Liang<sup>8-10</sup>, Michael A. Mancini<sup>4,15</sup>, Christophe Herman<sup>1,3,5,17</sup>, Kyle M. Miller<sup>4,6,17</sup> &  
10 Susan M. Rosenberg<sup>1-5,7,18</sup>

11 <sup>1</sup>Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas  
12 77030, USA.

13 <sup>2</sup>Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston,  
14 Texas 77030, USA.

15 <sup>3</sup>Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston,  
16 Texas 77030, USA.

17 <sup>4</sup>Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas  
18 77030, USA.

19 <sup>5</sup>Graduate Program in Integrative Molecular and Biomedical Sciences, Baylor College of Medicine,  
20 Houston, Texas 77030, USA.

21 <sup>6</sup>Department of Molecular Biosciences, Institute for Cellular and Molecular Biology, University  
22 of Texas at Austin, Austin, Texas 78712 USA.

23 <sup>7</sup>Systems, Synthetic and Physical Biology Program, Rice University, Houston, Texas 77030, USA.

24 <sup>8</sup>Graduate Program in Structural and Computational Biology and Molecular Biophysics, Baylor  
25 College of Medicine, Houston, Texas 77030, USA.

26 <sup>9</sup>Department of Bioinformatics and Computational Biology, The University of Texas MD  
27 Anderson Cancer Center, Houston, Texas 77030, USA.

28 <sup>10</sup>Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston,  
29 Texas 77030, USA.

30 <sup>11</sup>Department of Bioengineering, Rice University, Houston, Texas 77030, USA.

31 <sup>12</sup>Institute of Biosciences and Technology, Texas A&M University, Houston, Texas 77030, USA.

32 <sup>13</sup>Department of Biochemistry and Biophysics, Texas A&M University and Texas AgriLife  
33 Research, College Station, TX 77843, USA.

34 <sup>14</sup>Department of Neurosurgery, Baylor College of Medicine, Houston, 77030, Texas USA.

35 <sup>15</sup>Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas  
36 77030, USA.

37 <sup>16</sup>Department of Genome Sciences, University of Washington, Seattle, Washington 98195.

38 <sup>17</sup>Senior author

39 <sup>18</sup>Lead author

40 <sup>19</sup>These authors contributed equally to this work.

41 †Present address: Graduate School of the Stowers Institute for Medical Research,1000 East 50th  
42 Street, Kansas City, MO 64110, USA.

43 ‡Present address: Doctorate in Biomedical Science, Universidad Nacional Autónoma de México,  
44 México.

45 § Present address: Multidisciplinary Centre for Advance Research and Studies (MCARS), Jamia  
46 Millia Islamia, New Delhi 110025, India.

47 ¶Present address: DuPont Industrial Biosciences, 200 Powder Mill Road. Wilmington, DE 19803.

48

49 \*Correspondence: [herman@bcm.edu](mailto:herman@bcm.edu) (CH), [kyle.miller@austin.utexas.edu](mailto:kyle.miller@austin.utexas.edu) (KMM),  
50 [smr@bcm.edu](mailto:smr@bcm.edu) (SMR)

51

52 **SUMMARY**

53

54 DNA damage provokes mutations and cancer, and results from external carcinogens or  
55 endogenous cellular processes. Yet, the intrinsic instigators of DNA damage are poorly  
56 understood. Here we identify proteins that promote endogenous DNA damage when  
57 overproduced: the DNA-damaging proteins (DDPs). We discover a large network of DDPs  
58 in *Escherichia coli* and deconvolute them into six DNA-damage-causing function clusters,  
59 demonstrating DDP mechanisms in three: reactive-oxygen increase by transmembrane  
60 transporters, chromosome loss by replisome binding, and replication stalling by transcription  
61 factors. Their 284 human homologs are over-represented among known cancer drivers, and their  
62 expression in tumors predicts heavy mutagenesis and poor prognosis. Half of tested human  
63 homologs, when overproduced in human cells, promote DNA damage and mutation, with DNA-  
64 damaging mechanisms like those in *E. coli*. Together, our work reveals DDP networks that  
65 provoke endogenous DNA damage and may indicate functions of many human known and newly  
66 implicated cancer-promoting proteins.

67

## 68 INTRODUCTION

69  
70 DNA damage often underlies “spontaneous” mutations (Hastings et al., 1976; Tubbs and  
71 Nussenzweig, 2017), which drive cancer, genetic diseases, pathogen drug resistance and evasion  
72 of immune responses, and evolution generally. DNA damage can be caused by exogenous agents  
73 such as radiation or tobacco smoke, and indeed the vast majority of known carcinogens are DNA-  
74 damaging agents, and because of that, mutagens (Chatterjee and Walker, 2017). However, most  
75 DNA damage is generated endogenously within cells (Jackson and Loeb, 2001; Tubbs and  
76 Nussenzweig, 2017), by intrinsic cellular processes that involve macromolecule components  
77 including proteins. Presumably, proteins that promote endogenous DNA damage are required by  
78 cells, but cause DNA damage as side effects of their necessary functions and/or when dysregulated.  
79 The identities and functions of the proteins that promote endogenous DNA damage in cells in any  
80 organism are poorly understood or unknown (Figure 1A). We sought to identify these proteins  
81 systematically, and to understand how they might promote endogenous DNA damage, here.

82 One way to identify the proteins that *promote* endogenous DNA damage is by  
83 overproduction, which is a natural event that occurs frequently by copy-number alteration and  
84 other routes, and is a major source of cancer-driving functions (Zack et al., 2013). Given the  
85 conservation of DNA biology across the tree of life (Aravind et al., 1999; Makarova and Koonin,  
86 2013), identification of proteins that promote spontaneous endogenous DNA damage carried out  
87 in any organism could potentially inform strategies for prevention, diagnosis, and treatment of  
88 disease, including therapeutic inhibition of cancer development, aging, and evolution of pathogens  
89 (Fitzgerald et al., 2017).

90 Some proteins that *prevent* or *reduce* endogenous DNA damage levels in cells have been  
91 identified by loss-of-function mutations/knock-downs that increase DNA damage (Alvaro et al.,  
92 2007; Lovejoy et al., 2009; Paulsen et al., 2009). DNA-repair proteins are among this category  
93 because they *reduce* levels of endogenous DNA damage. Similarly, proteins that *prevent/reduce*  
94 endogenous DNA damage, along with other kinds of proteins, will be among genes the loss-of-  
95 function of which promotes mutagenesis or genome instability (Putnam et al., 2016; Yuen et al.,  
96 2007). By contrast, no unbiased screen has been reported for proteins that actively *promote*  
97 endogenous DNA damage in cells. Though a limited nucleus-specific screen identified some  
98 (Lovejoy et al., 2009), the range of functions and numbers of proteins, processes, and mechanisms  
99 that cause endogenous DNA damage are unknown.

100 Here we report the comprehensive discovery in *Escherichia coli* of a large, diverse network  
101 of proteins that promote endogenous DNA damage when overproduced: the “DNA-damaging”  
102 proteins (DDPs). We show that their upregulation promotes mutagenesis, and use massive  
103 function-based assays to identify kinds, causes, and consequences of intrinsic DNA damage  
104 provoked by overproduction of the 208 *E. coli* DDPs. We found that they group into six discreet  
105 function clusters, and determine molecular mechanisms of DNA-damage generation from three of  
106 these. We identify their human homologs, also a large network, and find that they are  
107 overrepresented among known cancer instigators, and that their expression in human cancers  
108 predicts poor outcomes and high mutation loads. We show that overproduction of human  
109 homologs in human cells also promotes endogenous DNA damage and mutation. We determine  
110 the mechanisms of DNA-damage instigation for two cancer-associated human DDPs, both of  
111 which mimic bacterial mechanisms and suggest unexpected roles in cancer. The identities and  
112 functions of the proteins in bacterial and human DDP networks provide an important general  
113 model for illuminating mechanisms of genesis of endogenous DNA damage, and may inform

114 cancer-promoting function discovery of many known and newly discovered cancer-driving  
115 proteins.

116

## 117 **RESULTS**

### 118 **Large Diverse Protein Network Promotes DNA Damage**

119 We screened an inducible overproduction library of all >4000 *E. coli* proteins in two steps to  
120 identify clones with increased endogenous DNA-damage levels (STAR Methods, Figure 1B). For  
121 both the primary and secondary screens, we measured fluorescence of cells that carry a  
122 fluorescence-reporter gene driven by an SOS DNA-damage-response-activated promoter at a non-  
123 genic chromosomal site (Nehring et al., 2016) (Figure 1B). The promoter fusion reports DNA-  
124 damage-response induction, and not spurious promoter firing (Pennington and Rosenberg, 2007)  
125 (Figures S1A and S1B). First, in the primary screen, we used a fluorescence plate-reader, which is  
126 high-throughput but low-resolution, to identify potential clones with increased DNA damage and  
127 so increased fluorescence (Figures 1B and 1C). This identified potential positive candidates (414  
128 proteins). Second, we eliminated false positives from the primary plate-reader screen using a  
129 sensitive flow-cytometry secondary screen in the same strains (Figures 1B and 1D). Flow  
130 cytometry, though low-throughput, is highly sensitive and reports DNA damage at the single-cell  
131 level (Pennington and Rosenberg, 2007) (STAR Methods, Figure 1D). The stringent, high-  
132 sensitivity flow-cytometry secondary screen validated 208 of the proteins identified in the primary  
133 screen as genuine DDPs that cause increased DNA damage when overproduced (Figures 1D-G;  
134 Table S1).

135 Further, we tested a representative sample of 66 of the DDP-overproduction clones (Table  
136 S1) for whether their increased fluorescence requires the SOS-response-activator protein RecA  
137 and a functioning (inducible) LexA SOS repressor, as expected if the fluorescence results from  
138 activation of the SOS DNA-damage response (Pennington and Rosenberg, 2007). All 66 showed  
139 RecA- and LexA-dependent high fluorescence, demonstrating the presence of DNA damage and  
140 a genuine SOS response (Figures 1H and S1C; Table S1). We also ruled out the possibility that  
141 DDP overproduction might increase mCherry protein fluorescence itself, independently of DNA  
142 damage, by showing that a separate representative sample of 40 of the 208 DDPs did not cause  
143 increased fluorescence from the same mCherry reporter gene under the control of a non-SOS  
144 promoter (Figure S1D; Table S1).

145 DNA-damage-promotion by overproduction of the 208 DDPs is observed additionally in  
146 three ways. First, 95% of the 208 validated *E. coli* DDPs displayed an independent DNA-damage-  
147 related phenotype in at least one of nine assays that are either less sensitive or more DNA-damage-  
148 type specific than the SOS-flow cytometric assay in the secondary screen. For example, we tested  
149 a representative sample of 67 of the DDP-overproduction clones for the presence of damaged,  
150 single-stranded DNA using a less sensitive assay for microscopically visible foci of a fluorescent  
151 DNA-damage-sensor protein RecA\*GFP (Renzette et al., 2005), which is less sensitive because it  
152 uses a partially functional RecA protein (Renzette et al., 2005). The data nevertheless show a  
153 significant association of RecA foci with SOS-positive (DDP) clones in that 32 of the 67 tested  
154 showed increased foci ( $r = 0.7$ ,  $p = 1.3 \times 10^{-10}$ , Pearson's correlation) (Figure 1I; Table S1 for clone-  
155 by-clone results). Also, later in this paper, we explored the kinds and causes of endogenous DNA  
156 damage promoted by the 208 *E. coli* DDPs, using seven assays for specific kinds of DNA  
157 damage—all more DNA-damage-type-specific than the SOS-response assay used here, and we  
158 additionally assayed DDPs for mutagenesis, described below (summarized Table S1; Figure 1J).  
159 All but 12 of the 208 clones were positive in either the RecA\*GFP-focus assay, and/or one of the

160 7 assays described below, or mutagenesis (summarized [Table S1](#)). This equates to 95% of the 208  
161 proteins showing DNA-damage-related phenotypes in an independent assay. Finally, all of the  
162 twelve not validated in a non-SOS-based assay ([Table S1](#)) were shown to increase fluorescence  
163 SOS-response dependently, showing only RecA- LexA-dependent fluorescence increase ([Figures](#)  
164 [1H and S1C](#); [Table S1](#)) and not general fluorescence increase ([Figure S1D](#); [Table S1](#)). Collectively,  
165 these data demonstrate independently that all 208 DDPs promote DNA damage when  
166 overproduced.

167 The 208 proteins span many different classes that function in diverse cellular and metabolic  
168 processes ([Figure 1F](#); [Table S1](#)), and only 8% encode known DNA-repair proteins (blue font,  
169 [Figure 1F](#); [Table S1](#)). Although DNA-repair proteins *reduce* DNA damage when expressed  
170 normally, their overproduction, here, increased DNA damage, which might occur by perturbing  
171 undamaged DNA, by titrating repair partner proteins away from DNA damage and/or inhibiting  
172 DNA repair. We call all of these proteins DNA-damaging proteins (DDPs).

173 The DDPs constitute a network both functionally and by protein-protein associations.  
174 Functionally, they cause the same phenotype—increased DNA damage on overproduction—but  
175 their reported protein functions are remarkably diverse ([Figure 1F](#); [Table S1](#)). We used STRING—  
176 a database that contains known and predicted associations between protein pairs—to examine  
177 whether these diverse proteins had any other known or predicted connections indicative of a  
178 network. STRING measures protein-protein associations or interactions of many kinds including  
179 indirect associations (e.g., co-occurrence in different organisms' genomes, or in papers in the  
180 literature) and direct protein-protein interactions, among others ([STAR Methods](#)). Using STRING  
181 with an interaction score cut-off of  $\geq 0.6$  (medium-to-high confidence, [STAR Methods](#)), we found  
182 that the 208 DDPs form a significant network via protein-protein interaction data ([Figure 1G](#),  
183 specific interactions, [Figure S2A](#)) with more interactions than random sets of 208 *E. coli* proteins  
184 ( $p = 2.0 \times 10^{-31}$ , hypergeometric test, [Supplemental Discussion 1](#)). When known DNA-repair  
185 proteins are removed, the STRING network is still significant compared with random sets of the  
186 same number of *E. coli* proteins ( $p = 9 \times 10^{-7}$ , hypergeometric test), indicating that this association  
187 network is not solely via DNA-repair-protein associations. When both DNA-repair and DNA-  
188 replication proteins are removed—both known to interact directly with DNA—the STRING  
189 network is no longer significant compared with random sets of the same number of *E. coli* proteins  
190 ( $p = 0.08$ , hypergeometric test). These data suggest that, as might be expected from the highly  
191 diverse protein functions ([Figure 1F](#)), these proteins work in many different cellular processes that  
192 may share only their various effects on DNA damage, seen by significant association as a network  
193 only when DNA-repair and replication proteins are included, which we identify as the hubs of the  
194 DDP STRING interaction network ([Figure 1G](#)).

195 The DDP network is estimated to be larger than the 208 proteins identified ([Supplemental](#)  
196 [Discussion 2](#), [Figure S1E](#)). Although the premier overproduction (Mobile) library was used ([Saka](#)  
197 [et al., 2005](#)), its composition of some native genes and some genes encoding five additional amino  
198 acids is indicated by our data to have prevented detection of some additional DDPs ([Supplemental](#)  
199 [Discussion 2](#)).

200

### 201 **Endogenous DNA Damage Increases Mutations**

202 We tested the hypothesis that triggering endogenous DNA damage would increase mutation rates  
203 ([Figure 1A](#)) using DDPs: a useful test because they were discovered based on DNA damage,  
204 rather than genome instability/mutation rate. Mutation rates of a sample of 32 representative *E.*  
205 *coli* DDP clones were assayed by a modified forward-mutation fluctuation-test assay ([Figure 1J](#),

206 **STAR Methods**). We chose 10 DDP clones from the low-damage group (<5-fold increase in  
207 endogenous DNA-damage levels) and 22 from the high-damage group with a >5-fold increase in  
208 endogenous DNA-damage levels (**Supplemental Discussion 3**; **Table S1**). The data in **Figure 1J**  
209 show that increased endogenous DNA-damage levels are associated significantly with elevated  
210 mutation rates. We confirmed that the mutagenesis assay reported genuine loss-of-function  
211 mutations in the *cI* mutation-reporter gene (**Figure S1F**), rather than gene-regulatory or epigenetic  
212 changes, by sequencing mutations in a sample of independent isolated mutants of 10 representative  
213 DDP clones (**Figure S1F**). The sequence analyses of selected DDP clones revealed additionally  
214 that high DNA damage led to various kinds of mutations including base substitutions, indels,  
215 transposition events, and gross chromosomal rearrangements (GCRs, including large deletions,  
216 **Figure S1F**, right). These mutations mimic the increased small mutations and GCRs seen in various  
217 cancers (**Stratton, 2011**). Although the SOS response induces mutations by upregulation of low-  
218 fidelity DNA polymerases (Pols) V and IV (**Kobayashi et al., 2002**; **Maor-Shoshani et al., 2000**;  
219 **Wagner and Nohmi, 2000**), some of the mutations (**Figure S1F**, blue font) differ from common Pol  
220 V and Pol IV errors (**Figure S1F**, red font). The data suggest that the type of DNA damage, and  
221 not merely induction of the SOS response, may influence the kinds and rates of mutations made  
222 (**Figures 1J and S1F**, **Table S1**). The data show that overproduction of many functionally diverse  
223 *E. coli* proteins (**Figure 1F**; **Table S1**) causes increased DNA-damage loads (**Figures 1C-E**; **Table**  
224 **S1**), and genome instability with mutations of essentially all kinds (**Figures 1J and S1F**; **Table S1**).

225

### 226 **Human Homologs of Bacterial DDPs a Network Associated with Cancers**

227 As an unbiased quantitative way to find human DDPs, we identified 284 human homologs of the  
228 *E. coli* DDPs via BLASTp and deltaBLAST searches (**STAR Methods**, **Figure 2A**; **Table S2**).  
229 “Homologs” are defined here as proteins with amino-acid similarity that may result from possible  
230 evolutionary relatedness (**STAR Methods**). The 284 human homologs are used here as candidate  
231 human DDPs (hDDPs), and are homologs of 68 of the *E. coli* DDPs (shown, **Table S2**). The  
232 remaining *E. coli* DDPs are mostly analogs of human proteins, which function similarly but are  
233 not homologous (**Serres et al., 2001**), and many are of unknown function. The hDDP candidate  
234 proteins also constitute a protein-protein interaction network (**Figure 2B**, specific interactions  
235 **Figure S2B**), with significantly more interactions than sets of 284 random human proteins ( $p = 1.2$   
236  $\times 10^{-327}$ , hypergeometric test), or random human homologs of *E. coli* proteins, which also differ  
237 from random human proteins, but less so ( $p = 1.8 \times 10^{-49}$ , hypergeometric test, discussed  
238 **Supplemental Discussion 1**). Only 5.6% of the human homologs are known DNA-repair proteins  
239 (blue font, **Figure 2A**), again indicating a different class of candidate genome-integrity-affecting  
240 proteins. Like the *E. coli* network (**Figure 1G**), DNA-repair and -replication proteins are central  
241 hubs (**Figure 2B**).

242 We tested whether the human homologs of *E. coli* DDPs are both relevant to human  
243 cancers, and behave as a network, by examining their associations with various kinds of data from  
244 human cancers. We observe strong associations of the 284-protein network in cancer data of  
245 several kinds. First, the human homologs (**Figure 2A**; **Table S2**) of *E. coli* DDPs are significantly  
246 overrepresented among known (**Forbes et al., 2015**) and predicted (**D'Antonio and Ciccarelli,**  
247 **2013**) cancer drivers in a curated consensus in the Sanger Institute’s Catalogue of Somatic  
248 Mutations In Cancer (COSMIC) (**Forbes et al., 2015**) and the database of D’Antonio and Ciccarelli  
249 (**D'Antonio and Ciccarelli, 2013**) ( $p = 0.0002$ , Fisher’s exact test; **Figure 2C**; **Table S3**), which  
250 contain gain- and loss-of-function drivers. Human homologs of random *E. coli* proteins are not  
251 overrepresented ( $p = 0.48$ , Fisher’s exact test). Thus, the cancer association is specific to DDP

252 homologs, not conserved proteins generally. The human homologs remain overrepresented among  
253 known and predicted drivers when homologs of *E. coli* DNA-repair proteins and other known  
254 human DNA-repair proteins (Figure 2A) are excluded ( $p = 0.05$ , Figure 2C). No other  
255 comprehensive overexpression screen for DNA damage has been reported; however, we analyzed  
256 cancer association in published data from a limited, selected-candidate overexpression screen in  
257 human cells (Lovejoy et al., 2009), and found that these also show cancer association  
258 (Supplemental Discussion 4). These overlap with our 284 hDDP candidate network by only one  
259 protein—FIGNL—indicating that many new candidates were revealed by the *E. coli* screen.

260 Additionally, we found that candidate human DDP genes show increased copy numbers in  
261 26 cancer types in the cohort of patients in The Cancer Genome Atlas (Gao et al., 2013) (TCGA)  
262 (Figures 2D and S3A-C; Table S4). About 40% of the 284 human homolog genes have increased  
263 copy numbers in cancers (GISTIC threshold copy-number gain  $\geq 1$ ), either cancer-specifically or  
264 across cancers, compared with fewer than 20% of non-DDP genes amplified in those cancers  
265 (Figure 2D). The fractions of patients with increased copy numbers of each of the genes encoding  
266 the 284 human homologs of *E. coli* DDPs are shown for all 284 in Table S4 (examples, Figure  
267 S3A-C). The human homologs are enriched as copy-number increases in cancers compared with  
268 non-DDP human genes (Figure 2D,  $p = 0.04$ , one-way Fisher's exact test), suggesting that their  
269 overexpression is associated with cancers.

270 We next examined the outcomes for cancer survival relative to mRNA levels of the 284  
271 candidate human DDPs using cancer-patient and RNA data in TCGA (Gao et al., 2013). We found  
272 that in at least four cancer types, increased levels of the 284 RNAs, relative to the total RNAs, is  
273 associated with decreased overall survival (Figure 2E). This association results not just from the  
274 known (Forbes et al., 2015) and predicted (D'Antonio and Ciccarelli, 2013) cancer driver genes in  
275 the network, but is seen also in the network genes not known previously to drive cancers (Figure  
276 S3D-F). These data indicate an association of candidate hDDP gene overexpression with poor  
277 survival in these cancers, and further highlight the network properties/predictive power of the 284  
278 DDP-homolog protein/gene set. Moreover, increase of the 284 human DDP-homolog RNAs,  
279 relative to all RNAs, is also associated with total genomic mutation burden in cancers (relative to  
280 the patient normal tissue) in at least 12 cancer types in TCGA (Gao et al., 2013) (Figure 2F). Even  
281 stronger association is seen for the subset of the 284 homologs that are known (Forbes et al., 2015)  
282 or predicted (D'Antonio and Ciccarelli, 2013) cancer-driving genes (Figure 2F). These data support  
283 the possibility that overexpression in the candidate hDDP network is associated with mutagenesis  
284 in human cancers.

285

### 286 **Human Homologs Promote DNA Damage and Mutation**

287 We validated a sample of human candidate DDPs as genuine DNA-damage instigators in human  
288 cells (Figure 3). We tested our hypothesis that overproduction of these proteins, which can result  
289 from gene amplification, can promote DNA damage relevant to cancers by testing a sample in  
290 which about half the homologs were known to be amplified in cancers in TCGA (Gao et al., 2013)  
291 and the other half were not (Supplemental Discussion 5). We were also limited by availability in  
292 human cDNA-clone collections (Yang et al., 2011) (Supplemental Discussion 5). Because many  
293 genes in those collections are not full length (Table S5), we cloned several de novo (STAR  
294 Methods) to create 70 full-length sequence-verified overexpression GFP-fusion genes encoding  
295 human homologs of *E. coli* DDPs, 3 human homologs of *E. coli* damage-down proteins, as possible  
296 negative controls (Table S5), and 20 control random non-DDPs (Table S5, ~half of which are  
297 random human homologs of *E. coli* proteins). Using transient transfection of these human



298 overexpression clones, we performed three flow-cytometric assays, which we developed (Figure  
299 3A), to screen for increased DNA damage at the single-cell level in human cells that produce the  
300 candidate hDDPs, shown by GFP (Supplemental Discussion 6 for the infeasibility of stable clones).  
301 We screened for—(i) increased  $\gamma$ H2AX levels, a marker for DNA double-strand breaks (DSBs)  
302 (Kinner et al., 2008); (ii) increased  $\gamma$ H2AX in a sensitized screen in cells treated with a  
303 nonhomologous-break-repair (DNA-PK) inhibitor; and (iii) increased levels of the DNA-damage  
304 marker protein phospho-p53, which indicates activation of the DNA-damage response (Sakaguchi  
305 et al., 1998). The data show that the human homologs are enriched for genuine DDPs that increase  
306 DNA damage upon overproduction (Figure 3B). Among the 73 human homologs, we found that  
307 45% (33 of the 73) showed increased DNA damage (Figure 3B). This is highly significant ( $p <$   
308 0.0001 one-way Fisher's exact test) compared with the 20 random human proteins (Figures S3G-  
309 I; Table S6). Of the 33 validated hDDPs, only one (FIGNL1) was known previously to increase  
310 DNA damage upon overproduction (Lovejoy et al., 2009). Thus, we identified and validated 33  
311 genuine human DDPs.

312 We note, however, that the human-cell DNA-damage assays used here favor detection of  
313 DSBs, not all DNA-damage types comprehensively. Thus, many more of the human homologs  
314 may be DNA-damage instigating for other kinds of DNA damage than is estimated here.

315 As in *E. coli*, we found that overproduction of validated hDDPs increased mutation rates  
316 in human cells. Using a forward-mutation fluctuation-test assay for hypoxanthine-guanine  
317 phosphoribosyl transferase (HPRT) deficiency (STAR Methods), we found increased mutation  
318 rates for 4 out of 4 overproduced high-DNA-damage hDDP clones compared with cell-only,  
319 vector-only, and GFP-tubulin-overproducing negative controls (Figure 3C and Supplemental  
320 Discussion 8). Thus, increased mutation rates result from overproduction of validated hDDPs in  
321 human cells. These results support the hypothesis that hDDPs may drive cancers based on their  
322 ability to increase genome instability—a known cancer-driving phenotype (Hanahan and  
323 Weinberg, 2011).

324 As shown in Figure 3E, 32 of the 33 validated human DDPs are *E. coli* DDP homologs  
325 from the following categories: (i) 16% that are both known (Forbes et al., 2015) or predicted  
326 (D'Antonio and Ciccarelli, 2013) cancer drivers and amplified in TCGA cancers; (ii) 53% that are  
327 amplified in cancers and not known or predicted drivers; (iii) 6% known/predicted cancer drivers  
328 that are not known to be amplified in cancers; and (iv) 25% that are neither gene-amplified in  
329 cancers nor previously known or predicted drivers. None of these classes was predicted previously  
330 to be DNA-damage promoting, and some might not have been hypothesized to potentially promote  
331 cancer via overproduction (e.g., classes iii and iv). In Supplemental Discussion 7, we use the rates  
332 of validation in each class tested to estimate that there are likely to be many additional hDDPs  
333 among the 284-protein candidate hDDP network, that would test positive in our assays.

334 Bioinformatically, ~75% of the validated hDDP genes show cancer-associated copy-  
335 number increases in the TCGA patient-cohort data (Gao et al., 2013) (GISTIC threshold copy-  
336 number gain  $\geq 1$ , Figure 3D). The fraction of cancer-specific or across-cancer copy-number-  
337 increased genes among the validated hDDP genes is higher than the candidates we tested that were  
338 not validated (Figure 3D,  $p = 0.02$ , one-way Fisher's exact test). The data provide support for our  
339 hypothesis that validated hDDP genes may drive cancer via DNA damage when overexpressed,  
340 and imply that our cell-based DNA-damage assays relate to human cancer biology.

341

## 342 **Functional Systems Biology**

343 Having identified DDPs in *E. coli* and human, we used the tractable *E. coli* model for further

344 function discovery. We sought to create a multi-parameter, minable data set of phenotypes to bin  
345 the 208 *E. coli* DDPs into function clusters that reflect the kinds, causes, and consequences of  
346 DNA damage provoked by their overproduction. Our phenotypes are based on seven quantitative  
347 functional assays, many at the single-cell level (Figure 4). Two of these employ synthetic proteins  
348 that trap, fluorescently label, and allow quantification, as well as genomic mapping, of specific  
349 DNA-damage-intermediate structures in single living cells (Shee et al., 2013; Xia et al., 2016). We  
350 use the data to predict, then demonstrate, mechanisms by which dysregulation of diverse conserved  
351 proteins increase endogenous DNA damage.  
352

### 353 **Proteins that Instigate DNA Double-Strand Breaks**

354 We used the engineered double-strand-break (DSB)-end-specific binding protein GamGFP (Shee  
355 et al., 2013) to quantify DSBs in single living cells. GamGFP “traps” DSB ends and prevents their  
356 repair in *E. coli* and mammalian cells (Shee et al., 2013). GamGFP produced from a chromosomal  
357 regulatable gene cassette labels one-ended and two-ended DSBs as fluorescent foci in *E. coli* at an  
358 estimated 70% efficiency (Shee et al., 2013) (i.e., 30% of DSBs present are not seen as foci). We  
359 quantified GamGFP foci in each of the 208 DDP-overproducing clones by automated microscopy  
360 (STAR Methods). We found that 87 of the 208 DDP-overproducing clones displayed significantly  
361 more GamGFP foci than vector-only controls (Figures 4A-B and S4A, Table S1, Supplemental  
362 Discussion 9) and than 25 random SOS-negative (non-DDP) clones, none of which had increased  
363 GamGFP foci (Figure S4A). Our finding of 121 DDP-overproducing clones without increased  
364 GamGFP foci suggests that single-stranded (ss)DNA, the inducing signal for the SOS DNA-  
365 damage response, frequently accumulates at sites other than DSBs. The 41% of *E. coli* DDP clones  
366 with elevated GamGFP DSB foci are not enriched in any gene-function category (Table S1),  
367 implying that DSBs—a common result of many DNA-damaging mechanisms (Merrikh et al.,  
368 2012)—result from various cellular processes.  
369

### 370 **Stalled Reversed Replication Forks**

371 Stalling of DNA replication leads to DNA damage (Jackson and Bartek, 2009) and can create four-  
372 way DNA junctions when stalled replication forks “reverse” such that the new DNA strands  
373 basepair with each other (Figure 4C, reversed fork, RF) (Seigneur et al., 1998). Reversed forks  
374 (RFs) block resumption of DNA replication, lead to replication-fork breakage (Seigneur et al.,  
375 1998; Yeeles et al., 2013), and so are both a kind of DNA damage, and reflect a cause of DNA  
376 damage—stalled replication. We quantified stalled, RFs as fluorescent foci of the engineered 4-  
377 way-junction-specific DNA-binding protein RuvCDefGFP (RDG) in cells lacking homology-  
378 directed-repair protein RecA ( $\Delta recA$ ), in which essentially all RDG foci represent RFs (Xia et al.,  
379 2016). RDG labels 4-way junctions with about 50% efficiency in live *E. coli* (Xia et al., 2016).  
380 We found that 106 of the 208 DDP-overproducing clones showed increased RDG (RF) foci  
381 relative to the vector-only control (Figures 4D and S4B, Table S1) and to 30 control, SOS-negative  
382 overproducing clones (Figure S4B; Table S1). Among the 106 clones with increased RDG foci,  
383 49 also show increased DSBs (Table S1), detected as GamGFP foci, showing significant  
384 correlation ( $p = 0.03$ ,  $r = 0.15$  Spearman’s correlation). Overall, at least 51% of DDPs promote  
385 replication stalling on overproduction, indicating the importance of DNA replication to DNA-  
386 damage generation by many of the overproduced proteins, but also suggesting that mechanisms in  
387 addition to replication may underlie DNA damage induced by dysregulation of many other DDPs.  
388

### 389 **Reactive Oxygen via Transporters and Metabolism**

390 We quantified intracellular levels of reactive oxygen species (ROS) in single cells using the  
391 peroxide-indicator dye, dihydrorhodamine (DHR) (Gutierrez et al., 2013) and flow cytometry  
392 (Figures 4E, F and S4C, D). We found that 56 of the overproduced DDPs caused increased ROS  
393 levels (Figures 4F and S4C, D). We show that the high ROS levels contribute to DNA damage in  
394 at least 16 of the 56 ROS-elevated DDP-producing clones, in which the DNA damage was  
395 significantly reduced by the ROS-quenching agent thiourea (Keren et al., 2013), compared with  
396 the vector-only control (Figure 4G). Thus, high endogenous ROS levels underlie DNA damage in  
397 a subset of the DDP-producing clones. These (Figure 4G) comprise five membrane-spanning  
398 transporters (investigated below), an excess compared with the prevalence of transporters among  
399 *E. coli* proteins ( $p=0.002$ , hypergeometric test). The other eleven proteins relate to metabolism  
400 processes (Table S1), implying that perturbation of metabolic pathways can cause DNA damage  
401 by increasing ROS.

402

### 403 DNA Loss

404 Loss of DNA in cells can result from various problems including chromosome-segregation failure  
405 (Joshi et al., 2013), for example, from incomplete DNA replication or incomplete homology-  
406 directed repair between chromosomes, either of which can leave two chromosomes attached at cell  
407 division (Hendricks et al., 2000). We identified 67 DDP clones with increased frequencies of  
408 DNA-depleted (“anucleate”) cells (Figures 4H, I and S4E, F; Table S1) using flow cytometry of  
409 single cells with DNA and cell membranes stained separately. Overproduced DNA-repair and  
410 replication proteins are enriched among these clones ( $p = 0.04$ , one-way Fisher’s exact test, Table  
411 S1), implying that excessive DNA-repair and replication proteins promote DNA damage that leads  
412 to DNA erosion or chromosome-segregation failure. Their overproduction might alter  
413 stoichiometry of and hinder DNA-repair or replication complexes, and/or perturb DNA directly.

414

### 415 Reduced DNA-repair Capacity via Specific Proteins

416 Reduction of DNA-repair capacity could increase DNA-damage levels, and could result either  
417 from saturation of repair pathways with excessive DNA damage, or from overproduction of  
418 proteins that interfere directly with DNA-repair. Either would mimic repair-deficiency (and  
419 mutator phenotype), without a DNA-repair-gene mutation. We assayed DNA-repair capacity  
420 indirectly, as sensitivity to DNA-damaging agents that produce damage repaired by specific DNA-  
421 repair mechanisms: DSB-, ssDNA-break-, and ROS-instigator phleomycin (Steighner and Povirk,  
422 1990); base-oxidizing agent hydrogen peroxide ( $H_2O_2$ ); and DNA cross-linking agent mitomycin-  
423 C (MMC). These cause DNA damage repaired by homology-directed repair (HR, phleomycin),  
424 base-excision repair (“BER”,  $H_2O_2$ ), and, for MMC, both nucleotide-excision repair and HR  
425 (Friedberg et al., 2005). We found that 106, 75, and 10 of the 208 DDP clones were sensitive to  
426 phleomycin (Figures 4J and S5A-B),  $H_2O_2$  (Figures 4L and S5C), and MMC (Figures 4K and S5D,  
427 E), respectively, shown by reduced cell densities in cultures (normalized for any effects of protein  
428 overproduction on overall growth rates, STAR Methods). Collectively, 140 DDP-overproducing  
429 strains were sensitive to at least one DNA-damaging agent (Figure S5G; Table S1), and 45 to  
430 multiple drugs (Figure S5G; Table S1). Non-DDP overproduction clones were not enriched for  
431 sensitivity to DNA-damaging agents and differ from the DDP-network group for sensitivity to  
432 phleomycin and  $H_2O_2$ , but not for MMC (Figure S5). The data suggest that overproduction of  
433 various DDPs provoke different kinds of DNA damage that overwhelm or inhibit distinct DNA-  
434 repair mechanisms.

435 We excluded the possibility that most DNA-damage sensitivities resulted from DDP-

436 induced heritable mutation, by showing no sensitivity *after* removal from DNA damage (Figure  
437 S5H, Supplemental Discussion 10). We also excluded transcriptional downregulation of DNA-  
438 repair genes, by RNA-seq of DNA repair genes (Figure S5F, Supplemental Discussion 10). The  
439 data suggest that specific DNA-repair pathways are either inhibited directly or saturated by DNA  
440 damage caused by overproduction of specific DDPs and imply that dysregulating diverse proteins,  
441 such as by gene copy-number alteration, can create DNA-repair deficiency without mutation of  
442 DNA-repair genes.

443

#### 444 **Clustering *E. coli* Function Data Implicates Mechanisms**

445 We grouped the quantitative data from the functional assays using stability-based clustering [(Hu  
446 et al., 2015), Progeny clustering] (Figures 4M,N and S5G). The quantitative data on RDG (RF)  
447 foci analyzed with three other quantitative parameters measured in single-cells—ROS levels, DNA  
448 loss, and DSBs (all discussed above)—revealed that high RF loads are enriched in a specific cluster  
449 (Figure 4M). The RF-dense cluster is significantly enriched for DNA-binding transcription factors  
450 (examined below), with 29%, compared with 12% among the network as a whole ( $p = 0.002$ , one-  
451 way Fisher's exact test, Figure 4M; Table S1). The data indicate that distinct protein functions  
452 preferentially stall replication.

453 Grouping all quantitative data sets revealed six discreet function clusters (Figure 4N; Table  
454 S1), which may indicate at least six different potential mechanisms and cellular consequences of  
455 DNA-damage promotion by DDPs (reduced DNA-damage classes discussed Supplemental  
456 Discussion 11). We compared the function clusters with protein-protein-association data in the  
457 DDP network (Figures 4N and S2A, Table S1). Whereas the entire DDP network shows  
458 significantly more protein-protein associations than sets of 208 random *E. coli* proteins,  
459 superimposition of the function clusters onto the protein-protein interaction network indicates that  
460 cluster 2 shows even more protein-protein interactions than the DDP network as a whole ( $p =$   
461  $0.0007$ , one-way Fisher's exact test). These data support associations of function clusters with  
462 particular biological mechanisms, three examined below.

463

#### 464 **Transcription Factor Binding to DNA Promotes Replication Stalls**

465 Clusters 5 and 6 of Figures 4N (listed Table S1) show increased replication stalling/reversed forks  
466 (RFs, per Figure 4M) and are most enriched for DNA-binding transcription factors: transcriptional  
467 activators and repressors. We hypothesized that persistent binding of a protein to DNA might  
468 create a replication “roadblock”, stall forks, and cause RFs. RFs can be regarded as DNA damage  
469 and also cause additional DNA damage when cleaved by endonucleases (Seigneur et al., 1998). In  
470 support of this hypothesis, we found, first, that mutational ablation of the DNA-binding-domains  
471 (DBDs) of three of the transcription factors—CsgD, HcaR and MhpR—abolished both their  
472 abilities to promote SOS-inducing DNA damage (Figures 5A-C), and RDG (RF) foci (Figures 5D-  
473 E and S6A). The data indicate that these transcription factors must bind DNA to provoke DNA  
474 damage and RFs upon overproduction. Second, we created an mCherry (red) fusion of the CsgD  
475 transcription factor (Ogasawara et al., 2011), and see that it forms foci DBD-dependently (Figure  
476 5F and S6B), suggesting that foci reflect the DNA-bound transcription factor. We found that most  
477 of the CsgD-mCherry foci, and also HcaR-mCherry foci, co-localized with RDG (RF) foci  
478 (Figures 5F-H), suggesting that RFs form near the DNA-bound transcription factors. Foci of DNA-  
479 bound proteins are distinguishable at ~50kb apart on DNA, e.g., (Shee et al., 2013); thus, these  
480 data indicate that RDG/RF foci accumulate in the vicinity of the sites of transcription-factor  
481 binding to DNA (Figures 5G and 5H). High resolution mapping of RDG (RFs) by ChIP-seq in the

482 genome of CsgD-overproducing cells showed RDG (RFs) enriched near the transcription factor's  
483 target DNA-binding sites CsgD-DBD-dependently (Figure 5I), supporting the hypothesis that the  
484 bound transcription factor stalls replication causing fork reversal nearby. CsgD has 10  
485 experimentally well-characterized binding sites (Ogasawara et al., 2011), and we found that the  
486 CsgD-DBD-dependent RDG (RF) ChIP-seq peaks are very significantly enriched in 10kb regions  
487 surrounding known CsgD DNA-binding sites (representative peaks, Figure 5I; Supplemental  
488 Discussion 12, rest of known sites; Figure S7). CsgD-DBD-dependent RDG (RF) ChIP-seq peaks  
489 occurred both upstream and downstream of the binding sites in the replication paths (Figure S7,  
490 discussed Supplemental Discussion 12, and Figure 5J). Our data support a model (Figure 5J) in  
491 which overproduced DNA-bound transcription factors can create roadblocks to replication, which  
492 leads to increased fork stalling and reversal near where the transcription factors bind, causing DNA  
493 damage.

494

### 495 ***E. coli* and Human Transporter Overproduction Elevates ROS**

496 Membrane-spanning transporters are the largest category of human homologs of the *E. coli* DDPs,  
497 and several are both overrepresented among known cancer drivers and also provoke DNA damage  
498 on overproduction (Figures 2A, Tables S2 and S3). We found that *E. coli* membrane transporters  
499 are overrepresented at 26% in the high-ROS cluster in Figure 4M compared with 11% over the  
500 whole network ( $p = 0.004$ , one-way Fisher's exact test, Figure 6A-C; Table S1). Further, sixteen  
501 DDP clones with high ROS caused DNA damage ROS-dependently in that the damage was  
502 reduced by ROS quenching (Figure 4I). These include five transporters, the increased ROS and  
503 ROS-dependent DNA damage of which are shown in Figures 6B-D. Three of the five are H<sup>+</sup>  
504 symporters, a significant enrichment compared with the frequency of H<sup>+</sup> symporters encoded in  
505 the genome (Keseler et al., 2017) ( $p = 2.7 \times 10^{-5}$ , hypergeometric test), one transports polypeptides,  
506 and the remaining one Mg<sup>2+</sup>.

507 Proton (H<sup>+</sup>) symporters import molecules concurrently with H<sup>+</sup>. We found that  
508 overproduction of each of the three H<sup>+</sup> symporters conferred reduced intracellular pH (increased  
509 H<sup>+</sup>) (Figures 6E-G), implying that overproduction increased their symporter activities. However,  
510 their induction of ROS was not well correlated with their reduction of pH (Figure 6H), suggesting  
511 that other cargos that they import may cause the increased ROS and DNA damage, or that simply  
512 compromising membrane integrity and cellular boundaries may provoke ROS and DNA damage.  
513 A specific model for XanQ, the strongest ROS-promoter among them, is illustrated in (Figure 6I),  
514 discussed Supplemental Discussion 13. Overall, the data reveal that DNA-damage induction can  
515 result from increased transporter activity, leading to high levels of DNA-damaging ROS (Figures  
516 6A-C). The data suggest that disturbing cellular boundaries can cause DNA damage via ROS.

517 CorA, an inner membrane Mg<sup>2+</sup> transporter, which transports Co<sup>2+</sup> and Ni<sup>2+</sup> less efficiently  
518 (Kehres and Maguire, 2002), elevates ROS (Figures 6C-D) and DNA damage (Figure 6B) when  
519 overproduced. Both might occur by increasing the usually minimal import of Co<sup>2+</sup> and Ni<sup>2+</sup> (Figure  
520 6I). Ni<sup>2+</sup> is toxic and induces DNA damage via oxidative stress (Cameron et al., 2011) because  
521 Ni<sup>2+</sup> binds sulfhydryl groups commonly found in anti-oxidative enzymes (Schmidt et al., 2009).  
522 Increased Mg<sup>2+</sup> import is unlikely to underlie the ROS and DNA damage because Mg<sup>2+</sup> is the most  
523 abundant metal ion in cells and excessive Mg<sup>2+</sup> does not seem to affect the activities of the many  
524 Mg<sup>2+</sup>-utilizing enzymes (Hartwig, 2001).

525 In human cells, multiple DNA-damaging mechanisms are implicated. First, a survey of the  
526 subcellular localization of all 33 overproduced, validated hDDPs showed that 16 were cytoplasmic;  
527 10 were nuclear, and 7 were found throughout the cell (Figures 6J), suggesting that direct contact

528 with DNA is not needed for many overproduced hDDPs' instigation of DNA damage.

529 We screened a sample of thirteen validated hDDP-producing clones for those with DNA  
530 damage that could be suppressed by ROS quencher N-acetyl cysteine (NAC), to identify those that  
531 instigate ROS-dependent DNA damage. We found that overproduction of a membrane-spanning  
532 transporter promotes DNA damage via ROS. KCNAB1/2 promote high DNA damage (Figure 6K),  
533 are cytoplasmic when overproduced (Figure 6J), and are subunits of intracellular voltage-gated K<sup>+</sup>  
534 channels that function in redox transformations of xenobiotics (Hlavac et al., 2014). Increased  
535 *KCNAB2* mRNA is found in breast cancer (Hlavac et al., 2014), but how KCNAB1/2  
536 overproduction might promote cancer is unknown. We found that DNA-damage promotion by  
537 KCNAB1/2 relies at least partly on ROS, in that ROS-quenching NAC treatment reduced DNA-  
538 damage induction by KCNAB1 or KCNAB2 overproduction (Figure 6K). Cells overproducing  
539 several other validated hDDPs showed no reduction in DNA damage with NAC treatment (Figure  
540 6K), indicating that these DDPs promote DNA damage by other or additional mechanisms.

541  
542 ***E. coli* Pol IV and Human DNMT1 Promote DNA Damage via Replisome-Clamp Interaction**

543 DNA polymerase (Pol) IV, encoded by *dinB*, is among the highest DNA-damage generators in the  
544 *E. coli* DDP network (Figures 7A-C; Table S1), generating both DSBs seen by increased GamGFP  
545 foci (Table S1) and ssDNA gaps, inferred as follows. SOS DNA-damage-response induction by  
546 overproduced Pol IV was partially RecB- (DSB) and partially RecF- (ssDNA-gap) dependent  
547 (Figures 7D-E); and RecB and RecF are required for SOS induction by DSBs and ssDNA gaps,  
548 respectively (McPartland et al., 1980), implicating DSBs and ssDNA gaps as Pol IV-induced  
549 damage. Overproduced Pol IV also promotes chromosome loss (Figure 4E). We show, that Pol  
550 IV-induced DNA damage occurs via its interaction with the replisome sliding clamp as follows.

551 Pol IV is a poorly processive, low-fidelity DNA polymerase that traverses specific  
552 damaged bases that more efficient DNA polymerases cannot copy (Wagner et al., 2000). Pol IV  
553 competes with more processive DNA polymerases (Frisch et al., 2010; Hastings et al., 2010), by  
554 competition for binding the replisome sliding clamp protein, beta (Dohrmann et al., 2016; Heltzel  
555 et al., 2012). We hypothesized that the documented ability of Pol IV to slow replication-fork  
556 progression (Heltzel et al., 2012; Uchida et al., 2008) might underlie its generation of DNA damage  
557 when overproduced. In support of this hypothesis, we found, first, that overproducing Pol IV  
558 simultaneously with DNA Pol II, its competitor for the replisome (Frisch et al., 2010), caused a  
559 roughly 50% reduction in the Pol IV-dependent DNA damage (Figures 7B-C). Second, cells  
560 producing a mutant replisome clamp-loader protein with reduced Pol IV loading and increased  
561 loading of the major replicative DNA polymerase, Pol III (Dohrmann et al., 2016), also showed  
562 reduced DNA damage from Pol IV overproduction (Figures 7D-E, *dnaX* tau-only), but no  
563 reduction of SOS on its own (Figure 7F). Third, a C-terminal Pol IV deletion that abolishes Pol IV  
564 interaction with the replisome beta sliding clamp (Uchida et al., 2008) also abolished DNA damage  
565 upon Pol IV overproduction ( $\Delta$ BBD, Figures 7B-C). We conclude that Pol IV interaction with the  
566 replisome clamp is required for its generation of DNA damage on overproduction.

567 Perhaps surprisingly, Pol IV catalytic activity (DNA synthesis) was not required for all of  
568 its DNA-damage induction; the catalytically-inactive Pol IV R49F mutant (Wagner et al., 1999)  
569 reduced only half the DNA damage caused by overproduction (Pol IV cat<sup>-</sup>, Figures 7B and 7C),  
570 without reducing Pol IV protein levels (Uchida et al., 2008; Wagner et al., 1999) (Figure S7D).  
571 Thus, mere binding of Pol IV to the replisome, not only its poorly processive catalytic activity,  
572 appears sufficient to cause DNA damage. The synthesis-dependent component of DNA damage  
573 might have resulted from the ability of Pol IV to incorporate oxidized guanine (8-oxo-dG) into

574 DNA, per (Foti et al., 2012), which leads to two different strand-breaking BER processes that  
575 begin with base removal by MutM and MutY DNA glycosylases (Foti et al., 2012). However, loss  
576 of neither glycosylase diminished DNA damage caused by Pol IV overproduction (Figures 7E and  
577 7G). The data imply that BER following 8-oxo-dG incorporation is not how excess Pol IV  
578 promotes most DNA damage. Overall, Pol IV promotes DNA damage dependently on replisome-  
579 clamp interaction, and only partly dependently on catalysis (model, Figure S7E).

580 We found that human DNMT1 overproduction also induces DNA damage in human cells  
581 based on binding the replisome clamp, and independently of its catalytic activity: a non-canonical  
582 potential cancer-driving role. DNMT1 is the major human DNA methyltransferase that methylates  
583 DNA upon replication (Jin and Robertson, 2013). Hypomorphic mutations in *DNMT1* promote  
584 microsatellite instability (Jin and Robertson, 2013). Increased DNMT1 is common to several  
585 cancer types, and causes hypermethylation, proposed to downregulate tumor-suppressor genes  
586 (Biniszkiwicz et al., 2002), which would constitute a cell-biological, rather than DNA-based,  
587 tumor-promoting role. Surprisingly, we found that, in addition, DNMT1 promotes DNA damage  
588 independently of its DNA-methylation activity, in that overproduction of DNMT1 catalytically-  
589 dead mutant proteins (Figure 7H) increased DNA damage similarly to wild-type DNMT1 (Figures  
590 7I and 7J). Overproduction of two other DNA methyltransferases did not increase DNA-damage  
591 levels (Figure 7I). DNMT1 truncations (Figure 7H) revealed that DNMT1 promotion of DNA  
592 damage required its PCNA-binding domain (PBD), which binds the replisome sliding clamp:  
593 PCNA (Figures 7I, S3L and S3M). Rad18-mediated monoubiquitination of PCNA, a DNA damage  
594 response (Mortusewicz et al., 2005), also resulted from DNMT1 overproduction, also methylase-  
595 independently and requiring the DNMT1 PBD (Figures 7J and S3M). These data suggest that mere  
596 binding of overproduced DNMT1 to the replisome clamp promotes DNA damage, and a resulting  
597 DNA-damage response, independently of methylation. The finding that both *E. coli* DNA  
598 polymerase IV and human DNMT1 promote DNA damage dependently on replisome-clamp  
599 binding and independently of their catalytic activities (Figure 7A-G) indicates generality of this  
600 mode of generation of DNA damage. The data suggest that promotion of DNA damage by  
601 DNMT1-PCNA complexes (Figures 7H-J), and resulting mutagenesis (Figure 3C), may promote  
602 cancers other than or in addition to via the known cell-biological/regulatory function of DNMT1  
603 in DNA methylation, and that many clamp-binding proteins may act similarly when their genes  
604 are overexpressed/amplified.

605

606

## 607 DISCUSSION

608

609 The identities and functions of proteins in the *E. coli* and human DNA-damaging-protein networks  
610 reveal that multiple diverse proteins, cellular processes, and molecular mechanisms underlie  
611 genesis of endogenous DNA damage. Although obtained in an overexpression screen, these are  
612 likely to represent natural causes of spontaneous endogenous DNA damage, first, because gene  
613 overexpression in cells in populations is remarkably common, on the order of tens of percents of  
614 bacterial cells for any given gene (Elowitz et al., 2002), with copy-number gains of any  
615 chromosomal region occurring in  $10^{-3}$  of cells (Reams et al., 2010), and expected to be comparable  
616 in human cells (Hastings et al., 2009). Second, the association of the 284 human DDP homologs  
617 with four aspects of human cancer data indicates natural biological relevance (reviewed below).

618

## 619 Endogenous DNA Damage in Cancer

620 The 284 human homologs of *E. coli* DDP genes are overrepresented among known (Forbes et al.,  
621 2015) and predicted (D'Antonio and Ciccarelli, 2013) cancer drivers (Figure 2C), overrepresented  
622 in cancers as amplified (Figures 2D and S3A-C, Table S3), and their increased expression in  
623 human cancers associated with poor outcomes (Figures 2E and S3D-F) and heavy mutation loads  
624 (Figure 2F). These associations support their overexpression being both biologically relevant, and  
625 relevant to cancer biology specifically.

626 The DDPs appear likely to represent a new broad function class of cancer-promoting  
627 proteins, and the earliest in cancer. Cancer-gene functions have been grouped into multiple specific  
628 categories (Hanahan and Weinberg, 2011) that fit into two broad classes of function (Kinzler and  
629 Vogelstein, 1997): the cancer-cell-biology-altering “gatekeepers”, mutations in which make cell  
630 biology more cancer-like, and the genomic “caretakers”—the DNA-repair genes, mutations in  
631 which elevate mutation rate and so drive cancer by increasing gatekeeper mutations (Figure 7K).  
632 The DDPs are expected to act *before* and upstream of DNA-repair functions promoting the  
633 endogenous DNA damage that necessitates repair (Figure 7K), and so instigating some of the  
634 earliest events in cancer development.

635 The large number of DDPs span diverse protein functions, the cancer-driving functions of  
636 many of which may be obscure or mis-assigned. Some of the mechanisms of DDP action may  
637 necessitate reevaluation of their cancer driving roles, and also of the drugs designed to inhibit them.  
638 For example, we found that human DNA methyltransferase DNMT1 causes DNA damage  
639 independently of its methylation activity, via its interaction with the replisome sliding clamp  
640 (Figure 7H-J). Current cancer drugs against DNMT1 target the methylase activity (Jones et al.,  
641 2016), and not replisome binding. It is unclear which activities of DNMT1 promote cancer, and so  
642 which should be drugged. Our finding may inform the development of and use of DNMT1-  
643 targeting strategies, taking into account its multifunctionality, broadly across cancer types. These  
644 results underscore the importance of determining all functions of a protein that are cancer  
645 promoting.

### 646 647 **The *E. coli*-to-Cancer Gene-function Atlas of Bacterial and Human DDP Phenotypes**

648 Our data from seven quantitative assays for kinds, causes, and consequences of endogenous DNA  
649 damage promoted by *E. coli* DDPs constitute a rich resource and framework for within- and cross-  
650 species discovery of conserved DNA-damage-generating mechanisms. We used them to identify  
651 six main function or phenotype clusters (Figure 4N), and implicate, then test and demonstrate,  
652 three *E. coli* DDP mechanisms (Figures 5-7), two also identified in human cells (Figures 6 and 7).  
653 We created a minable web-based resource for searching the complete *E. coli* function data, and the  
654 functional data from the validated human DDPs: the *E. coli*-to-Cancer Gene-function Atlas  
655 (ECGA) (<https://microbialphenotypes.org/wiki/index.php/Special:ECGA>). The ECGA data can be  
656 searched via the bacterial proteins' or their human homologs' names or by function key words.  
657 ECGA can be used for querying/generation of hypotheses for *E. coli* and potential conserved  
658 human-protein functions, and as it develops in future, for other organisms.

### 659 660 **Mechanisms that Cause Endogenous DNA Damage**

661 In *E. coli* DNA-binding transcription factors caused replication-fork stalling and reversal (Figure  
662 5) by apparent blocking of replication forks by the bound transcription factors (Figure 5J). Though  
663 replication-transcription conflicts have been engineered by reversing chromosome segments  
664 (Tehranchi et al., 2010), engineering multiple transcription-factor binding sites into long arrays  
665 (Magnan et al., 2015), or knock out of RNA-removal proteins (Wahba et al., 2016), the kinds of



666 DNA damage generated were not identified, nor was it known that any of these mechanisms could  
667 occur in natural genomes with only an endogenous protein upregulated, as often occurs in cells.  
668 Our results indicate that fork reversal is common and protein-function specific. Nearly 10% of  
669 human genes encode transcription factors (Levine and Tjian, 2003), including many cancer-driving  
670 overproduction (onco-)proteins, some known to promote DNA damage when overproduced, e.g.,  
671 c-Myc, and E2F1 (Pickering and Kowalik, 2006; Vafa et al., 2002). Thus, based on our observation  
672 of transcription-factor binding and DNA-damage-production in *E. coli*, many onco-protein  
673 transcription factors might promote cancer similarly to *E. coli* transcription factors—by causing  
674 genome-destabilizing DNA damage, potentially RFs. Moreover, in *E. coli* and human cells, we  
675 discovered that increased transmembrane transporter activities of several different kinds elevate  
676 ROS levels causing DNA damage (Figures 4M and 6A-F). This previously unknown mechanism,  
677 also apparent with the human KCNAB1/2 transporter, might explain the KCNAB2 association  
678 with cancers (Hlavac et al., 2014)—a hypothesis that remains to be tested. Further, we found that  
679 both *E. coli* DNA polymerase IV (Figure 7A-G) and human DNMT1 (Figures 7H-J, and S3L and  
680 M) provoke DNA damage via binding their respective replisome sliding clamps when  
681 overproduced, independently of their catalytic activities. Disruption of the replisome leading to  
682 replication-fork collapse (or other means Figure S7E), is thought to be an important source of DNA  
683 damage (Kuzminov, 1995) likely to apply to dysregulation of many kinds of proteins.

684

### 685 **DNA Damage as Potential Cancer Biomarker**

686 The existence of many diverse means of increasing endogenous DNA damage, and the predicted  
687 large sizes and diversity of both bacterial and human DDP networks indicate that dysregulation of  
688 any of many proteins is likely to be mutagenic via DNA damage (Figures 1J, 2F and S1F). Because  
689 many different proteins, processes, and mechanisms instigate DNA damage, DNA damage itself  
690 might be a robust predictor of cancer and genetic-disease susceptibility. The ability to detect high  
691 DNA damage could potentially make DNA-damage screening attractive for early identification of  
692 at-risk individuals, at a time before genome-sequencing would identify disease-associated  
693 mutations. Additionally, the success of cancer immune therapy “checkpoint inhibitors” is limited  
694 to high-mutagenesis cancers, apparently because mutagenesis creates diverse tumor antigens that  
695 can be attacked by the stimulated immune system (Germano et al., 2017). Thus, immune therapy  
696 is currently aimed primarily at some DNA-repair-defective cancers (Germano et al., 2017). Our  
697 data suggest that DNA damage, or upregulation of DDP network genes, may predict additional  
698 susceptibilities in various cancers.

699

### 700 **REFERENCES**

701

702 Alvaro, D., Lisby, M., and Rothstein, R. (2007). Genome-wide analysis of Rad52 foci reveals  
703 diverse mechanisms impacting recombination. *PLoS Genet* 3, e228.

704 Aravind, L., Walker, D.R., and Koonin, E.V. (1999). Conserved domains in DNA repair proteins  
705 and evolution of repair systems. *Nucleic Acids Res* 27, 1223-1242.

706 Asad, N.R., Asad, L.M.B.O., Almeida, C.E.B.d., Felzenszwalb, I., Cabral-Neto, J.B., and Leitão,  
707 A.C. (2004). Several pathways of hydrogen peroxide action that damage the *E. coli* genome.  
708 *Genetics and Molecular Biology* 27, 291-303.

- 709 Benjamini, Y., and Hochberg, Y. (1995). Controlling the false discovery rate: a practical and  
710 powerful approach to multiple testing. *Journal of the royal statistical society Series B*  
711 (Methodological), 289-300.
- 712 Berkopec, A. (2007). HyperQuick algorithm for discrete hypergeometric distribution. *Journal of*  
713 *Discrete Algorithms* 5, 341-347.
- 714 Biniszkiwicz, D., Gribnau, J., Ramsahoye, B., Gaudet, F., Eggan, K., Humpherys, D.,  
715 Mastrangelo, M.A., Jun, Z., Walter, J., and Jaenisch, R. (2002). Dnmt1 overexpression causes  
716 genomic hypermethylation, loss of imprinting, and embryonic lethality. *Mol Cell Biol* 22, 2124-  
717 2135.
- 718 Bolger, A.M., Lohse, M., and Usadel, B. (2014). Trimmomatic: a flexible trimmer for Illumina  
719 sequence data. *Bioinformatics* 30, 2114-2120.
- 720 Bonocora, R.P., and Wade, J.T. (2015). ChIP-seq for genome-scale analysis of bacterial DNA-  
721 binding proteins. *Methods Mol Biol* 1276, 327-340.
- 722 Boratyn, G.M., Schaffer, A.A., Agarwala, R., Altschul, S.F., Lipman, D.J., and Madden, T.L.  
723 (2012). Domain enhanced lookup time accelerated BLAST. *Biol Direct* 7, 12.
- 724 Brombacher, E., Dorel, C., Zehnder, A.J., and Landini, P. (2003). The curli biosynthesis  
725 regulator CsgD co-ordinates the expression of both positive and negative determinants for  
726 biofilm formation in *Escherichia coli*. *Microbiology* 149, 2847-2857.
- 727 Cameron, K.S., Buchner, V., and Tchounwou, P.B. (2011). Exploring the molecular mechanisms  
728 of nickel-induced genotoxicity and carcinogenicity: a literature review. *Rev Environ Health* 26,  
729 81-92.
- 730 Carrasco, B., Cozar, M.C., Lurz, R., Alonso, J.C., and Ayora, S. (2004). Genetic recombination  
731 in *Bacillus subtilis* 168: contribution of Holliday junction processing functions in chromosome  
732 segregation. *J Bacteriol* 186, 5557-5566.
- 733 Chatterjee, N., and Walker, G.C. (2017). Mechanisms of DNA damage, repair, and mutagenesis.  
734 *Environ Mol Mutagen* 58, 235-263.
- 735 D'Antonio, M., and Ciccarelli, F.D. (2013). Integrated analysis of recurrent properties of cancer  
736 genes to identify novel drivers. *Genome Biol* 14, R52.
- 737 Dohrmann, P.R., Correa, R., Frisch, R.L., Rosenberg, S.M., and McHenry, C.S. (2016). The  
738 DNA polymerase III holoenzyme contains gamma and is not a trimeric polymerase. *Nucleic*  
739 *Acids Res* 44, 1285-1297.
- 740 Dudin, O., Geiselmann, J., Ogasawara, H., Ishihama, A., and Lacour, S. (2014). Repression of  
741 flagellar genes in exponential phase by CsgD and CpxR, two crucial modulators of *Escherichia*  
742 *coli* biofilm formation. *J Bacteriol* 196, 707-715.

- 743 Elowitz, M.B., Levine, A.J., Siggia, E.D., and Swain, P.S. (2002). Stochastic gene expression in  
744 a single cell. *Science* 297, 1183-1186.
- 745 Fitzgerald, D.M., Hastings, P., and Rosenberg, S.M. (2017). Stress-induced mutagenesis:  
746 implications in cancer and drug resistance. *Annu Rev Cancer Biol* 1, 119-140.
- 747 Forbes, S.A., Beare, D., Gunasekaran, P., Leung, K., Bindal, N., Boutselakis, H., Ding, M.,  
748 Bamford, S., Cole, C., Ward, S., *et al.* (2015). COSMIC: exploring the world's knowledge of  
749 somatic mutations in human cancer. *Nucleic Acids Res* 43, D805-811.
- 750 Foster, P.L. (2006). Methods for determining spontaneous mutation rates. *Methods Enzymol*  
751 409, 195-213.
- 752 Foti, J.J., Devadoss, B., Winkler, J.A., Collins, J.J., and Walker, G.C. (2012). Oxidation of the  
753 guanine nucleotide pool underlies cell death by bactericidal antibiotics. *Science* 336, 315-319.
- 754 Friedberg, E.C., Walker, G.C., Siede, W., and Wood, R.D. (2005). DNA repair and mutagenesis  
755 (American Society for Microbiology Press).
- 756 Frisch, R.L., Su, Y., Thornton, P.C., Gibson, J.L., Rosenberg, S.M., and Hastings, P.J. (2010).  
757 Separate DNA Pol II- and Pol IV-dependent pathways of stress-induced mutation during double-  
758 strand-break repair in *Escherichia coli* are controlled by RpoS. *J Bacteriol* 192, 4694-4700.
- 759 Galhardo, R.S., Almeida, C.E., Leitao, A.C., and Cabral-Neto, J.B. (2000). Repair of DNA  
760 lesions induced by hydrogen peroxide in the presence of iron chelators in *Escherichia coli*:  
761 participation of endonuclease IV and Fpg. *J Bacteriol* 182, 1964-1968.
- 762 Gao, J., Aksoy, B.A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S.O., Sun, Y., Jacobsen, A.,  
763 Sinha, R., Larsson, E., *et al.* (2013). Integrative analysis of complex cancer genomics and  
764 clinical profiles using the cBioPortal. *Sci Signal* 6, p11.
- 765 Gao, R., Davis, A., McDonald, T.O., Sei, E., Shi, X., Wang, Y., Tsai, P.C., Casasent, A., Waters,  
766 J., Zhang, H., *et al.* (2016). Punctuated copy number evolution and clonal stasis in triple-negative  
767 breast cancer. *Nat Genet* 48, 1119-1130.
- 768 Germano, G., Lamba, S., Rospo, G., Barault, L., Magri, A., Maione, F., Russo, M., Crisafulli, G.,  
769 Bartolini, A., Lerda, G., *et al.* (2017). Inactivation of DNA repair triggers neoantigen generation  
770 and impairs tumour growth. *Nature* 552, 116-120.
- 771 Gutierrez, A., Laureti, L., Crussard, S., Abida, H., Rodriguez-Rojas, A., Blazquez, J., Baharoglu,  
772 Z., Mazel, D., Darfeuille, F., Vogel, J., *et al.* (2013). beta-Lactam antibiotics promote bacterial  
773 mutagenesis via an RpoS-mediated reduction in replication fidelity. *Nat Commun* 4, 1610.
- 774 Hanahan, D., and Weinberg, R.A. (2011). Hallmarks of cancer: the next generation. *Cell* 144,  
775 646-674.
- 776 Hanzelmann, S., Castelo, R., and Guinney, J. (2013). GSEA: gene set variation analysis for  
777 microarray and RNA-seq data. *BMC Bioinformatics* 14, 7.

- 778 Hartwig, A. (2001). Role of magnesium in genomic stability. *Mutat Res* 475, 113-121.
- 779 Hastings, P.J., Hersh, M.N., Thornton, P.C., Fonville, N.C., Slack, A., Frisch, R.L., Ray, M.P.,  
780 Harris, R.S., Leal, S.M., and Rosenberg, S.M. (2010). Competition of Escherichia coli DNA  
781 polymerases I, II and III with DNA Pol IV in stressed cells. *PLoS One* 5, e10862.
- 782 Hastings, P.J., Lupski, J.R., Rosenberg, S.M., and Ira, G. (2009). Mechanisms of change in gene  
783 copy number. *Nat Rev Genet* 10, 551-564.
- 784 Hastings, P.J., Quah, S.K., and von Borstel, R.C. (1976). Spontaneous mutation by mutagenic  
785 repair of spontaneous lesions in DNA. *Nature* 264, 719-722.
- 786 Heckman, K.L., and Pease, L.R. (2007). Gene splicing and mutagenesis by PCR-driven overlap  
787 extension. *Nat Protoc* 2, 924-932.
- 788 Heltzel, J.M., Maul, R.W., Wolff, D.W., and Sutton, M.D. (2012). Escherichia coli DNA  
789 polymerase IV (Pol IV), but not Pol II, dynamically switches with a stalled Pol III\* replicase. *J*  
790 *Bacteriol* 194, 3589-3600.
- 791 Hendricks, E.C., Szerlong, H., Hill, T., and Kuempel, P. (2000). Cell division, guillotining of  
792 dimer chromosomes and SOS induction in resolution mutants (*dif*, *xerC* and *xerD*) of  
793 Escherichia coli. *Mol Microbiol* 36, 973-981.
- 794 Hlavac, V., Brynychova, V., Vaclavikova, R., Ehrlichova, M., Vrana, D., Pecha, V., Trnkova,  
795 M., Kodet, R., Mrhalova, M., Kubackova, K., *et al.* (2014). The role of cytochromes p450 and  
796 aldo-keto reductases in prognosis of breast carcinoma patients. *Medicine (Baltimore)* 93, e255.
- 797 Hu, C.W., Kornblau, S.M., Slater, J.H., and Qutub, A.A. (2015). Progeny Clustering: A Method  
798 to Identify Biological Phenotypes. *Sci Rep* 5, 12894.
- 799 Hu, C.W., and Qutub, A.A. (2016). progenyClust: an R package for Progeny Clustering. *R*  
800 *JOURNAL* 8, 328-338.
- 801 Jackson, A.L., and Loeb, L.A. (2001). The contribution of endogenous sources of DNA damage  
802 to the multiple mutations in cancer. *Mutat Res* 477, 7-21.
- 803 Jackson, S.P., and Bartek, J. (2009). The DNA-damage response in human biology and disease.  
804 *Nature* 461, 1071-1078.
- 805 Jin, B., and Robertson, K.D. (2013). DNA methyltransferases, DNA damage repair, and cancer.  
806 *Adv Exp Med Biol* 754, 3-29.
- 807 Johnson, S.C. (1967). Hierarchical clustering schemes. *Psychometrika* 32, 241-254.
- 808 Jones, P.A., Issa, J.P., and Baylin, S. (2016). Targeting the cancer epigenome for therapy. *Nat*  
809 *Rev Genet* 17, 630-641.

- 810 Joshi, M.C., Magnan, D., Montminy, T.P., Lies, M., Stepankiw, N., and Bates, D. (2013).  
811 Regulation of sister chromosome cohesion by the replication fork tracking protein SeqA. *PLoS*  
812 *Genet* 9, e1003673.
- 813 Kehres, D.G., and Maguire, M.E. (2002). Structure, properties and regulation of magnesium  
814 transport proteins. *Biomaterials* 15, 261-270.
- 815 Kelley, E.E., Khoo, N.K., Hundley, N.J., Malik, U.Z., Freeman, B.A., and Tarpey, M.M. (2010).  
816 Hydrogen peroxide is the major oxidant product of xanthine oxidase. *Free Radic Biol Med* 48,  
817 493-498.
- 818 Keren, I., Wu, Y., Inocencio, J., Mulcahy, L.R., and Lewis, K. (2013). Killing by bactericidal  
819 antibiotics does not depend on reactive oxygen species. *Science* 339, 1213-1216.
- 820 Keseler, I.M., Mackie, A., Santos-Zavaleta, A., Billington, R., Bonavides-Martinez, C., Caspi,  
821 R., Fulcher, C., Gama-Castro, S., Kothari, A., Krummenacker, M., *et al.* (2017). The EcoCyc  
822 database: reflecting new knowledge about *Escherichia coli* K-12. *Nucleic Acids Res* 45, D543-  
823 D550.
- 824 Kim, S.R., Matsui, K., Yamada, M., Gruz, P., and Nohmi, T. (2001). Roles of chromosomal and  
825 episomal *dinB* genes encoding DNA pol IV in targeted and untargeted mutagenesis in  
826 *Escherichia coli*. *Mol Genet Genomics* 266, 207-215.
- 827 Kinner, A., Wu, W., Staudt, C., and Iliakis, G. (2008). Gamma-H2AX in recognition and  
828 signaling of DNA double-strand breaks in the context of chromatin. *Nucleic Acids Res* 36, 5678-  
829 5694.
- 830 Kinzler, K.W., and Vogelstein, B. (1997). Cancer-susceptibility genes. Gatekeepers and  
831 caretakers. *Nature* 386, 761, 763.
- 832 Kobayashi, S., Valentine, M.R., Pham, P., O'Donnell, M., and Goodman, M.F. (2002). Fidelity  
833 of *Escherichia coli* DNA polymerase IV. Preferential generation of small deletion mutations by  
834 dNTP-stabilized misalignment. *J Biol Chem* 277, 34198-34207.
- 835 Kuzminov, A. (1995). Collapse and repair of replication forks in *Escherichia coli*. *Mol Microbiol*  
836 16, 373-384.
- 837 Kuzminov, A. (2011). Homologous Recombination-Experimental Systems, Analysis, and  
838 Significance. *EcoSal Plus* 4.
- 839 Levine, M., and Tjian, R. (2003). Transcription regulation and animal diversity. *Nature* 424, 147-  
840 151.
- 841 Li, H. (2013). Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM.  
842 arXiv preprint arXiv:13033997.
- 843 Loiselle, F.B., and Casey, J.R. (2010). Measurement of Intracellular pH. *Methods Mol Biol* 637,  
844 311-331.

- 845 Lovejoy, C.A., Xu, X., Bansbach, C.E., Glick, G.G., Zhao, R., Ye, F., Sirbu, B.M., Titus, L.C.,  
846 Shyr, Y., and Cortez, D. (2009). Functional genomic screens identify CINP as a genome  
847 maintenance protein. *Proc Natl Acad Sci U S A* *106*, 19304-19309.
- 848 Magnan, D., Joshi, M.C., Barker, A.K., Visser, B.J., and Bates, D. (2015). DNA Replication  
849 Initiation Is Blocked by a Distant Chromosome-Membrane Attachment. *Curr Biol* *25*, 2143-  
850 2149.
- 851 Makarova, K.S., and Koonin, E.V. (2013). Archaeology of eukaryotic DNA replication. *Cold*  
852 *Spring Harb Perspect Biol* *5*, a012963.
- 853 Maor-Shoshani, A., Reuven, N.B., Tomer, G., and Livneh, Z. (2000). Highly mutagenic  
854 replication by DNA polymerase V (UmuC) provides a mechanistic basis for SOS untargeted  
855 mutagenesis. *Proc Natl Acad Sci U S A* *97*, 565-570.
- 856 McClure, R., Balasubramanian, D., Sun, Y., Bobrovskyy, M., Sumbly, P., Genco, C.A.,  
857 Vanderpool, C.K., and Tjaden, B. (2013). Computational analysis of bacterial RNA-Seq data.  
858 *Nucleic Acids Res* *41*, e140.
- 859 McPartland, A., Green, L., and Echols, H. (1980). Control of *recA* gene RNA in *E. coli*:  
860 regulatory and signal genes. *Cell* *20*, 731-737.
- 861 Merrikh, H., Zhang, Y., Grossman, A.D., and Wang, J.D. (2012). Replication-transcription  
862 conflicts in bacteria. *Nat Rev Microbiol* *10*, 449-458.
- 863 Michaels, M.L., Pham, L., Cruz, C., and Miller, J.H. (1991). MutM, a protein that prevents G.C--  
864 --T.A transversions, is formamidopyrimidine-DNA glycosylase. *Nucleic Acids Res* *19*, 3629-  
865 3632.
- 866 Miller, J. (1993). A short course in bacterial genetics: a laboratory manual and handbook for  
867 *Escherichia coli* and related bacteria. *Trends in Biochemical Sciences-Library Compendium* *18*,  
868 193.
- 869 Mortusewicz, O., Schermelleh, L., Walter, J., Cardoso, M.C., and Leonhardt, H. (2005).  
870 Recruitment of DNA methyltransferase I to DNA repair sites. *Proc Natl Acad Sci U S A* *102*,  
871 8905-8909.
- 872 Nehring, R.B., Gu, F., Lin, H.Y., Gibson, J.L., Blythe, M.J., Wilson, R., Bravo Nunez, M.A.,  
873 Hastings, P.J., Louis, E.J., Frisch, R.L., *et al.* (2016). An ultra-dense library resource for rapid  
874 deconvolution of mutations that cause phenotypes in *Escherichia coli*. *Nucleic Acids Res* *44*,  
875 e41.
- 876 Ogasawara, H., Yamamoto, K., and Ishihama, A. (2011). Role of the biofilm master regulator  
877 CsgD in cross-regulation between biofilm formation and flagellar synthesis. *J Bacteriol* *193*,  
878 2587-2597.

- 879 Paulsen, R.D., Soni, D.V., Wollman, R., Hahn, A.T., Yee, M.C., Guan, A., Hesley, J.A., Miller,  
880 S.C., Cromwell, E.F., Solow-Cordero, D.E., *et al.* (2009). A genome-wide siRNA screen reveals  
881 diverse cellular processes and pathways that mediate genome stability. *Mol Cell* 35, 228-239.
- 882 Pennington, J.M., and Rosenberg, S.M. (2007). Spontaneous DNA breakage in single living  
883 *Escherichia coli* cells. *Nat Genet* 39, 797-802.
- 884 Pickering, M.T., and Kowalik, T.F. (2006). Rb inactivation leads to E2F1-mediated DNA  
885 double-strand break accumulation. *Oncogene* 25, 746-755.
- 886 Putnam, C.D., Srivatsan, A., Nene, R.V., Martinez, S.L., Clotfelter, S.P., Bell, S.N., Somach,  
887 S.B., de Souza, J.E., Fonseca, A.F., de Souza, S.J., *et al.* (2016). A genetic network that  
888 suppresses genome rearrangements in *Saccharomyces cerevisiae* and contains defects in cancers.  
889 *Nat Commun* 7, 11256.
- 890 Rahman, M., Jackson, L.K., Johnson, W.E., Li, D.Y., Bild, A.H., and Piccolo, S.R. (2015).  
891 Alternative preprocessing of RNA-Sequencing data in The Cancer Genome Atlas leads to  
892 improved analysis results. *Bioinformatics* 31, 3666-3672.
- 893 Ramirez, F., Dundar, F., Diehl, S., Gruning, B.A., and Manke, T. (2014). deepTools: a flexible  
894 platform for exploring deep-sequencing data. *Nucleic Acids Res* 42, W187-191.
- 895 Reams, A.B., Kofoid, E., Savageau, M., and Roth, J.R. (2010). Duplication frequency in a  
896 population of *Salmonella enterica* rapidly approaches steady state with or without recombination.  
897 *Genetics* 184, 1077-1094.
- 898 Renzette, N., Gumlaw, N., Nordman, J.T., Krieger, M., Yeh, S.P., Long, E., Centore, R.,  
899 Boonsombat, R., and Sandler, S.J. (2005). Localization of RecA in *Escherichia coli* K-12 using  
900 RecA-GFP. *Mol Microbiol* 57, 1074-1085.
- 901 Saito, Y., Uraki, F., Nakajima, S., Asaeda, A., Ono, K., Kubo, K., and Yamamoto, K. (1997).  
902 Characterization of endonuclease III (nth) and endonuclease VIII (nei) mutants of *Escherichia*  
903 *coli* K-12. *J Bacteriol* 179, 3783-3785.
- 904 Saka, K., Tadenuma, M., Nakade, S., Tanaka, N., Sugawara, H., Nishikawa, K., Ichiyoshi, N.,  
905 Kitagawa, M., Mori, H., Ogasawara, N., *et al.* (2005). A complete set of *Escherichia coli* open  
906 reading frames in mobile plasmids facilitating genetic studies. *DNA Res* 12, 63-68.
- 907 Sakaguchi, K., Herrera, J.E., Saito, S., Miki, T., Bustin, M., Vassilev, A., Anderson, C.W., and  
908 Appella, E. (1998). DNA damage activates p53 through a phosphorylation-acetylation cascade.  
909 *Genes Dev* 12, 2831-2841.
- 910 Schmidt, K., Wolfe, D.M., Stiller, B., and Pearce, D.A. (2009). Cd<sup>2+</sup>, Mn<sup>2+</sup>, Ni<sup>2+</sup> and Se<sup>2+</sup>  
911 toxicity to *Saccharomyces cerevisiae* lacking YPK9p the orthologue of human ATP13A2.  
912 *Biochem Biophys Res Commun* 383, 198-202.
- 913 Seigneur, M., Bidnenko, V., Ehrlich, S.D., and Michel, B. (1998). RuvAB acts at arrested  
914 replication forks. *Cell* 95, 419-430.

- 915 Serres, M.H., Gopal, S., Nahum, L.A., Liang, P., Gaasterland, T., and Riley, M. (2001). A  
916 functional update of the *Escherichia coli* K-12 genome. *Genome Biol* 2, RESEARCH0035.
- 917 Shee, C., Cox, B.D., Gu, F., Luengas, E.M., Joshi, M.C., Chiu, L.Y., Magnan, D., Halliday, J.A.,  
918 Frisch, R.L., Gibson, J.L., *et al.* (2013). Engineered proteins detect spontaneous DNA breakage  
919 in human and bacterial cells. *Elife* 2, e01222.
- 920 Sottoriva, A., Kang, H., Ma, Z., Graham, T.A., Salomon, M.P., Zhao, J., Marjoram, P.,  
921 Siegmund, K., Press, M.F., Shibata, D., *et al.* (2015). A Big Bang model of human colorectal  
922 tumor growth. *Nat Genet* 47, 209-216.
- 923 Stanton, R.C. (2012). Glucose-6-phosphate dehydrogenase, NADPH, and cell survival. *IUBMB*  
924 *Life* 64, 362-369.
- 925 Steighner, R.J., and Povirk, L.F. (1990). Bleomycin-induced DNA lesions at mutational hot  
926 spots: implications for the mechanism of double-strand cleavage. *Proc Natl Acad Sci U S A* 87,  
927 8350-8354.
- 928 Stern, M.J., Ames, G.F., Smith, N.H., Robinson, E.C., and Higgins, C.F. (1984). Repetitive  
929 extragenic palindromic sequences: a major component of the bacterial genome. *Cell* 37, 1015-  
930 1026.
- 931 Stratton, M.R. (2011). Exploring the genomes of cancer cells: progress and promise. *Science*  
932 331, 1553-1558.
- 933 Sun, G., Chung, D., Liang, K., and Keles, S. (2013). Statistical analysis of ChIP-seq data with  
934 MOSAiCS. *Methods Mol Biol* 1038, 193-212.
- 935 Szklarczyk, D., Franceschini, A., Wyder, S., Forslund, K., Heller, D., Huerta-Cepas, J.,  
936 Simonovic, M., Roth, A., Santos, A., Tsafou, K.P., *et al.* (2015). STRING v10: protein-protein  
937 interaction networks, integrated over the tree of life. *Nucleic Acids Res* 43, D447-452.
- 938 Tehranchi, A.K., Blankschien, M.D., Zhang, Y., Halliday, J.A., Srivatsan, A., Peng, J., Herman,  
939 C., and Wang, J.D. (2010). The transcription factor DksA prevents conflicts between DNA  
940 replication and transcription machinery. *Cell* 141, 595-605.
- 941 Thomason, L.C., Costantino, N., and Court, D.L. (2007). *E. coli* genome manipulation by P1  
942 transduction. *Curr Protoc Mol Biol* Chapter 1, Unit 1 17.
- 943 Tipparaju, S.M., Liu, S.Q., Barski, O.A., and Bhatnagar, A. (2007). NADPH binding to beta-  
944 subunit regulates inactivation of voltage-gated K(+) channels. *Biochem Biophys Res Commun*  
945 359, 269-276.
- 946 Torkelson, J., Harris, R.S., Lombardo, M.J., Nagendran, J., Thulin, C., and Rosenberg, S.M.  
947 (1997). Genome-wide hypermutation in a subpopulation of stationary-phase cells underlies  
948 recombination-dependent adaptive mutation. *EMBO J* 16, 3303-3311.



- 949 Tubbs, A., and Nussenzweig, A. (2017). Endogenous DNA Damage as a Source of Genomic  
950 Instability in Cancer. *Cell* 168, 644-656.
- 951 Uchida, K., Furukohri, A., Shinozaki, Y., Mori, T., Ogawara, D., Kanaya, S., Nohmi, T., Maki,  
952 H., and Akiyama, M. (2008). Overproduction of Escherichia coli DNA polymerase DinB (Pol  
953 IV) inhibits replication fork progression and is lethal. *Mol Microbiol* 70, 608-622.
- 954 Vafa, O., Wade, M., Kern, S., Beeche, M., Pandita, T.K., Hampton, G.M., and Wahl, G.M.  
955 (2002). c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53  
956 function: a mechanism for oncogene-induced genetic instability. *Mol Cell* 9, 1031-1044.
- 957 Wagner, J., Fujii, S., Gruz, P., Nohmi, T., and Fuchs, R.P. (2000). The beta clamp targets DNA  
958 polymerase IV to DNA and strongly increases its processivity. *EMBO Rep* 1, 484-488.
- 959 Wagner, J., Gruz, P., Kim, S.R., Yamada, M., Matsui, K., Fuchs, R.P., and Nohmi, T. (1999).  
960 The dinB gene encodes a novel E. coli DNA polymerase, DNA pol IV, involved in mutagenesis.  
961 *Mol Cell* 4, 281-286.
- 962 Wagner, J., and Nohmi, T. (2000). Escherichia coli DNA polymerase IV mutator activity:  
963 genetic requirements and mutational specificity. *J Bacteriol* 182, 4587-4595.
- 964 Wahba, L., Costantino, L., Tan, F.J., Zimmer, A., and Koshland, D. (2016). S1-DRIP-seq  
965 identifies high expression and polyA tracts as major contributors to R-loop formation. *Genes*  
966 *Dev* 30, 1327-1338.
- 967 Xia, J., Chen, L.T., Mei, Q., Ma, C.H., Halliday, J.A., Lin, H.Y., Magnan, D., Pribis, J.P.,  
968 Fitzgerald, D.M., Hamilton, H.M., *et al.* (2016). Holliday junction trap shows how cells use  
969 recombination and a junction-guardian role of RecQ helicase. *Sci Adv* 2, e1601605.
- 970 Yang, X., Boehm, J.S., Yang, X., Salehi-Ashtiani, K., Hao, T., Shen, Y., Lubonja, R., Thomas,  
971 S.R., Alkan, O., Bhimdi, T., *et al.* (2011). A public genome-scale lentiviral expression library of  
972 human ORFs. *Nat Methods* 8, 659-661.
- 973 Yeeles, J.T., Poli, J., Mariani, K.J., and Pasero, P. (2013). Rescuing stalled or damaged  
974 replication forks. *Cold Spring Harb Perspect Biol* 5, a012815.
- 975 Yuen, K.W., Warren, C.D., Chen, O., Kwok, T., Hieter, P., and Spencer, F.A. (2007). Systematic  
976 genome instability screens in yeast and their potential relevance to cancer. *Proc Natl Acad Sci U*  
977 *S A* 104, 3925-3930.
- 978 Zack, T.I., Schumacher, S.E., Carter, S.L., Cherniack, A.D., Saksena, G., Tabak, B., Lawrence,  
979 M.S., Zhsng, C.Z., Wala, J., Mermel, C.H., *et al.* (2013). Pan-cancer patterns of somatic copy  
980 number alteration. *Nat Genet* 45, 1134-1140.
- 981
- 982 **AUTHOR CONTRIBUTIONS**
- 983 Conceptualization, S.M.R., J.X., K.M.M., L-Y.C., C.H.; Methodology, J.X., S.M.R., C.H., R.B.N.,  
984 M.A.B., J.P.P., Y.Z., Y.W., Q.M., R.T.P., A.J., C.W.H., M.L.M.G., D.M.F., C.C., M.A.M., K.L.S.,  
985 H.L., C.Q.; A.T.S., D.B., S.G.H., J.C.H., D.A.S; Investigation, J.X., L-Y.C., R.B.N., M.A.B.N.,


986 Q.M., C.W.H., M.P., D.M.F., J.P.P., Y.Z., Y.W., Q.M., A.J., A.M.L., C.W.H., M.L.M.G., M.C.J.,  
987 M.R.; Writing – Original Draft, S.M.R., J.X., K.M.M., L-Y.C.; Writing – Review & Editing, all  
988 authors; Funding Acquisition, S.M.R., K.M.M, C.H., D.B., P.J.H., C.Q., K.L.S., H.L., C.C.,  
989 M.A.M., D.M.F.

990

## 991 **ACKNOWLEDGEMENTS**

992 Sequencing data are available in the European Nucleotide Archive (ENA) under study accession  
993 no. PRJEB21034 (RNA-Seq), PRJEB21035 (ChIP-Seq). A pre-publication draft of the *E. coli*-to-  
994 Cancer Gene-function Atlas (ECGA) is available to reviewers prepublication at  
995 <https://microbialphenotypes.org/wiki/index.php/Special:ECGA>) at which the complete ECGA  
996 will be publically available after publication.

997 This paper is dedicated to the memory of our coauthor, colleague and friend Ken Scott whose  
998 scientific acumen, intensity, and generosity inspired us. We thank M Ellis, G Ira, H Dierick, V  
999 Lundblad, RS Harris, M Wang, H Zoghbi, and C Zong for helpful comments on the manuscript,  
1000 M Yamada and T Nohmi for antiserum against Pol IV, and I Matic, SJ Sandler and JD Wang for  
1001 bacterial strains. This work was supported by a National Institutes of Health (NIH) Director's  
1002 Pioneer Award DP1-CA174424 (SMR), a gift from the WM Keck Foundation (SMR, KMM), and  
1003 the following grants: an NIH Director's New Innovator Award DP20-OD008371 (CQ); R01-  
1004 GM102679 (DB); NIH grant R01-GM088653 (CH); R01-GM089636 (JCH, DAS); R01-  
1005 GM106373 (PJH); R35-GM122598 (SMR); Cancer Prevention and Research Institute of Texas  
1006 (CPRIT) grants R1116 (KMM); RP170295 and RP170005 (CC); RP150578 (MAM); RP140553  
1007 (SMR, KMM); and RP160283 Baylor College of Medicine Comprehensive Cancer Training  
1008 Program Postdoctoral Fellowship (DMF); and RP150578 (MAM); NIH U01-CA168394 (KLS);  
1009 NIH/NCI R01CA175486, U24 CA209851, and CPRIT RP140462 to HL; the National Aeronautics  
1010 and Space Administration through the NASA Astrobiology Institute under Cooperative Agreement  
1011 No. NNA13AA91A issued through the Science Mission Directorate (PJH); the BCM Cytometry  
1012 and Cell Sorting Core with funding from the NIH P30-AI036211, P30-CA125123, and S10-  
1013 RR024574; and the BCM Integrated Microscopy Core with funding from the NIH HD007495,  
1014 DK56338, and CA125123; the Dan L Duncan Comprehensive Cancer Center, and the John S.  
1015 Dunn Gulf Coast Consortium for Chemical Genomics.  
1016



1018 **Figure 1. Comprehensive Discovery of *E. coli* DNA-Damaging-Protein Network**

1019 (A) We sought comprehensive identification of gain-of-function *E. coli* “DNA-damaging”  
1020 proteins (DDPs): proteins that provoke DNA damage when overproduced, modeling frequent  
1021 protein overproduction via various mechanisms common in cancers and bacteria. Although  
1022 hypotheses for the origins of endogenous DNA damage have been suggested (shown), how these  
1023 may arise, whether they are common naturally/spontaneously, and what proteins cause them are  
1024 unclear.

1025 (B) Scheme of *E. coli* comprehensive overproduction screen for DDPs. (1) Primary screen: the  
1026 complete *E. coli* overexpression Mobile library was screened by plate reader for increased  
1027 fluorescence from an SOS-DNA-damage-response-reporter gene, *P<sub>sulAm</sub>Cherry* (Nehring et al.,  
1028 2016). (2) Secondary screen: potential positive clones from the primary screen were validated,  
1029 and false-positives eliminated, by sensitive flow-cytometric assay, which reports fluorescence per  
1030 cell at the single-cell level.

1031 (C) Representative results of primary plate-reader screen: afu, arbitrary fluorescence units (SOS  
1032 activity), per OD<sub>600</sub> unit, indicating biomass. Red, potential “damage-up” DDP hits with fold  
1033 change >30%.

1034 (D) Representative flow-cytometric validation of SOS-positive (DDP) overexpression clones from  
1035 plate-reader screens. Dashed line, flow cytometry “gate” above which cells are scored as SOS-  
1036 positive (STAR Methods). Validated DDP clones have significantly higher frequencies of SOS-  
1037 positive cells than the vector control. Blue, vector control; red, DDP-overproduction clones.

1038 (E) Quantification of increased DNA damage measured as % SOS-positive cells in the 208  
1039 validated *E. coli* DDP clones (identities with data, Table S1).

1040 (F) *E. coli* DDP network summary; proteins of many different functions are DDPs. Functions of  
1041 the 208 *E. coli* DDPs (Table S1). Few (8%) are known DNA-repair proteins (blue, Table S1).

1042 (G) Protein-protein associations of the *E. coli* over-production DDP network, CytoScape software  
1043 generated from STRING 10.0 database. Other, defined Table S1; specific protein associations,  
1044 Figure S2 (discussed, text).


1045 (H) LexA-dependence of increased fluorescence of representative DDPs shows that fluorescence  
1046 results from activation of the SOS DNA-damage response.

1047 (I) Correlation of DDP (SOS-positive) phenotype with RecA\*GFP foci, indicating persistent  
1048 single-stranded (ss)DNA. A representative sample of 67 DDPs overproduced showed 32 (48%)  
1049 with significantly more RecA\*GFP foci than the vector control ( $p < 0.05$ , unpaired two-tail  $t$ -test),  
1050 a less sensitive assay than the stringent flow-cytometric assay for SOS-positive cells. RecA\*GFP  
1051 foci are correlated positively with the SOS-response assay:  $r = 0.7$ ,  $p = 1.3 \times 10^{-10}$ , Pearson’s  
1052 correlation. **Left**, DDP clones assayed. Each dot, one DDP clone, assayed twice (mean). Blue,  
1053 negative control; orange, low SOS activity (DNA damage); green moderate DNA damage; purple,  
1054 high DNA damage, strain-by-strain data, Table S1. **Right**, representative foci.


1055 (J) Mutation-rate increase in representative DDP-overproducing clones. Above, *cI* mutation assay  
1056 design (Gutierrez et al., 2013). Loss-of-function mutations in a chromosomal *cI* gene, encoding  
1057 phage lambda transcriptional repressor, allow transcription of *tetA*, which confers tetracycline  
1058 resistance (TetR) (STAR Methods). Below, increased mutation rates are associated with increased  
1059 DNA-damage levels (SOS induction, flow-cytometric assay) in *E. coli* DDP-overproducing  
1060 clones. Each bar, the mean mutation rate ( $\pm$  SEM) of each strain, 3 experiments (fluctuation tests,  
1061 STAR Methods). The DDPs overproduced (Supplemental Discussion 3) represent various classes  
1062 (Table S1). Table S1 for mutation rates.  $P$ -values, one-way Fisher’s exact test of the number of

1063 clones with mutation rate significantly higher than the vector-only control (unpaired 2-tailed  
1064 Student's *t*-test).  
1065

1066




1067 **Figure 2. Human Homologs of *E. coli* DDPs a Network Associated with Cancers**  
1068 (A) Summary of 284 human proteins identified as homologs of *E. coli* DDPs (STAR Methods).  
1069 Only 5.6% are known DNA-repair genes (blue, Table S2).  
1070 (B) Protein-protein association network of human homologs of *E. coli* DDPs (Figure S2 for  
1071 specific interactions). Network displayed per Figure 1G. Other, defined Table S2.  
1072 (C) Human homologs of *E. coli* DDPs (hDDP candidates) are significantly overrepresented among  
1073 known (Forbes et al., 2015) and predicted (D'Antonio and Ciccarelli, 2013) cancer drivers (blue  
1074 bar). After subtracting known DNA-repair (“caretaker”) genes, the remaining hDDP candidate  
1075 genes are still enriched for known and predicted cancer drivers (red bar).  
1076 (D) hDDP candidate genes are enriched among genes with cancer-associated copy-number  
1077 increases, indicating selection for overexpression in cancers. Pan-Cancer copy-number-increase  
1078 analysis (GISTIC threshold copy-number gain  $\geq 1$ ) of the 284 hDDP candidates in 26 cancer types  
1079 (per Figure S3). Blue, human genes with increased copy numbers across cancers ( $p < 0.05$ , FDR  
1080  $< 0.10$ , Wilcoxon test); orange, genes with cancer-specific copy-number increase; grey, not  
1081 particularly cancer associated. Complete data for the network Table S4.  
1082 (E) Decreased cancer survival is associated with high DDP-homolog RNA levels in cancers [our  
1083 analyses of data from TCGA (Gao et al., 2013), STAR Methods]. BRCA, breast invasive  
1084 carcinoma; LGG+GBM, gliomas (low-grade glioma + glioblastoma multiforme); HNSC, head and  
1085 neck squamous cell carcinoma; UCEC, uterine corpus endometrial carcinoma. \*, \*\*, \*\*\*, survival  
1086 of the cancers with high and low levels of the 284 RNAs differ at  $p \leq 0.05$ ;  $\leq 0.01$ , and  $\leq 0.001$   
1087 respectively, log-rank test.  
1088 (F) High RNA levels of the 284 hDDP candidates are associated with tumor mutation burden in  
1089 data from TCGA (Gao et al., 2013). Each dot represents a Pearson correlation coefficient between  
1090 the RNA-enrichment score, relative to total RNAs, of a gene set and mutation burden in the tumor.  
1091 The average correlation strength of 284 hDDP-candidate RNA levels with mutation loads across  
1092 20 TCGA cancers was in the top 0.5% of correlations for randomly selected groups of genes across  
1093 all human genes. Blown-up: correlation of increased mutation loads (y axis) with increased hDDP-  
1094 candidate RNA enrichment scores (x axis, STAR Methods) in three represented cancers. Cancer-  
1095 types: OV ovarian serous cystadenocarcinoma; THCA thyroid carcinoma; COAD colon  
1096 adenocarcinoma; KIRC kidney renal clear cell carcinoma; KIRP kidney renal papillary cell  
1097 carcinoma; CESC cervical squamous cell carcinoma and endocervical adenocarcinoma; READ  
1098 rectum adenocarcinoma; BLCA bladder urothelial carcinoma; LAML acute myeloid leukemia;  
1099 LIHC liver hepatocellular carcinoma; SKCM skin cutaneous melanoma; LUSC lung squamous  
1100 cell carcinoma; PRAD prostate adenocarcinoma; STAD stomach adenocarcinoma; LUAD lung  
1101 adenocarcinoma.  
1102  
1103





1105 **Figure 3. Overproduced Human Homologs Promote DNA Damage in Human Cells**  
1106 (A) Scheme for validating hDDPs. 70 full-length sequence-verified human homolog candidate-  
1107 hDDP-GFP N-terminal fusions (and 3 damage-down-, plus 20 non-DDP-GFP fusion controls)  
1108 were transiently overproduced in MRC5-SV40 or HEK293T cell lines and green cells screened  
1109 for high DNA damage by flow cytometry.  
1110 (B) DNA-damage assays with candidate hDDPs identify 33 validated hDDPs. **Upper:**  
1111 representative flow cytometric DNA-damage assay data ([STAR Methods](#), [Figure S3G-I](#); [Table](#)  
1112 [S6](#)). **Lower:** heatmap of the flow-cytometric data normalized to GFP-tubulin. Data from each of  
1113 the three DNA-damage assays, with 2 replicates each, ranked by a cumulative DNA-damage score  
1114 that sums the fold changes of each DNA-damage assay for each candidate protein. Highlighting  
1115 colors: green, significantly damage-up in  $\geq 2$  assays (two-tailed unpaired *t*-test with FDR  
1116 correction); gray, significantly damage-up in one assay; yellow, homologs of *E. coli* damage-down  
1117 proteins; white, not damage-up. 45% validated, significantly more than among 20 random human  
1118 genes ( $p < 0.0001$ , two-tailed unpaired *t*-test with FDR correction, [Figure S3G-I](#)), indicating that  
1119 homologs of *E. coli* DDPs are enriched for hDDPs.  
1120 (C) Increased mutation rates in human cells overproducing validated hDDPs, assayed by human-  
1121 cell *HPRT* forward-mutation assays in fluctuation tests ([STAR Methods](#)). **Upper:** *HPRT* assay  
1122 scheme. *HPRT* loss-of-function mutants are selected as 6-thioguanine (6-TG)-resistant clones.  
1123 **Lower:** mutation rates of selected hDDP overproducers shown with their DNA-damage levels;  
1124 error bars, 95% confidence intervals.  
1125 (D) Validated hDDP genes are enriched among genes with cancer-associated copy-number  
1126 increases compared with the candidates that were tested but not validated ( $p = 0.02$ , one-way  
1127 Fisher's exact test).  
1128 (E) New and known potential cancer-promoters predicted among 33 validated hDDPs. The 33  
1129 validated hDDP genes comprise genes that are—(i) both amplified in TCGA cancers and known  
1130 ([Forbes et al., 2015](#)) or predicted ([D'Antonio and Ciccarelli, 2013](#)) cancer drivers (16%); (ii)  
1131 amplified in TCGA cancers and were not known or predicted cancer-driving genes (53%); (iii)  
1132 known or predicted cancer drivers that are not found to be amplified in cancers (6%); and (iv) not  
1133 found to be amplified in cancers in TCGA, and not known or predicted cancer drivers (25%). The  
1134 data suggest potential overexpression cancer-promoting roles for the genes in all classes.  
1135  
1136



1137 **Figure 4. Kinds, Causes and Consequences of DNA Damage from *E. coli* DDPs Reveal**  
 1138 **Function Clusters**

1139 **Figure 4. Kinds, Causes and Consequences of DNA Damage from *E. coli* DDPs Reveal**  
1140 **Function Clusters**

1141 (A) Identification of DDPs that increase DNA double-strand breaks (DSBs), detected as GamGFP  
1142 foci, per (Shee et al., 2013). Representative image in cells overproducing DDP XanQ, a membrane-  
1143 spanning transporter. Diagram: lines, DNA strands; green balls, GamGFP.

1144 (B) 87 of the 208 *E. coli* DDPs promote DSBs. Quantification of GamGFP foci in 208 DDP-  
1145 overproducing clones (means of two experiments, >1000 cells each; data by clone Table S1).

1146 (C) Detection of stalled, reversed replication forks (RFs) as RDG foci in *recA* cells. Engineered  
1147 protein RuvCDefGFP (RDG) traps 4-way DNA-junctions, and in *recA* cells detects only RFs (Xia  
1148 et al., 2016). Representative image in cells overproducing DDP CsgD. Diagram: lines, DNA  
1149 strands; red lines, newly synthesized strands; green balls, RDG.

1150 (D) 106 of the 208 *E. coli* DDPs cause fork stalling and reversal. Quantification of RDG foci in  
1151 208 DDP-overproducing clones (data by clone, Table S1).

1152 (E-I) Flow-cytometric assays for—

1153 (E) elevated ROS measured as peroxide by dihydrorhodamine (DHR) fluorescence. Representative  
1154 flow-cytometric histogram, XanQ overproducer, and

1155 (F) quantified in all 208 DDP-overproducing clones, mean fluorescence intensity; afu, arbitrary  
1156 fluorescence units (2 experiments, mean) shows 56 (27%) of DDP clones (data by clone, Table  
1157 S1).

1158 (G) Increased DNA damage in 16 of 56 high-ROS DDP clones is reduced by ROS-quenching  
1159 agent thiourea (TU) indicating that the high ROS underlie the DNA damage. *P* values, unpaired  
1160 two-tailed *t* test. Data by clone, Table S1.

1161 (H) DNA loss: the fraction of cells with no DNA (anucleate cells), representative example, Pol IV  
1162 overproducer (DAPI indicates DNA, membrane dye FM464 indicates cells); events below the  
1163 horizontal line scored as anucleate, DNA loss,

1164 (I) quantified in all 208 DDP-overproducing clones (2 experiments, mean), showing 67 (32%) of  
1165 DDP clones (data by clone, Table S1).

1166 (J-L) Sensitivity to DNA-damaging agents in DDP-overproducing clones implies DNA-repair-  
1167 pathway reduction (possible saturation) as a potential consequence of elevated DNA damage.  
1168 Positive controls: relevant DNA-repair-defective mutants indicated. Each measured as slowed  
1169 growth curves per J left (STAR Methods). Data by clone, Table S1.

1170 (J) Phleomycin sensitivity (reduced homology-directed DSB repair) seen in 106 of the DDP clones  
1171 (51%).


1172 (K) Mitomycin C (MMC) sensitivity (reduced nucleotide-excision repair and/or homology-  
1173 directed repair) seen 10 of the DDP clones (5%).

1174 (L) H<sub>2</sub>O<sub>2</sub> sensitivity (reduced base-excision repair) seen in 75 of the DDP clones (36%).

1175 (M) Stalled replication (RFs) is clustered among particular DDP overproducers; DNA breakage is  
1176 not. Progeny clustering (STAR Methods).

1177 (N) Cluster analysis of Z (significance) scores of assays: H<sub>2</sub>O<sub>2</sub>, hydrogen-peroxide sensitivity;  
1178 Phleo, phleomycin sensitivity; DNA loss (anucleate cells); ROS (ROS levels); MMC, mitomycin-  
1179 C sensitivity; RFs (reversed forks), RDG (RF) foci; DSBs, GamGFP (DSB) foci. Vertical bars  
1180 along the x axis: the phenotype of each DDP clone. The 6 clusters indicate 6 DNA-damage  
1181 signatures and suggest at least 6 different mechanisms of DNA-damage generation in the DDP  
1182 network. Protein categories significantly increased in each cluster shown above (one-way Fisher's  
1183 exact test), cluster 2 at *p* = 0.01, cluster 4 at *p* = 0.01, and clusters 5 and 6 at *p* = 0.03.

1184




1185 **Figure 5. *E. coli* Transcription Factors Promote Replication-fork Stalling and Reversal**  
 1186 **DNA-binding-domain Dependently**

1187 (A) DNA-binding transcription factors (TFs) are enriched among DDP clones with high RFs ( $p$   
 1188 =0.002, one-way Fisher's exact test).

1189 (B) DNA-binding ability is required for DNA damage/SOS activity caused by overproduced DNA-  
 1190 binding TFs. Representative flow cytometry histograms of SOS induction, three TFs and their  
 1191 corresponding mutants: ΔDBD, DNA-binding domain in-frame deletion; D59N, D59E, single  
 1192 amino-acid changes that reduce CsgD DNA-binding (Ogasawara et al., 2011).

1193 (C) Mean  $\pm$  SEM of  $\geq 3$  experiments.  
1194 (D) DNA-binding ability of overproduced TFs is required for increased RDG (RF) foci (blue  
1195 arrows). Representative images. [Figure S6A](#), all genotypes.  
1196 (E) Mean  $\pm$  SEM of  $\geq 3$  experiments.  
1197 (F and G) mCherry-protein fusions of DNA-binding TFs form foci that co-localize with RDG (RF)  
1198 foci, placing TF binding and RFs in relative proximity (within 50kb, text) in the 4.6MB *E. coli*  
1199 genome.  
1200 (F) Representative data. CsgD-mCherry foci co-localize with RDG foci dependently on the CsgD  
1201 DNA-binding domain (DBD). Blue arrows, co-localized red and green (CsgD-mCherry and RDG)  
1202 foci. [Figure S6B](#), all genotypes.  
1203 (G) Mean  $\pm$  SEM of  $\geq 3$  experiments with CsgD-, HcaR-, and YahB-mCherry co-localization with  
1204 RDG.  
1205 (H) Co-localization of CsgD-mCherry foci with RDG foci requires CsgD DNA-binding ability;  
1206 quantification.  
1207 (I) RDG ChIP-Seq peaks in HR-defective  $\Delta recA$  cells (RFs) are enriched near CsgD-binding sites  
1208 (green squares;  $p = 0.01$ , two-tailed z-test compared with simulated data, see [Supplemental](#)  
1209 [Discussion 12](#)). Representative peaks shown; [Figure S7](#) for the complete set of RF peaks.  
1210 (J) Model: overproduced TFs (orange circles) binding to DNA (parallel lines, basepaired strands)  
1211 cause RFs by replication roadblock. Green circles, RDG bound to RF.  
1212



1214 **Figure 6. *E. coli* and Human Transmembrane Transporters Promote DNA Damage via**  
1215 **Increased ROS**

1216 (A) *E. coli* high ROS cluster is enriched for membrane-spanning transporters ( $p = 0.004$  one-way  
1217 Fisher's exact test).

1218 (B) DNA damage (SOS activity) from five overproduced *E. coli* transporters is partially reversed  
1219 by ROS-scavenger thiourea (TU), implying ROS-dependent DNA damage. Quantification of flow  
1220 cytometry per blow up. Mean  $\pm$  range, 2 experiments. Blow up: representative flow cytometry for  
1221 DNA damage: cells with chromosomal SOS-promoter-mCherry fusion.

1222 (C) ROS levels increase upon overproduction of various *E. coli* membrane-spanning transporters.  
1223 ROS measured as H<sub>2</sub>O<sub>2</sub> shown by DHR stain and flow cytometry. Representative data (Table S1  
1224 for all). Gray, vector only; red, H<sup>+</sup> symporters; green, ion transporter; cyan, polypeptide  
1225 transporter.

1226 (D) Means  $\pm$  range of 2 experiments.

1227 (E-H) Increased *E. coli* H<sup>+</sup> symporter activity is caused by overproduction, shown by reduced  
1228 cellular pH. (E) Detection of *E. coli* intracellular pH by pHrodo-green dye staining followed by  
1229 flow cytometry. Cells with the vector were exposed to buffers with varied pH levels and pHrodo-  
1230 green dye was used to stain the cells. Control vector-bearing cells exposed to low pH cells had  
1231 subpopulations with increased pHrodo-green intensity.

1232 (F, G) Reduced intracellular pH in clones overproducing the PlaP, XanQ, or NanT H<sup>+</sup> symporters,  
1233 or the TatB polypeptide transporter, indicates that overproduction causes gain-of-function, overall  
1234 increased activity per cell of these transporters. Cyan, vector only. (F) Quantification: mean  $\pm$   
1235 range of two experiments. (G) Representative flow-cytometry histograms.


1236 (H) Reduced pH in *E. coli* transporter-overproducing clones—the three H<sup>+</sup> symporters and TatB  
1237 polypeptide transporter—is not correlated quantitatively with increased ROS ( $R^2=0.05$ , Pearson's  
1238 correlation analysis), suggesting that the specific cargoes, not low pH, promote DNA damage.

1239 (I) Models for ROS-dependent DNA-damage promotion by overproduction of the *E. coli* XanQ  
1240 and CorA transporters. Left: Overproduced H<sup>+</sup> symporter XanQ might cause ROS by increased  
1241 import of xanthine which is oxidized by the ROS-generating xanthine oxidase (Kelley et al., 2010).  
1242 Right: CorA overproduction might cause DNA damage via increased import of Ni<sup>2+</sup>, which inhibits  
1243 anti-oxidative enzymes (Schmidt et al., 2009) and causes DNA damage ROS-dependently  
1244 (Cameron et al., 2011).

1245 (J) Overproduced validated human (h)DDPs are localized in various subcellular compartments,  
1246 implying various DDP mechanisms. Of the 33 overproduced validated hDDPs, 16 were detected  
1247 only in the cytoplasm, 10 only in the nucleus, and 7 throughout the cell. All show qualitatively  
1248 repeatable subcellular localization.

1249 (K) ROS underlie at least some of the DNA damage caused by human KCNAB1/2 transporter  
1250 overproduction. NAC: N-acetyl-cysteine, an ROS quencher (STAR Methods). \*  $p < 0.05$  relative  
1251 to the NAC-untreated GFP-tubulin control; \*  $p < 0.05$  relative to the corresponding NAC-untreated  
1252 control.

1253



1254  
1255  
1256  
1257

**Figure 7. *E. coli* DNA Pol IV and Human DNMT1 Promote DNA Damage via Interaction with the Replisome Clamp**

(A) *E. coli* function cluster with high DNA loss includes DNA Pol IV.



1258 (B) *E. coli* Pol IV promotion of DNA damage is reduced by co-overproduction of its competitor  
1259 at the replisome, DNA Pol II (left). Right: Pol IV promotion of DNA damage requires its  
1260 interaction with beta replisome sliding clamp, seen by dependence on the Pol IV beta clamp-  
1261 binding domain (BBD), and is partly independent of Pol IV catalytic activity (cat<sup>-</sup> mutant).  
1262 Representative data.  
1263 (C) Mean  $\pm$  SEM of  $\geq 3$  experiments.  
1264 (D) Reduction of *E. coli* Pol IV-induced DNA damage in a clamp loader tau-only mutant, which  
1265 interacts with replicative DNA Pol III in preference to Pol IV (Dohrmann et al., 2016). RecB- and  
1266 RecF-dependence of the SOS response induced by overproduced Pol IV implicates DSBs and  
1267 single-strand gaps, respectively, as DNA-damage types produced. Representative data.  
1268 (E) Mean  $\pm$  SEM of  $\geq 3$  experiments. Pol IV is induced by IPTG.  
1269 (F) The clamp-loader *dnaX* tau-only mutant is not generally deficient in SOS-response induction,  
1270 but merely reduces the DNA damage (SOS activity) caused by Pol IV upregulation (D, E).  
1271 (G) Neither the *E. coli* MutM 8-oxo-dG glycosylase nor the MutY adenine glycosylase are required  
1272 for DNA damage instigated by Pol IV, indicating DNA damage produced independently of  
1273 incorporation of 8-oxo-dG into DNA. Representative data, quantified (E).  
1274 (H) Constructs for production of human wild-type and truncated DNA methyltransferase DNMT1  
1275 in human cells. PBD, PCNA-binding domain; U, UHRF1, ubiquitin-like containing PHD and  
1276 RING-finger domains 1 binding domain; RFTS, replication-focus-targeting sequence, recruits  
1277 DNMT1 to DNA-methylation sites; Cat, catalytic domain for methyltransferase activity; C1226A,  
1278 mutation of the catalytic active site.  
1279 (I) Human DNMT1 overproduced in human cells promotes  $\gamma$ H2AX (DNA-break indicator)  
1280 accumulation methylase-independently and replisome-clamp-interaction dependently.  
1281 Overproduction of two DNMT1 catalytically dead mutants increased DNA damage similarly to  
1282 overproduced WT DNMT1. Overproduction of two other de novo DNA methyltransferases  
1283 (DNMT3A, DNMT3B) did not elevate DNA damage. DNA-damage promotion by DNMT1  
1284 requires the DNMT1 PBD domain, required for DNMT1 binding to the human replisome clamp:  
1285 PCNA.  
1286 (J) Human DNMT1 overproduction promotes PCNA monoubiquitination, a replication-stress  
1287 indicator, in a replisome-interaction-dependent manner. Monoubiquitination determined by  
1288 western blot with anti-PCNA antibody (STAR Methods).  
1289 (K) The endogenous DDP model for cancer promotion and mechanisms: DDPs a cancer-protein  
1290 functional class upstream of DNA repair. Excessive endogenous DNA damage is proposed to  
1291 titrate (thick blue -|) or inhibit (thin black -|) DNA repair causing DNA-repair (“caretaker”)-protein  
1292 deficiency in cells without a DNA-repair-gene mutation. Repair deficiency increases mutation rate,  
1293 leading to cancer- (or evolution-) driving mutations in the cell-biology altering “gatekeeper” genes  
1294 that cause the cancer cell-biological phenotypes.  
1295  
1296  
1297

1298 **STAR★METHODS**

1299 **KEY RESOURCES TABLE**

REAGENT or RESOURCE	SOURCE	IDENTIFIER
<b>Antibodies</b>		
anti-PCNA	Santa Cruz	sc-56
anti- $\gamma$ H2AX	Millipore	05-636
anti-phospho-P53	Cell Signaling	9286
anti-RAD18	Cell Signaling	9040S
anti-Tubulin	Abcam	ab6046
anti-GFP	ThermoFisher Scientific	A11122
Anti-rabbit IgG, HRP-linked Antibody	Cell Signaling	7074
Anti-mouse IgG, HRP-linked Antibody	Cell Signaling	7076
Goat anti-Mouse IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 647	Invitrogen	A21236
anti-Pol IV polyclonal	Kim et al., 2001	N/A
anti-RuvC (5G9/3) monoclonal	Santa Cruz	sc-53437
anti-Mouse IgG	Bethyl Laboratories	A90-116D5
anti-Goat IgG	Bethyl Laboratories	A50-100D5
<b>Bacterial and Virus Strains</b>		
<i>E. coli</i> mobile plasmid overexpression library	( <a href="#">Saka et al., 2005</a> )	N/A
See Table S7 for all bacterial strains used		
<b>Human cell lines</b>		
MRC5-SV40	Stephen P. Jackson Lab	N/A
HEK293T	ATCC	CRL3216
<b>Plasmid</b>		
See Tables S5 and 7 for all plasmids used		
<b>Chemicals</b>		
GenJet™ In Vitro DNA Transfection Reagent	SignaGen Laboratories	SL100489
Polyethylenimine	Polysciences	23966
Lipofectamine RNAiMAX Transfection Reagent	Invitrogen	13778030
N-acetyl cysteine	Sigma	A7250
DNA-PK inhibitor	Tocris Bioscience	NU7441
6-thioguanine	Sigma	A4882
<b>Critical Commercial assays</b>		
FM® 4-64FX	Thermal Fisher	F34653

DHR123	Thermal Fisher	D23806
pHrodo® Green AM Intracellular pH indicator	Thermal Fisher	P35373
RNeasy Mini Kit	Qiagen	74104
RiboZero	Illumina	MRZB12424
TruSeq Stranded mRNA Library Preparation Kit	Illumina	RS-122-2001
qPCR-based Illumina Library Quantification Kit	KAPA Biosystems	KK4828
Dneasy Blood & Tissue kits	Qiagen	69506
QIAprep Spin Miniprep Kit	Qiagen	27106
Gateway™ LR Clonase™ II Enzyme mix	Invitrogen	11791100
SuperScript™ III Reverse Transcriptase	Invitrogen	18080-093
Q5 High-Fidelity DNA Polymerase	New England Biolabs	M0491S
<b>Oligonucleotides</b>		
ON-TARGETplus Non-targeting Pool	Dharmacon	D-001810-10-05
siRAD18 ACUCAGUGUCCAACUUGCU	Sigma	N/A
cl forward primer ACCGCGGCGTGGGTAGTAAAGT	(Gutierrez et al., 2013)	N/A
cl reverse primer GCCAATCCCCATGGCATCGAGTAAC	(Gutierrez et al., 2013)	N/A
<b>Deposited Data</b>		
RNA-Seq data	This paper	ENA: PRJEB21034
ChIP-Seq data	This paper	ENA: PRJEB21035
<b>Software and Algorithms</b>		
cBioportal	Cerami et al., 2012; Gao et al., 2013	<a href="http://www.cbioportal.org/">http://www.cbioportal.org/</a>
R programming language	R Development Core Team, 2015.	<a href="https://www.R-project.org/">https://www.R-project.org/</a>
<i>E. coli</i> -to-Cancer Gene-function Atlas (ECGA)	This paper	<a href="https://microbialphenotypes.org/wiki/index.php/Special:ECGA">https://microbialphenotypes.org/wiki/index.php/Special:ECGA</a>
R package for progeny clustering: <i>ProgenyClust</i>	CRAN	<a href="https://cran.r-project.org/">https://cran.r-project.org/</a>
Trimmomatic	Bolger et al., 2014	N/A
BWA-MEM	Li, 2013	N/A
deepTools	Ramirez et al., 2014	N/A
MOSAIICS	Sun et al., 2013	N/A
Rockhopper	McClure et al., 2013	N/A
Prism	GraphPad	<a href="https://www.graphpad.com/scientific-software/prism/">https://www.graphpad.com/scientific-software/prism/</a>

R programming language	R Development Core Team, 2015. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.	<a href="https://www.R-project.org/">https://www.R-project.org/</a>
FlowJo 10.2	FLOWJO	<a href="https://www.flowjo.com/">https://www.flowjo.com/</a>
STRING 10.0	( <a href="#">Szklarczyk et al., 2015</a> )	<a href="https://string-db.org/">https://string-db.org/</a>
FACSDivaTM	BD Biosciences	<a href="http://www.bdbiosciences.com">http://www.bdbiosciences.com</a>
Advanced imaging collection in Pipeline pilot 8.5 or 9.2	Biovia-Dassault Systems	N/A
Softworx	GE	N/A
BLASTp and delta BLAST	NCBI	<a href="https://blast.ncbi.nlm.nih.gov/Blast.cgi">https://blast.ncbi.nlm.nih.gov/Blast.cgi</a>
RNA-sequencing data	The Cancer Genome Atlas ( <a href="#">Gao et al., 2013</a> )	N/A
Gene-Set Enrichment Analysis (ssGSEA) using GSVA package	( <a href="#">Hanzelmann et al., 2013</a> )	N/A

1300

1301

### 1302 **CONTACT FOR REAGENT AND RESOURCE SHARING**

1303 Corresponding authors, S. M. Rosenberg ([smr@bcm.edu](mailto:smr@bcm.edu)) and K. M. Miller  
1304 ([kyle.miller@austin.utexas.edu](mailto:kyle.miller@austin.utexas.edu)) are the contacts for reagents and resource sharing.

1305

### 1306 **EXPERIMENTAL MODEL AND SUBJECT DETAILS**

1307 *Escherichia coli* K-12 (strains MG1655 and W3110) and isogenic derivatives were used for all  
1308 bacterial experiments. Human MRC5-SV40 and HEK293T cells were used for all human cell line  
1309 experiments.

1310

### 1311 **METHOD DETAILS**

#### 1312 ***Escherichia coli* strains and media**

1313 *E. coli* K12 strains and plasmids used in this work are shown in [Table S7](#). Strains were grown in  
1314 Luria Bertani Herskowitz (LBH) ([Torkelson et al., 1997](#)) rich medium or M9 minimal medium  
1315 ([Miller, 1993](#)) supplemented with thiamine (10µg/ml) and 0.1% glucose or glycerol as a carbon  
1316 source. Other additives were used at the following concentrations: ampicillin (100µg/ml),  
1317 carbenecillin (20µg/ml), chloramphenicol (25µg/ml), kanamycin (30µg/ml), and sodium citrate  
1318 (20 mM). P1 transductions were performed as described ([Thomason et al., 2007](#)). Genotypes were  
1319 verified by antibiotic resistance, polymerase chain reaction (PCR) followed by sequencing, and,  
1320 when relevant, UV sensitivity.

1321

1322 **Synthesis and generation of *E. coli* mutant and fusion genes**

1323 Mutant or truncated genes were synthesized to introduce site-specific mutations or small deletions  
1324 in (GenScript) pUC57 backbone plasmids, and subsequently cloned into plasmid pNT3-SD to  
1325 allow *E. coli* conjugation. Genes that encode wild-type and mutant DNA-binding transcription  
1326 factors were fused with *mCherry* of (Shee et al., 2013) with a 4-6 alanine linker as described  
1327 (Heckman and Pease, 2007). The plasmids mentioned above are shown in Table S7.

1328

1329 ***E. coli* mobile plasmid overexpression library**

1330 The mobile-plasmid collection is an ordered library of all 4229 *E. coli* protein-coding genes in a  
1331 conjugation transferrable plasmid (Saka et al., 2005). Of these genes, 1017 (or 24%) encode the  
1332 native *E. coli* protein, whereas 3212 (or 76%) encode the *E. coli* protein with an additional three  
1333 N-terminal amino acids (Met-Arg-Ala) and an additional two C-terminal amino acids (Gly-Leu),  
1334 with genes randomly distributed to one or the other kind. We found that native proteins were over-  
1335 represented significantly as positive for DNA damage in our screens (**RESULTS, A Larger**  
1336 **Network Predicted**), implying that the 5 additional amino acids in some of the clones are more  
1337 likely to confer false-negative results for the proteins that carry them than false-positive results.  
1338 Table S1 shows the 208 validated DDP-gene clones and indicates the clones that produce native  
1339 proteins with \* next to the clone-ID number, and those with the five additional amino acids with  
1340 an unmarked clone-ID number.

1341

1342 **Whole-genome primary DDP screen of ordered *E. coli* overexpression library**

1343 The ordered mobile-plasmid collection of 4229 *E. coli* genes in a conjugation transferrable plasmid  
1344 (Saka et al., 2005) was mobilized into SOS-response-reporter strain SMR17962 (Nehring et al.,  
1345 2016), to generate a DNA-damage screenable *E. coli* overproduction library. Protein  
1346 overproduction is controlled by the IPTG-inducible  $P_{tac}$  promoter in cells that fluoresce red when  
1347 they experience SOS-inducing DNA damage (single-stranded DNA) (Nehring et al., 2016). We  
1348 adapted a high-throughput 96-well plate reader and robotics to screen for potential DDP-positive  
1349 strains with increased mCherry fluorescence. Fluorescence intensity per unit of OD<sub>600</sub> was  
1350 compared in each well. Primary screens were performed on cells grown in M9 glucose or M9  
1351 glycerol medium (to survey two different conditions), each in duplicate. Ordered *E. coli*  
1352 overproduction strains were grown to saturation overnight with shaking at 37°C in clear 96-well  
1353 plates containing 150µl medium per well, then each well diluted 1:100 into 150µl IPTG-containing  
1354 medium in 96-well plates (µ-clear, black, Greiner Bio-One, Monroe, NC, USA). The plates were  
1355 shaken at 37°C for another 24h and analyzed in a Synergy 2 fluorescence plate reader (BioTek,  
1356 Winooski, VT). We set thresholds of 20% (for glucose with IPTG induction) or 30% (for glycerol  
1357 with IPTG induction) compared with the median fluorescence intensity per unit of OD<sub>600</sub> of each  
1358 individual 96-well plate to identify primary hits. Primary hits were called when two replicates done  
1359 in the same medium were both above the threshold. Altogether, 414 candidate proteins were  
1360 identified in this high-throughput plate-reader screen, then tested by flow cytometry for increased  
1361 endogenous DNA-damage levels to eliminate false positives from the lower resolution/noisier  
1362 plate-reader assay.

1363

1364 ***E. coli* flow-cytometry secondary screen for increased endogenous DNA damage**

1365 We screened candidate-protein hits from the primary (plate-reader) screen with our more sensitive  
1366 flow-cytometric assays for SOS-induction/DNA damage (Pennington and Rosenberg, 2007). Each  
1367 strain identified as positive from the primary plate-reader screen was grown at 37°C to saturation

1368 overnight in M9 glucose medium, diluted 1:100 into M9 glycerol medium, and grown for 9 hrs to  
1369 early exponential phase at which time IPTG was added to 100 $\mu$ M to induce plasmid-protein  
1370 overproduction. After 8 hours of induction, the cultures were diluted 1:100 in filtered M9 glycerol  
1371 medium. Samples were analyzed in a LSR Fortessa flow cytometer (BD Biosciences) and  
1372 analyzed with BD FACSDiva<sup>TM</sup> and FlowJo software. For these analyses, 10<sup>5</sup> events were  
1373 collected per strain, per experiment, with each strain assayed in three independent repeats.  
1374 Student's *t*-test (*p* value  $\leq$  0.05) and False Discovery Rate (FDR)  $q < 0.1$  were calculated and  
1375 applied based on Benjamini multiple comparison (Benjamini and Hochberg, 1995) to determine  
1376 whether overproduction strains had significantly increased levels of endogenous DNA damage.  
1377 Two-hundred and eight of the original 414 *E. coli* candidate proteins were validated as genuine  
1378 DNA-damage-inducing DDPs when overproduced (shown Table S1).

1379

#### 1380 ***E. coli* assay for RecA\*GFP foci indicating single-stranded DNA**

1381 *E. coli* containing the chromosomal *recA4155gfp* allele, encoding RecA\*GFP (Renzette et al.,  
1382 2005), and the flow-cytometrically validated mobile-plasmid carriers were grown to saturation in  
1383 M9 glucose medium at 37°C, then diluted 1:100 into M9 0.1% glycerol and grown for 9h to early  
1384 log phase. IPTG was added to 100 $\mu$ M to induce protein overproduction for 8h as described above,  
1385 then images taken and analyzed.

1386

#### 1387 ***E. coli* assays for GamGFP and RDG foci**

1388 Saturated cultures of *E. coli* strains (GamGFP: SMR14334; RDG [RuvCDefGFP]: SMR19406)  
1389 containing each of the 208 validated DDP-encoding mobile plasmids were grown and induced as  
1390 described in flow-cytometric assays for DNA damage. 100ng/ml of doxycycline were added to  
1391 induce GamGFP for 3h and RDG for 2h prior to harvesting. Cells were fixed with 1%  
1392 paraformaldehyde for 15 min. and washed with PBS buffer three times before being concentrated  
1393 for microscopy.

1394

#### 1395 ***E. coli* microscopy and image analysis for RecA\*GFP, GamGFP and RDG foci**

1396 Images were acquired using a 100x/NA = 1.4 immersion oil objective (Olympus) on a DeltaVision  
1397 Elite deconvolution microscope (Applied Precision, GE). A z-series was acquired sampling every  
1398 0.2 microns for a total of 15-25 sections. The z-series was then deconvolved, and a maximum  
1399 projection image rendered using Softworx (GE). Image analysis was performed using the  
1400 Advanced Imaging collection in Pipeline Pilot 8.5 or 9.2 (Biovia-Dassault Systemes, San Diego).  
1401 Projected images from the DeltaVision were read into Pipeline Pilot and metadata data parsed from  
1402 the file name and path. A rolling ball background subtraction was applied to improve the signal-  
1403 to-background ratio, and to facilitate further segmentation. Individual bacterial cells were then  
1404 identified and segmented by applying a global threshold on images of the fluorescently labeled  
1405 protein. Morphological manipulations (smoothing, opening and closing) were applied to refine the  
1406 segmentation edges and a watershed was then performed to separate neighboring objects. Filtering  
1407 was then applied to remove bacteria that fell outside a certain area threshold and that did not  
1408 contain DNA. Foci were then identified using a more aggressive per-object background subtraction  
1409 and peak identification method. Objects tentatively identified by this method were subsequently  
1410 filtered by circularity, signal-to-background ratio, and size. Focus-positive bacteria were then  
1411 determined using the co-localized objects component in the Advanced-imaging library in Pipeline  
1412 Pilot. A binary metric, whether the cells were focus-positive or not, was calculated in addition to  
1413 recording the total area and count of foci for those bacteria that were positive.

1414  
1415  
1416  
1417  
1418  
1419  
1420  
1421  
1422  
1423  
1424  
1425  
1426  
1427  
1428  
1429  
1430  
1431  
1432  
1433  
1434  
1435  
1436  
1437  
1438  
1439  
1440  
1441  
1442  
1443  
1444  
1445  
1446  
1447

### **STRING/network analyses**

Known protein-protein interactions were displayed using CytoScape V3.4.0 software. Protein-protein interaction linkage scores were taken from the STRING 10.0 database (Szklarczyk et al., 2015) to identify interaction pairs. We used STRING, all parameters, with an interaction score cut-off of  $\geq 0.6$  (medium-to-high confidence). Random controls were produced by examining equal-size groups of random *E. coli* genes. *P* values were calculated with a hypergeometric test (Berkopec, 2007). The *E. coli* DDP network has network properties that are defined as scale-free and “small-world”, and it has significantly more edges (connectivity) compared with a random network (Figure 1G, S2A, Results). The human candidate-DDP network was generated similarly, and also has more connectivity than a random human-gene network or random human genes with *E. coli* homologs (Figures 2B, S2B, Results).

### ***E. coli* forward-mutation assay**

We used the forward-mutation assay of Matic and colleagues (Gutierrez et al., 2013) in which *E. coli* wild-type strain MG1655 harbors a chromosomal phage lambda *cI* transcriptional repressor gene, and a CI-repressible *tetA* gene, such that mutations that inactivate *cI* are scored as tetracycline-resistant ( $Tet^R$ ) mutant cfu. Into this strain, we conjugated 32 validated *E. coli* DDP genes in their mobile-plasmid-library vector (genes tested Table S1; Supplemental Discussion 3, and Table S1 for their mobile-library clone names). We developed a modified higher-throughput fluctuation-test assay for determining numbers of cultures with  $Tet^R$  mutants from which to calculate  $Tet^R$  mutation rates. Each DDP overproducer was grown overnight to saturation in M9 glucose with 20 $\mu$ g/ml carbenicillin at 37°C shaking, then diluted 1:10,000 into M9 glycerol carbenicillin and each culture split into 24 or 32 wells in 96-well-plates at 100 $\mu$ l per well. The plates were shaken at 37°C for 15h (early log phase), and IPTG added to attain 100 $\mu$ M in each well to induce protein overproduction for 8h, as described in flow-cytometric validation. From the end cultures, 5-10  $\mu$ l were moved into LBH medium containing 10 $\mu$ g/ml tetracycline to determine the fraction of cultures that contained no  $Tet^R$  cells after incubation and scoring of the wells in the plate reader for OD ( $Tet^R$  cells) versus failure to grow (no  $Tet^R$  cells). The viable cell counts were estimated by sampling three wells chosen randomly. The  $P_0$  method was used to estimate mutation rates for each genotype as described with correction for the fraction sampled (Foster, 2006). The data reported (Figure 1J; Table S1) are the mean mutation rates ( $\pm$  SEM) of three experiments of at least 24 cultures per strain for each of the 32 strains assayed.

### ***E. coli Tet<sup>R</sup>* mutation verification by sequencing**

We selected strains that overproduce the following 10 different DDPs with strong DNA-damage-up phenotypes: CsgD, TopB, CheA, YegL, MdtA, GrpE, HslU, YicR, UvrA, and Mrr. We selected 3-10 independent  $Tet^R$  mutant colonies, each from a separate culture from each strain, from which to sequence *cI* mutations. For the vector-only negative control, 19 independent  $Tet^R$  colonies were isolated. We amplified and sequenced a 1122nt region encompassing the *cI* gene as described (Gutierrez et al., 2013) to identify the mutations. For those  $Tet^R$  mutants that failed to yield PCR products, implying deletion of the *cI* gene, further outside primers (forward: ACCGCGGCGTGGGTAGTAAAGT, and reverse: GCCAATCCCCATGGCATCGAGTAAC) were used for PCR, and the products sequenced. In two cases (both TopB overproducers), whole-genome sequencing (WGS) was performed to determine the end-points for deletions that could not be determined via PCR and sequencing.

1460

1461 ***E. coli* whole-genome sequencing and analysis**

1462 Tet<sup>R</sup> mutants were grown at 37°C to saturation overnight in LBH with 10µg/ml tetracycline, and  
1463 genomic DNA was extracted and purified using DNeasy Blood & Tissue kits (Qiagen). Libraries  
1464 were prepared using Nextera XT kits (Illumina); sequencing was performed on an Illumina Mi-  
1465 Seq, and sequencing data analyzed as described (Xia et al., 2016). Sequencing reads were mapped  
1466 to the MG1655 genome (NCBI RefSeq Accession: NC\_000913.3). Low-quality reads and  
1467 duplicates were removed. WGS files were visualized and deletion endpoints were analyzed using  
1468 IGV software (Broad Institute, MA).

1469

1470 **Flow-cytometric assays for DNA loss**

1471 Quantification of anucleate cells by flow cytometry was adapted from (Joshi et al., 2013).  
1472 Saturated cultures of *E. coli* strains derived from SMR21384 containing each of the 208 validated  
1473 DDP-producing mobile plasmids were grown and induced as described in flow-cytometric assays  
1474 for DNA damage. Cells were resuspended in 100 µl PBS, and stained with membrane dye  
1475 FM® 4-64FX (Thermal Fisher) with a final concentration of 10 µg/ml. The mix was kept on  
1476 ice for 10 min. and then washed three times with PBS. A final concentration of 70% ethanol  
1477 (pre-chilled) was used to fix the cells at -20°C for 1h, after which cells were washed with  
1478 twice with PBS and resuspended in 100 µl PBS. 100 µl DAPI (5µg/µl) were used to stain  
1479 DNA at room temperature (RT) for another 10 min. Samples were filtered and analyzed as  
1480 described above.

1481

1482 **Flow-cytometric assay for intracellular ROS levels**

1483 Saturated cultures of *E. coli* strains derived from SMR21384 containing each of the 208 validated  
1484 DDP-producing mobile plasmids were grown and induced as described in flow-cytometric assays  
1485 for DNA damage. The ROS measurement protocol was modified from Gutierrez et al.  
1486 (Gutierrez et al., 2013). In brief, cells were incubated with ROS-staining dye DHR123  
1487 (Invitrogen), which measures H<sub>2</sub>O<sub>2</sub>, for 30 min. at 4°C in M9 buffer. After washing twice with  
1488 M9 buffer, flow cytometry analyses were performed immediately as described above.

1489

1490 **Flow-cytometric assay for intracellular pH**

1491 pHrodo® Green AM Intracellular pH Indicator (Thermal Fisher) was used to measure  
1492 intracellular pH in live *E. coli*. Protocols were adapted from (Loiselle and Casey, 2010). Cells  
1493 were first washed with live-cell imaging solution (LCIS) and then 10 µl of pHrodo™ Green AM  
1494 with 100 µl of PowerLoad™ concentrate were added to 10 ml of LCIS. The pHrodo™  
1495 AM/PowerLoad™/LCIS was mixed with cells and incubated at 37°C for 30 minutes. Cells were  
1496 then washed twice with PBS to remove excess dye before flow-cytometric analysis. Intracellular  
1497 pH calibration buffers (Thermal Fisher) were used as standards.

1498

1499 **Assays for sensitivity to DNA-damaging agents**

1500 Cultures of *E. coli* strain (SMR21384) containing each of the 208 validated DDP-producing mobile  
1501 plasmids were grown as described in flow-cytometric assays for DNA damage with the following  
1502 modifications: For hydrogen-peroxide (H<sub>2</sub>O<sub>2</sub>) treatment, 100 µM IPTG was used to induce  
1503 overproduction of each DDP. Each culture was split into two tubes, prior to addition of 5mM H<sub>2</sub>O<sub>2</sub>  
1504 into one of the tubes for 15min. The cells with and without H<sub>2</sub>O<sub>2</sub> were immediately diluted and  
1505 plated onto LBH plates for assay of viable cells as cfu after incubation for a day at 37°C. For  
1506 phleomycin or mitomycin C (MMC) treatment, saturated M9 glucose cultures were diluted into



1507 M9 glycerol medium with 100  $\mu$ M IPTG to induce overproduction in 96-well plates. The plates  
1508 were grown with shaking for 8 hours at 37°C to early log phase prior to addition of 1  $\mu$ g/ml  
1509 phleomycin or 0.05 $\mu$ g/ml MMC to each well. After 20 hours of continuous shaking, the OD600  
1510 was read using a BioTek microplate reader Synergy 2 (BioTek). DNA-damaging-agent  
1511 sensitivities of the DDP-producing clones are normalized to sensitivity of vector-only controls:  
1512 (treated/untreated DDP overproducer) / (treated/untreated vector-only) so that values < 1 indicate  
1513 sensitivity. For all three assays for sensitivity to DNA-damaging agents, Student's *t*-test (*p* value  
1514  $\leq 0.05$ ) with FDR adjustment ( $q \leq 0.1$ ) was used to determine whether DDP-overproducing strains  
1515 were significantly more sensitive to DNA-damaging agents than the vector-only control.  
1516

### 1517 **Clustering methods**

1518 For each DDP and DNA-damage outcome measure, raw data for each functional assay  
1519 (overproduction versus vector) were converted into z scores and were used to delineate groupings  
1520 of proteins with similar properties and patterns of response. Unsupervised discovery methods K-  
1521 means in combination with Progeny Clustering (Hu et al., 2015) were performed using the R  
1522 package *ProgenyClust* (Hu and Qutub, 2016) to determine the optimal number of protein clusters  
1523 for the 208 DDPs. Seven functional tests were clustered by hierarchical clustering to assess the  
1524 association of kinds, causes, and consequences of DNA damage.  
1525

### 1526 **RNA-seq library preparation and sequencing**

1527 *E. coli* cultures were grown as described for flow-cytometric assays for DNA damage, and RNA  
1528 was isolated from 1 ml of culture ( $\sim 10^8$  cells) for each of two biological replicates. Total RNA was  
1529 isolated using the RNeasy Mini Kit (Qiagen), according to the manufacturer's protocol.  
1530 RNAProtect Bacterial Reagent (Qiagen) was used to stabilize RNA during harvest and enzymatic  
1531 cell lysis. After elution, total RNA was treated with RNase-free DNase I (NEB), according to the  
1532 manufacturer's protocol. RNA was recovered by phenol-chloroform extraction and ethanol  
1533 precipitation. Ribosomal RNA was depleted using RiboZero (Epicentre/Illumina), according to  
1534 the manufacturer's protocol. Remaining RNA was concentrated by ethanol precipitation and  
1535 approximately 100 ng of rRNA-depleted RNA was used to construct libraries using the TruSeq  
1536 Stranded mRNA Library Preparation Kit (Illumina). Libraries were prepared according to the  
1537 manufacturer's protocol, using recommended modifications for previously isolated mRNA  
1538 (McClure et al., 2013) (poly-A RNA enrichment steps excluded). Final RNA-seq libraries were  
1539 run on a BioAnalyzer (Agilent) to estimate the average fragment size ( $\sim 800$  bp) and the  
1540 concentration of adapter-ligated library fragments was determined using the qPCR-based Illumina  
1541 Library Quantification Kit (KAPA Biosystems). Libraries were pooled and sequenced on an  
1542 Illumina NextSeq 500 using a High Output v2 Kit (2 x 75 bp paired-end reads).  
1543

### 1544 **Analysis and deposition of RNA-seq data**

1545 Read mapping, transcript assembly, and differential expression analysis were performed using  
1546 Rockhopper (McClure et al., 2013), a bacteria-specific RNA-seq analysis pipeline, using MG1655  
1547 (NC\_000913.3) as the reference genome. Genes were considered as differentially expressed if the  
1548 fold change was greater than or equal to 2 and *q*-value was less than 0.01. Sequencing data are  
1549 available in the European Nucleotide Archive (ENA) under study accession no. PRJEB21034.  
1550

### 1551 **RDG ChIP-seq library preparation, sequencing, and data analysis**

1552 Cells were grown as for focus quantification, then crosslinked, lysed and sonicated as described

1553 (Xia et al., 2016). Immunoprecipitation and library preparation methods are based on those of  
1554 (Bonocora and Wade, 2015) with small modifications as follows. RuvC antibody (Santa Cruz) was  
1555 first pre-incubated with Dynabead protein A, then the RuvC-antibody-coated Dynabeads were  
1556 incubated with cell lysates at 4°C overnight. Library preparation was performed while DNA  
1557 fragments were still on Dynabeads. Samples were barcoded using NEBNext Multiplex Oligos for  
1558 Illumina. Size selection of adaptor ligated DNA was performed on AMPure XP Beads as described  
1559 in NEBNext ChIP-Seq Library Prep guidelines. Because the concentrations of eluted ChIP DNA  
1560 are low, samples were amplified briefly prior to size selection, and a second amplification was  
1561 performed after size selection. Sequencing was performed on an Illumina MiSeq. The pipeline for  
1562 data analysis consists of the following steps: (i) reads were trimmed by Trimmomatic (Bolger et  
1563 al., 2014) removing sequencing adaptors and low quality bases; (ii) reads were aligned by BWA-  
1564 MEM (Li, 2013) to the W3110 genome [National Center for Biotechnology Information (NCBI)  
1565 Reference Sequence (RefSeq) Database accession: NC\_007779.1] and the plasmid pNT3 (Saka et  
1566 al., 2005); (iii) Secondary alignment and multiple-mapped reads were discarded, this results in  
1567 zero coverage in repetitive regions and regions present in both the genome and the plasmid,  
1568 including the *csgD* gene; (iv) potential PCR duplicates were removed by Picard Tools  
1569 MarkDuplicates; (v) bedGraph files were generated with deepTools (Ramirez et al., 2014) and  
1570 imported to R for plotting; and (vi) peak calling was performed with MOSAiCS (Sun et al., 2013).  
1571 Sequencing data are available in the European Nucleotide Archive (ENA) under study accession  
1572 no. PRJEB21035.

1573

#### 1574 **Western analyses of Pol IV protein levels**

1575 M9 glycerol cultures inducing wild-type, catalytically inactive, and  $\beta$ -binding-defective Pol IV  
1576 were normalized to OD<sub>600</sub> of 1.0, and 1 ml of each was pelleted, resuspended and boiled as  
1577 described (Kim et al., 2001). Proteins were separated by 10% SDS-PAGE and transferred to PVDF  
1578 membrane according to the manufacturer's instructions (Amersham, GE Healthcare). The  
1579 membranes were blocked with ECL Prime blocking agent (GE Healthcare) and probed with  
1580 primary anti-Pol IV polyclonal antibody (Kim et al., 2001) (1:2000). The membrane was further  
1581 probed with secondary polyclonal goat anti-rabbit IgG-Cy5 antibody (Bethyl Laboratories) and  
1582 visualized by scanning in multicolor imager Typhoon detection system (GE Healthcare).

1583

#### 1584 **Identification of human homologs using BLASTp and delta BLAST**

1585 "Homologs" are defined here as proteins with amino-acid similarity that could result from possible  
1586 evolutionary relatedness. We used two basic local alignment search tools: the BLASTp and Delta-  
1587 BLAST algorithms, searching protein sequences obtained from GenBank and other NCBI database  
1588 resources. For both we used e-value < 0.01 ( $\leq 1$  gene is identified by random chance in 100 queries)  
1589 and sequence identity of  $\geq 20\%$ . Note that  $\geq 20\%$  sequence identity between *E. coli* and human is  
1590 considerable. For example, known orthologs *E. coli* RecA and human RAD51 have 25% amino-  
1591 acid identity. Given a protein query, BLASTp returns the most similar protein sequences from the  
1592 protein database with e-value < 0.01 and identity  $\geq 20\%$ . Delta-BLAST uses multiple sequence  
1593 alignment with conserved domains found in the CDD (Conserved Domains database from NCBI)  
1594 and computes a Position Specific Score Matrix (PSSM) (Boratyn et al., 2012) with e-value < 0.01.  
1595 Both methods were compared against the human protein database of NCBI. Proteins identified  
1596 from either algorithm were identified as human homologs of the *E. coli* DDPs.

1597

#### 1598 **Analyses of cancer survival and mutation loads**

1599 RNA-sequencing data from The Cancer Genome Atlas (TCGA) (Gao et al., 2013) were processed  
1600 in the form of transcripts per million (TPM) as described (Rahman et al., 2015) and obtained via  
1601 Gene Expression Omnibus (accession number GSE62944). Only the TCGA cancer types that had  
1602 over 100 patients with RNA- and DNA-sequencing data were analyzed. Upon defining our gene  
1603 sets of interest, RNA data were subjected to single sample Gene-Set Enrichment Analysis  
1604 (ssGSEA) using GSVA package (Hanzelmann et al., 2013) in R. The resulting gene-set enrichment  
1605 score for each sample was used as a representation of gene-set RNA level in each sample. Somatic  
1606 mutation data for TCGA cancers were obtained in the form of mutation annotation files (raw or  
1607 final) from the Broad Institute Genome Data Analysis Center (GDAC). For each sample, the sum  
1608 of base-substitution and indel mutations was taken as the total mutation count, and  $\log_e$  of this  
1609 value was referred to as “mutation load.” Correlation analysis for “all human genes” was  
1610 performed via bootstrapping. Briefly, we computed the mean correlation coefficient of mutation  
1611 load with gene-set enrichment scores for 1000 randomly sampled gene sets, each consisting of a  
1612 random number, between 10 to 1000, of genes out of over all human genes for which expression  
1613 data were available. Kaplan Meier survival analysis was performed using “survival” package in R  
1614 comparing the top and bottom tertiles of samples based on their gene-set enrichment score.  
1615 Correlation analyses with mutation loads was performed in base R and correlation coefficients  
1616 were plotted using the “corrplot” package in R.  
1617

### 1618 **Cloning of human genes for DNA-damage analyses in human cells**

1619 Fifty-eight human DDP and 19 non-DDP cDNA clones (Table S5) in the Gateway entry vectors  
1620 pDONR221 and pDONR223 (Invitrogen) were subcloned from an augmented library of ~32,000  
1621 Orfeome V8.1 (Yang et al., 2011) stated to contain sequenced human full-length cDNA clones,  
1622 and additional full-length and commonest splice-variant length clones obtained from others  
1623 including CCsBroad gene libraries. The size of cDNA from each gene was confirmed by restriction  
1624 enzyme digestions. We also cloned, de novo, 15 candidate hDDP genes, one non-hDDP gene,  
1625 tubulin and two *de novo* methylase genes (Table S5) that were not present as full-length clones in  
1626 the Orfeome V8.1 (Yang et al., 2011) or CCsBroad gene libraries. These candidate genes were  
1627 amplified from cDNAs generated from mRNAs extracted from the human cancer-cell lines U2OS  
1628 or MRC5-SV40. PCR products of the correct size were cloned into the Gateway entry vector  
1629 pENTR11 at restriction enzyme cut sites or into pDONR201 using *attB* site-specific recombination  
1630 sites. Five DNMT1 truncated constructs were modified by using site-directed mutagenesis (Table  
1631 S5). Clones were sequenced and verified as the correct gene sequence based on the Reference  
1632 Sequence (RefSeq) database from NCBI. We subcloned each gene into a mammalian expression  
1633 vector containing a GFP epitope tag (pcDNA6.2/N-EmGFP-DEST, Invitrogen), which allows us  
1634 to analyze transfection efficiency and visualize protein localization in transfected cells. All human-  
1635 cell overexpression plasmids used in this study are listed in Table S5.  
1636

### 1637 **Human cell lines, plasmids, and reagents**

1638 MRC5-SV40 and HEK293T cells were maintained in Dulbecco’s modified Eagle’s medium  
1639 (DMEM) (Invitrogen) supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 100  
1640  $\mu\text{g}/\text{mL}$  penicillin, 100  $\mu\text{g}/\text{mL}$  and streptomycin. Transient transfections into human cells were  
1641 performed using GenJet (SignaGen Laboratories) for MRC5-SV40 and PEI (polyethylenimine,  
1642 Sigma) for HEK293T. Transfections for siRNA were carried out with lipofectamine RNAiMax  
1643 (Invitrogen) following the manufacturer’s instructions. The siRNAs were siNT: non-targeting pool  
1644 (Dharmacon) and siRAD18: ACUCAGUGUCCAACUUGCU (Sigma). DNA-PK inhibitor

1645 (NU7441, Tocris Bioscience) was used at 2.5  $\mu$ M 6 h prior to harvesting cells for flow cytometry.  
1646 NAC (N-acetyl-cysteine, Sigma) treatment was performed twice, with a final concentration of 5  
1647 mM, post-24hr and -48hr transfection. To create inducible stable clones to verify DNMT1 and  
1648 PCNA interaction, GFP-tubulin, GFP-DNMT1 and GFP-DNMT1- $\Delta$ PBD cDNAs were cloned into  
1649 pcDNA5/FRT/TO/Intron vector (Invitrogen, CA). Inducible HEK293T FlpIn Trex GFP-tubulin,  
1650 GFP-DNMT1 and GFP-DNMT1- $\Delta$ PBD cells were generated followed by manufacturer's protocol  
1651 and were cultured in the same normal medium with 15 $\mu$ g/ml Blasticidin and 80 $\mu$ g/ml hygromycin.  
1652 Doxycycline (Sigma) was added to medium to trigger the production of GFP fusions.

1653

### 1654 **Human-cell DNA-damage screens by flow cytometry**

1655 We screened for increased DNA damage by flow-cytometric quantification of  $\gamma$ H2AX- and  
1656 phospho-P53-antibody signals among GFP-positive transfectants. Immunostaining was performed  
1657 according to a standard procedure with minor modifications. Seventy-two hours post-transfection,  
1658 cells were collected and approximately  $1 \times 10^6$  cells taken for staining. For staining, cells were fixed  
1659 with 2% (v/v) formalin for 15 min on ice, washed twice in cold-PBS and permeabilized with 0.05%  
1660 (v/v) Triton-X for 15 min on ice followed by two washes with PBS. The fixed cells were then  
1661 blocked with 5% BSA-PBS for 1 hr, and stained with either  $\gamma$ H2AX (Millipore) or phosphorylated  
1662 p53 primary antibodies (Cell Signaling) overnight at 4°C. Cells were washed three times in 1%  
1663 BSA-PBS followed by an incubation of Alexa Fluor 647 goat anti-mouse IgG in 5% BSA-PBS  
1664 (Invitrogen) for 1 hr at room temperature in the dark, then washed three times with 1% BSA-PBS.  
1665 Stained samples were measured by a BD LSRFortessa flow cytometer and analyzed using FlowJo  
1666 software. Cells without transfection were used to set the threshold gating to determine the  
1667 percentage of GFP- and  $\gamma$ H2AX- or phosphorylated p53-positive cells, with 0.5% of control cells  
1668 gated as the damage threshold. The DNA-damage ratio caused by protein overproduction is  
1669 defined by  $(Q2/Q3)/(Q1/Q4)$ , where Q2 is the number of transfected damage-positive cells; Q3 is  
1670 the number of transfected damage-negative cells; Q1 is the number of untransfected damage-  
1671 positive cells; and Q4 is the number of untransfected damage-negative cells. Results were obtained  
1672 from at least two independent experiments. Statistical significance ( $p$  value) was determined using  
1673 two-tailed unpaired Student's  $t$ -test followed by false discovery rate ( $q$  value) correction. Both the  
1674  $\gamma$ H2AX and phosphorylated-p53 assays show linear responses to exogenous DNA damage caused  
1675 by ionizing radiation (Figures S3J and S3K), indicating their quantitative validity.

1676

### 1677 **HPRT mutagenesis assay**

1678 MRC5-SV40 cells were transfected with the plasmids indicated, and harvested 72 hours post-  
1679 transfection. The percentage of GFP-positive cells of each transfectant was scored as transfection  
1680 efficiency using a BD Accuri flow cytometer. The remaining cells were re-grown in 15 cm dishes  
1681 for an additional 4 days. After a week of transfection,  $3 \times 10^6$  cells were plated in 15 cm dishes  
1682 containing medium with 20 mM 6-thioguanine (Sigma), with five 15 cm dishes for each gene. In  
1683 addition, 600 cells were plated in triplicate, per well, in a 6-well plate without 6-TG to determine  
1684 plating efficiency. The plates were incubated at 37°C in a humidified incubator until colonies  
1685 formed. The colonies were stained with 0.005% crystal violet. These colonies were counted, and  
1686 mutation rates determined using the MSS-maximum likelihood estimator method with correction  
1687 for transfection efficiency. We verified that 6-TG resistant clones result from *HPRT* mutations by  
1688 sequencing the cloned *HPRT* cDNAs from four independent mutants (Supplemental Discussion  
1689 8). The *HPRT* cDNA is 657bp long, whereas *HPRT* including introns is 42kb, making sequencing  
1690 the cDNAs more practical.

1691

1692 **Human-cell immunoprecipitation and western blot analysis**

1693 After induction of protein production using doxycycline in FlpIn-inducible HEK293T cells  
1694 producing GFP-tubulin, GFP-DNMT1-WT or GFP-DNMT1- $\Delta$ PBD, cells were lysed with NETN  
1695 buffer (150 mM NaCl, 1mM EDTA, 10 mM Tris-HCl, pH 8.0, and 0.5% NP-40) containing  
1696 TurboNuclease (Accelagen) and 1 mM MgCl<sub>2</sub> for 1 h at 4°C. Cell lysates were then centrifuged  
1697 for 30 min at 4°C. GFP-tagged proteins were immunoprecipitated with 20  $\mu$ l of GFP-Trap\_A  
1698 (Chromotek) for 1 h at 4°C. Beads were then washed three times with NETN buffer. Protein  
1699 mixtures were eluted by boiling at 95°C with Laemmli buffer (4% (v/v) SDS, 20% (v/v) glycerol  
1700 and 120 mM Tris-HCl, pH 6.8). For whole cell extracts, cells were collected with Laemmli buffer,  
1701 and heated for 5 min at 95°C before loading. Samples were resolved by SDS-PAGE followed by  
1702 western blot analysis. Primary antibodies were used as follows: anti-GFP (Invitrogen), anti-PCNA  
1703 (Santa Cruz), anti-beta tubulin (Abcam), anti-RAD18 (Cell Signaling). Blots were analyzed by  
1704 standard chemiluminescence (GE Healthcare, Amersham ECL Prime system) using a Bio-Rad  
1705 molecular imager ChemiDoc XRS+ system.

1706

1707 **Statistics**

1708 All *E. coli* wet-bench experiments were performed at least three times independently, and a two-  
1709 tailed unpaired *t*-test was used to determine significant differences, unless otherwise specified.  
1710 Error bars represent 1 SEM except where otherwise indicated. Pearson's correlation coefficient  
1711 was computed to assess the relationship between two parameters. STRING enrichment analysis  
1712 was performed using hypergeometric tests with the correction for multiple comparisons. False  
1713 discovery rate (FDR) adjustments are used to limit the overall type I errors in both *E. coli* and  
1714 human DNA-damage flow-cytometry assays. The FDR (Benjamini Hochberg) method ([Benjamini  
1715 and Hochberg, 1995](#)) is the default *p*-value adjustment method in this paper. Fisher exact test is  
1716 used to determine whether two proportions are different. Wilcoxon rank-sum test was used to  
1717 determine whether each gene has cancer-associated copy-number increases.

1718

1719 **QUANTIFICATION AND STATISTICAL ANALYSIS**

1720 Statistical details can be found in the main text, figure legends, or in the Method Details section.

1721 **SUPPLEMENTAL INFORMATION**

1722 Supplemental information includes a discussion file, seven figures and seven tables that can be  
1723 found with article online at \*\*\*

1724

1725 **Supplemental Discussion 1**

1726 **Significant protein-protein interactions of random human homologs of *E. coli* proteins**

1727 Hypergeometric test analyses show that the 284 human homologs of *E. coli* DDPs have far more  
1728 significant association ( $p = 1.2 \times 10^{-327}$ ) than 284 random human proteins ( $p = 0.80$ ), and 284  
1729 random human homologs of *E. coli* proteins ( $p = 1.8 \times 10^{-49}$ ). Although not associated nearly as  
1730 strongly as the human homologs of DDPs ( $1.2 \times 10^{-327}$ ), the significant association of random  
1731 human homologs of *E. coli* proteins ( $1.8 \times 10^{-49}$ ) compared with random human proteins ( $p = 0.80$ )  
1732 could potentially result if highly conserved proteins generally have more interactions with each  
1733 other than random proteins. This might be because the most highly conserved, fundamental  
1734 aspects of biology, and proteins that participate in them, are enriched for conserved protein  
1735 machines (ribosomes, replisomes, transcription complexes, etc.), and/or fundamental pathways the  
1736 actors in which have remained associated. Alternatively, it might be that proteins that function as  
1737 part of interacting protein groups evolve more slowly, and so are overrepresented among  
1738 conserved proteins.

1739

1740 **Supplemental Discussion 2**

1741 **A larger network predicted and estimate of additional *E. coli* DDPs not discoverable in the  
1742 mobile plasmid library**

1743 The 208 proteins are a large network, and occupy 5% of *E. coli* genes, but are likely to represent  
1744 just over half of overproduction DDPs encoded in the *E. coli* genome. Per [Figure S1E](#), we found  
1745 that 1 of 99 random proteins not identified in the primary screen was positive in the sensitive flow-  
1746 cytometry secondary assay, predicting an additional undiscovered 38 DDPs in the overproduction  
1747 library used ([Figure S1E](#)). Further, although it is the most complete and least adulterated *E. coli*  
1748 overexpression library, the mobile plasmid library ([Saka et al., 2005](#)) contains some genes that  
1749 encode five additional amino acids, which our data indicate were biased against in our screens.  
1750 Twenty-four percent of clones in the library ([STAR Methods](#)) produce native *E. coli* proteins, and  
1751 the rest produce proteins with three extra N-terminal (Met-Arg-Ala) and two extra C-terminal  
1752 (Gly-Leu) amino acids, with the composition of genes in each class being random ([Saka et al.,  
1753 2005](#)) ([STAR Methods](#)). We found that both the initial DDP candidates identified in the plate-  
1754 reader primary screen and the 208 flow-cytometry-validated DDPs carried significantly higher  
1755 fractions of native proteins than the library; there were 158 native proteins in the initial 414  
1756 candidates identified in the primary plate-reader screen (38%, differs from the library at  $p = 1.7 \times$   
1757  $10^{-11}$ , Fisher's exact test), and 85 native proteins in the 208 validated DDPs, or 41% (shown in  
1758 [Table S1](#), differs from the library at  $p = 4.1 \times 10^{-8}$ , Fisher's exact test). The data imply that some  
1759 of the non-native proteins may have lost full function, and, because of that, gave false-negative  
1760 readings in the screens. We found that the native genes in the library were "hit" in the primary  
1761 screen at 16% (158 discovered out of 1015 native genes in the library), whereas the non-native  
1762 genes were identified at 8% efficiency (256 discovered out of 3214 non-native genes in the library).  
1763 If there are an additional 7.6% of the non-native proteins that would score as DNA-damage-  
1764 promoting in our primary screen, if they did not carry the extra amino acids, then among the 3214  
1765 non-native-protein-encoding genes in the library, we predict that there would be an additional 244  
1766 overproduction DDP candidates found in the primary screen (7.6% of 3214). We found that

1767 candidates from the primary screen were validated in the secondary screen at 208 validated out of  
1768 414 candidates (Figure 1F; Tables S1 and S2), or just over 50%, which predicts 123 additional  
1769 genuine DDPs among the predicted additional candidates.

1770

### 1771 **Supplemental Discussion 3**

#### 1772 ***E. coli* clones assayed for mutation rate**

1773 In Figure 1J, we assayed mutation rates in mutation-assay strains overproducing the following  
1774 DDPs. DDPs that cause < 5-fold increase in DNA damage: DsbG, YijF, CadA, Folds, YddG,  
1775 LeuO, UvrB, YajR, YbgQ, ORF 6106.1. DDPs that cause  $\geq$  5-fold increase in DNA damage:  
1776 HypF, ZipA, YedA, CueO, YefU, MacB, HcaR, MdtB, SetB, DinD, RusA, YdcR, CsgD, HslU,  
1777 SfsA, TopB, CorA, YegI, GrpE, PgrR, Mrr, MhpR. Non-DDPs: AceF, HprT, AceE, YaeG, YadF,  
1778 PdhR, HrpB, MrcB, FhuD, YadG, Dgt, FhuA, HtrE, EcpD, FhuC, YacH, YadK.

1779

### 1780 **Supplemental Discussion 4**

#### 1781 **Cancer association of human proteins from a select DNA-damage screen**

1782 We analyzed published data from the limited human overexpression DNA-damage-up screen of  
1783 (Lovejoy et al., 2009) by Fisher exact test against known (Forbes et al., 2015) and predicted  
1784 (D'Antonio and Ciccarelli, 2013) cancer-driving genes. This overexpression screen of a set of  
1785 nucleus/DNA-associated proteins discovered 96 human proteins (Lovejoy et al., 2009), which we  
1786 found are overrepresented among known and predicted cancer drivers at  $p = 0.0001$  and  $p = 0.0002$ ,  
1787 with DNA-repair proteins excluded (Fisher exact test, identities, Table S3). Only one protein was  
1788 identified in common between the *E. coli* DDP homologs and the human overproduction screen  
1789 (FIGNL1), indicating that the *E. coli* screen identified many new hDDP candidates, then validated  
1790 hDDPs. Overall, the candidate hDDPs identified from human screens and the *E. coli* screen are  
1791 highly significantly overrepresented among known (Forbes et al., 2015) and predicted (D'Antonio  
1792 and Ciccarelli, 2013) cancer driver genes, independently of DNA-repair proteins, supporting the  
1793 importance of DDPs to human cancer. We note that an unbiased screen of all human proteins for  
1794 DNA damage on overproduction is not possible because the best human overexpression libraries  
1795 contain a fraction of all human protein-coding genes, and many clones that are not full length. See  
1796 STAR Methods, **Cloning of human genes for DNA-damage analyses in human cells.**

1797

### 1798 **Supplemental Discussion 5**

#### 1799 **Choice of candidate hDDP and control proteins for validation in DNA-damage assays**

1800 Of the 284 human homologs, we identified 121 candidates of particular interest according to the  
1801 following criteria: (i) Many are encoded by genes amplified at high frequencies in cancer genomes  
1802 from TCGA (Gao et al., 2013) (Table S4). (ii) For a minority, the genes are mutated or deleted at  
1803 impressive, high frequencies in TCGA (Gao et al., 2013). (iii) Full-length clones that encode 90  
1804 of these appeared to be available in the Orfeome V8.1 or CCsBroad cDNA-clone collections (Yang  
1805 et al., 2011). We determined by restriction mapping that many of the human genes in those libraries  
1806 are not full length (Table S5), and cloned 18 genes including 15 candidate hDDP genes and three  
1807 controls de novo as full-length cDNA clones that we sequence-verified (STAR Methods). We  
1808 ultimately created 70 full-length overexpression GFP-fusion clones of human homologs of *E. coli*  
1809 DDP genes, and overexpression GFP-fusion clones of 3 human homologs of *E. coli* damage-down  
1810 genes, as possible negative controls (STAR Methods, Tables S5), 9 random human genes, and 11  
1811 random human homologs of *E. coli* non-DDP genes (Tables S5).

1812

## 1813 **Supplemental Discussion 6**

### 1814 **Superiority of transient transfection to stable integration of genes encoding hDDP candidates**

1815 We found transient transfection to be superior to creation of stable clones because of apparent  
1816 selection for mutations in the inducible hDDP candidate genes upon integration. Mutations in the  
1817 hDDP candidates or other DNA damage-response pathways are selected probably because the  
1818 gene products are toxic when overproduced and the genes are difficult to keep tightly “off”. The  
1819 GFP-hDDP-gene fusions allow transient transfection assays to identify immediate effects of the  
1820 DNA damage and to analyze only the minority population of cells that have been transfected  
1821 successfully and produce the protein of interest. This cell subpopulation is GFP-positive, and easily  
1822 identified in the flow-cytometric assays (e.g., [Figure 3B](#)).

1823

## 1824 **Supplemental Discussion 7**

### 1825 **Estimation of additional human DDPs demonstrable in assays used here**

1826 We evaluated the validation efficiencies of four classes of human homologs of *E. coli* DDP genes  
1827 (shown [Figure 3D](#)): genes that are—(i) both known ([Forbes et al., 2015](#)) or predicted ([D'Antonio](#)  
1828 [and Ciccarelli, 2013](#)) cancer drivers and amplified in TCGA cancers; (ii) amplified in cancers and  
1829 not known or predicted drivers; (iii) known/predicted cancer drivers that are not known to be  
1830 amplified in cancers; and (iv) neither amplified in cancers nor previously known/predicted cancer  
1831 drivers. Based on the number of candidates that we tested in each class among the 70 DDP  
1832 homologs tested, these data correspond to the following validation rates as DNA-damage-  
1833 promoting for each class: (i) 100%; (ii) 53%; (iii) 67%; and (iv) 27%. Based on the numbers of  
1834 homologs not yet tested in each of these classes, our data predict that the following numbers of  
1835 proteins among the remaining (284 - 70=214) human-homolog candidate hDDPs would be likely  
1836 to be validated in these particular DNA-damage assays: (i) 6; (ii) 38; (iii) 34; and (iv) 7, for a total  
1837 of at 85 more demonstrable hDDPs predicted among the 284-protein candidate hDDP network.  
1838 We note, however, that the human-cell DNA-damage assays used favor detection of DNA double-  
1839 strand breaks, not all DNA-damage types comprehensively. Thus, many more of the human  
1840 homologs may be DNA-damage promoting for other kinds of DNA damage than is estimated here.

1841

## 1842 **Supplemental Discussion 8**

### 1843 **Verification of *HPRT* Mutations in 6-Thioguanine Resistant Human-Cell Clones**

1844 Four independent 6-thioguanine-resistant clones were shown to result from *HPRT* mutations by  
1845 sequencing the cloned *HPRT* cDNAs. The mutations are: a single-basepair insertion between the  
1846 206-207nt of *HPRT* gene, and three identical deletions (from 403nt to 485nt). Two of the  
1847 sequenced clones were independent DNMT1-overproducing transfectants, and two were from  
1848 independent vector-only control transfected cells. The *HPRT* cDNA is 657bp long, whereas  
1849 *HPRT* including introns is 42kb, making sequencing the cDNAs more practical.

1850

## 1851 **Supplemental Discussion 9**

### 1852 **Controls**

1853 While analyzing RNA-Seq data, we identified a 2177bp deletion including the *lacI<sup>q</sup>* region on the  
1854 pNT3 empty vector. We have determined that this deletion does not alter results in any of our  
1855 assays or any of our conclusions. The phenotypes of the truncated empty vector were compared  
1856 with 10 non-DDP overproducers, and then with the full-length empty vector, in all 7 functional  
1857 assays, and, by one-way ANOVA analysis, there were no significant differences between the  
1858 means of all 11 strains in any of the 7 assays ( $p=0.19$  GamGFP foci;  $p=0.28$  RDG (reversed-fork))



1859 foci;  $p=0.99$  ROS;  $p=0.99$  anucleate cells/DNA loss;  $p=0.26$  phleomycin sensitivity;  $p=0.08$  H<sub>2</sub>O<sub>2</sub>  
1860 sensitivity;  $p=0.21$  mitomycin C sensitivity), and no difference between it and the full-length  
1861 vector ( $p=0.31$ ;  $p=0.44$ ;  $p=0.62$ ;  $p=0.32$ ;  $p=0.62$ ;  $p=0.28$ ; and  $p=0.78$ , respectively, two-tailed  
1862 unpaired *t*-test).

1863

## 1864 **Supplemental Discussion 10**

### 1865 **DNA-damage sensitivity not from mutations or *E. coli* DDP overproduction**

1866 We show that DNA-damage sensitivity does not result from heritable mutations in a sample of  
1867 DDP-producing clones tested. Even highly sensitive DDP-producing strains were sensitive during  
1868 overproduction, but not afterward, when colonies recovered after exposure were cultured and re-  
1869 exposed without DDP-gene induction (Figure S5H). The data imply that heritable mutations did  
1870 not confer the DNA-damage sensitivities. Further, we used RNA-seq to quantify mRNAs of a  
1871 panel of 32 *E. coli* DNA-repair genes, representing five DNA-repair mechanisms, in seven DDP-  
1872 overproducing clones that display DNA-damage sensitivity (Figure S5F; Table S1), and that  
1873 represent the six major biological DDP clusters (Figure 4N). The repair pathways represented were  
1874 nucleotide excision repair (*uvrA*, *uvrB*, *uvrC*, *uvrD*), base-excision repair (BER: *mutT*, *mutM*, *xthA*,  
1875 *nfo*, *ung*, *mug*, *nth*, *tag*, *alkA*, *nei*), mismatch repair (*mutS*, *mutL*, *uvrD*, *mutH*), homology-directed  
1876 repair (*recA*, *radA*, *ruvA*, *ruvB*, *ruvC*, *recT*, *recF*, *recO*, *recR*, *recG*, *recN*), and homology-directed  
1877 DSB repair (as for homology-directed repair with the addition of *recB*, *recC*, *recD*, and without  
1878 *recFOR*). Thirty-one of the DNA-repair gene mRNAs were not downregulated with DDP  
1879 overproduction, and 19 (*bamC*), 20 (*cusR*), 17 (*topA*), 4 (*aroP*), 8 (*hemX*), 14 (*yicR*) and 1 (*yqjD*)  
1880 were significantly upregulated, presumably resulting from SOS or other DNA-damage or  
1881 oxidative-stress responses (Figure S5F, Table S1). The sole DNA-repair-gene mRNA  
1882 downregulated was that of *mutM*, which encodes the BER protein MutM, a DNA glycosylase that  
1883 removes oxidized deoxy-guanine from DNA (Michaels et al., 1991), and which was decreased  
1884 with DNA Topoisomerase (Topo I) overproduction (Figure S5F, Table S1). The data from all of  
1885 the other genes show that reduced DNA-repair activities, inferred from DNA-damage sensitivities  
1886 during overproduction of the seven representative DDPs (Figure S5F), did not result from  
1887 transcriptional down-regulation of these DNA-repair genes. In the case of *mutM* mRNA reduction  
1888 during Topo I overproduction, this is unlikely to cause the H<sub>2</sub>O<sub>2</sub> sensitivity of Topo I  
1889 overproducing cells because *mutM* null mutants are resistant to the low H<sub>2</sub>O<sub>2</sub> levels we used (Asad  
1890 et al., 2004). The data exclude the hypothesis that most or all of the DNA-damage sensitivities  
1891 caused by overproduction of DDPs (Figures 4J-L and S5A-E; Table S1) result from transcriptional  
1892 downregulation of DNA-repair genes. Potential post-transcriptional regulation mechanisms are  
1893 not excluded. The data support the hypothesis that the DNA-damage sensitivities result from  
1894 excess DNA damage overwhelming DNA-repair capacity, potentially titrating DNA-repair  
1895 enzymes, or direct inhibition of DNA repair by the overproduced protein. Reduction of DNA-  
1896 repair capacity could produce phenotypes like those of DNA-repair mutants, which would drive  
1897 genome instability, in many DDP-gene dysregulated cells that do not possess DNA-repair-gene  
1898 mutations.

1899

## 1900 **Supplemental Discussion 11**

### 1901 **DNA damage reductions in some function clusters**

1902 Reduced ROS levels are apparent in a cluster in Figure 4M, as are reduced anucleate cells (DNA  
1903 loss) in that figure. Similarly, clusters 3, 4, and 6 (Figure 4N) show reduced sensitivity (greater  
1904 resistance than wild-type cells) to H<sub>2</sub>O<sub>2</sub>, and 2 and 3 (Figure 4N) show greater resistance to

1905 mitomycin C. A probable explanation for these “better-than-wild-type” phenotypes is that some  
1906 imbalance in these cells may induce a stress response, one of the consequences of which may be  
1907 improvement of the fidelity of, e.g., chromosome segregation (preventing anucleate cells),  
1908 reduction of ROS levels, or resistance to DNA-damaging agents, as is documented, for example,  
1909 for DNA-damage resistance induced by mild induction of the SOS response (Friedberg et al.,  
1910 2005), among other stress responses.

1911

## 1912 **Supplemental Discussion 12**

### 1913 **RDG ChIP-seq signals are enriched near known CsgD-binding sites, directionally**

1914 The RDG ChIP-seq experiments (Figures 5I and S7A-C) were performed twice, with peaks called  
1915 against the matched control DNA-binding domain mutant, CsgD $\Delta$ DBD. We identified 155 total  
1916 reproducible RDG ChIP-seq peaks with at least 2.5-fold increase in both repeats compared with  
1917 CsgD $\Delta$ DBD done in parallel. The following control simulations show that RDG ChIP-seq signals  
1918 are enriched near known CsgD binding sites. We simulated CsgD-overproduction ChIP-Seq data  
1919 by randomly distributing the called RDG peaks across the genome and analyzed, first, the number  
1920 of binding sites with at least one RDG peak within 10kb, and, second, the distance between each  
1921 known CsgD-binding site and the nearest RDG peak (median), for each of the 10 experimentally  
1922 validated CsgD-binding sites (Brombacher et al., 2003; Dudin et al., 2014; Keseler et al., 2017;  
1923 Ogasawara et al., 2011). Strikingly, there is at least one observed (actual) RDG peak within 10kb  
1924 of 9 out of the 10 known CsgD-binding sites (Figure S7A-C), whereas there are only 5 known  
1925 binding sites with at least one simulated RDG peak within 10kb of the 10 known binding sites in  
1926 our simulations, which is significantly less than the observed ( $p = 0.01$ , two-tailed z-test). Also,  
1927 the median distance between a given known CsgD-binding site and the nearest RDG ChIP-seq  
1928 peak is 2.8kb for the real peaks, which is significantly closer than the 10.3kb median distance in  
1929 our simulations ( $p = 0.009$ ).

1930 **CsgD-DBD-dependent stalled-fork RDG peaks not at known CsgD-binding sites.** For  
1931 the 142 CsgD-DBD-dependent RDG peaks that are not significantly near to a known CsgD binding  
1932 site, these could result from—(i) binding of CsgD to sites not yet identified in the literature, in  
1933 which no comprehensive high-resolution (ChIP-seq) genome-wide binding study has been done;  
1934 (ii) relaxation of the binding specificity of CsgD when overproduced such that sites not normally  
1935 bound are bound on overproduction; and (ii) downstream (indirect) effects of regulation of CsgD-  
1936 regulated genes by CsgD binding to its sites. For example, CsgD upregulation of other DNA-  
1937 binding transcription factors could cause peaks at their binding sites, among other indirect but  
1938 biologically real (CsgD-DBD-dependent) possibilities. The 142 of 155 RDG ChIP-seq peaks that  
1939 are not near known CsgD binding sites do not overlap significantly with palindromic REP  
1940 sequences, which are prone to form DNA cruciform structures (Stern et al., 1984) (four RDG peaks  
1941 overlap with REPs,  $p = 0.43$ , two-tailed z-test compared with median random distribution), or *terA-*  
1942 *terC* regions, which have higher frequencies of fork convergence (11 RDG peaks overlap with *ter*  
1943 sequences,  $p = 0.47$ , two-tailed z-test, compared with compared with median random distribution).

1944 **Upstream bias of RDG stalled-fork peaks at CsgD binding sites.** The 9 known CsgD-  
1945 binding sites with one or more observed CsgD-DBD-dependent RDG peaks within 10kb are of  
1946 two types: six show RDG peaks at or upstream of the binding sites in the replication path and five  
1947 show RDG peaks downstream. The observed number of CsgD binding sites with upstream or co-  
1948 localized RDG peaks is significantly higher than the median in the simulation ( $p = 0.04$ , two-tailed  
1949 z-test), whereas the number of CsgD binding sites with RDG peaks downstream is not quite  
1950 significant, at  $p = 0.13$ , two-tailed z-test. The analysis above suggests that direct binding of CsgD

1951 to its known binding sites underlies the RDG upstream and co-localized peaks, whereas the  
1952 downstream peaks may reflect a component of direct CsgD-DNA-induced fork reversal, and a  
1953 component of indirect effects, or binding to as yet unknown CsgD binding sites. One way that an  
1954 RDG stalled-fork peak might result *downstream* in the replichore, but still via direct interaction of  
1955 replication with bound CsgD, could be if some of the downstream stalled forks are caused by two  
1956 events (illustrated [Figure 5J](#), lower): first, slowing of replication forks by CsgD binding at its site,  
1957 which might make the replisome susceptible to an otherwise surmountable second barrier of any  
1958 kind downstream in the replication path.


1959

### 1960 **Supplemental Discussion 13**

#### 1961 **Model for DNA-damage promotion by the overproduced XanQ xanthine-proton symporter**

1962 Membrane transporters including proton ( $H^+$ ) symporters are overrepresented among DDPs that  
1963 cause increased ROS when overproduced ([Figures 6A-D](#)), and cause DNA damage ROS-  
1964 dependently ([Figure 6B](#)). The strongest generator of ROS-dependent DNA damage and ROS is  
1965 the XanQ xanthine symporter. Although overproduction of each of three proton symporters  
1966 decreases pH (increases  $H^+$ , [Figures 6F,G](#)), their ROS promotion is not well correlated with  
1967 decreased pH ([Figure 6H](#)), suggesting that the molecules they transport with  $H^+$  might underlie  
1968 generation of ROS and DNA damage. For XanQ, overproduction of which causes high ROS but  
1969 a moderate drop in pH ([Figures 6F,G](#)), one possibility ([Figure 6I](#)) is that the excess xanthine  
1970 imported may be oxidized by ROS-generator xanthine oxidase ([Kelley et al., 2010](#)), causing the  
1971 increased ROS, which damages DNA ([Figure 6I](#)). Other explanations are possible. Regardless of  
1972 specific hypotheses, overproduction of membrane transporters generally may promote DNA  
1973 damage, and for several, increased ROS, by any of many mechanisms that result from  
1974 compromising compartmentalization of the cell from its environment.

1975



1977 **Figure S1. Genuine SOS Response, Detection of DNA Damage by the SOS-reporter Gene,**  
1978 **and Evaluation of False Negatives in the Primary Screen**

1979 The *E. coli* DNA-damage assay detects fluorescence caused by upregulation of the SOS DNA-  
1980 damage-response-activated promoter  $P_{sulA}$  fused to mCherry in a non-genic chromosomal site  
1981 (Nehring et al., 2016; Pennington and Rosenberg, 2007). This assay was shown to report on DNA  
1982 damage, not spurious promoter firing with the demonstration that fluorescence induction requires  
1983 the DNA-damage-sensing protein RecA, and is inhibited by a mutant SOS-response transcriptional  
1984 repressor, LexAInd<sup>-</sup>, which does not de-repress the SOS genes during DNA damage (Pennington  
1985 and Rosenberg, 2007), both also shown here (A). Further, of the spontaneous SOS-inducing DNA  
1986 damage, previously 60% was shown to reflect DNA double-strand breaks (DSBs) and 40% single  
1987 stranded DNA not at DSBs (Pennington and Rosenberg, 2007), and the spontaneous DSB  
1988 frequency and rates per cell division and chromosome replication were confirmed in a direct,  
1989 independent assay for DSB ends (Shee et al., 2013). Thus, this reporter reports on DNA damage.

1990 (A) Fluorescence requires the ability to activate the SOS response, and so is absent in SOS-  
1991 induction-deficient  $\Delta recA$  or  $lexA3(\text{Ind}^-)$  mutant cells, demonstrating that DNA damage, not  
1992 spurious promoter firing, underlies fluorescence increases, per (Pennington and Rosenberg, 2007).  
1993 Using these negative controls, a flow-cytometry gate is set in each experiment, per (Pennington  
1994 and Rosenberg, 2007), at fluorescence at which  $10^{-4}$  of the  $lexA3(\text{Ind}^-)$  negative- control cells are  
1995 positive, shown as a vertical dashed line. The SOS-positive cells in the wild-type (WT) strain  
1996 represent spontaneous DNA damage, per (Pennington and Rosenberg, 2007). Representative flow-  
1997 cytometry histograms generated under the growth conditions used in the screens reported here.

1998 (B) Positive control, mCherry<sup>+</sup>  $lexA51(\text{Def})$  cells with constitutively activated SOS response, and  
1999 negative control,  $lexA3(\text{Ind}^-)$  SOS-off cells.


2000 (C) RecA-dependence of increased fluorescence in representative DDP clones.

2001 (D) Representative DDPs do not enhance mCherry fluorescence generally, when *mCherry* is  
2002 controlled by non-SOS promoter  $P_{BAD}$ .

2003 (E) Screen of 99 random *E. coli* proteins not identified in the primary plate-reader screen finds 1  
2004 SOS-positive clone. Because of its inherent noise level, the plate-reader primary screen is likely  
2005 to generate some false-negative results; *i.e.*, it might miss clones with subtle but real DNA damage-  
2006 up phenotypes. We therefore tested a sample of 99 random *E. coli* proteins that were not identified  
2007 in the plate-reader primary screen for increased DNA-damage fluorescence in the sensitive flow-  
2008 cytometry secondary assay, to estimate the frequency of possible false negatives. We found that 1  
2009 of the 99, or ~1%, was positive in the flow-cytometry assay. Thus, if the 3815 *E. coli* proteins that  
2010 were not identified in the primary screen (4229 protein-coding genes in the library - 414 proteins  
2011 found in the primary screen) also harbor 1% real but undiscovered DDPs, then an additional 38  
2012 overproduction DDPs are predicted to reside in the *E. coli* overproduction library, for an estimated  
2013 total network size of 246 (38 + 208) DDP genes in the overexpression library used. In  
2014 [Supplementary Discussion 2](#), we estimate an additional 123 *E. coli* overexpression DDP genes that  
2015 are likely to be in the *E. coli* genome, but would not be discoverable using the mobile plasmid  
2016 overexpression library.

2017 (F) *E. coli* TetR clones from *cI* mutation assay harbor genuine mutations. Sequences of *cI*  
2018 mutations from 10 different DDP-overproducing strains with strong damage-up phenotypes:  
2019 CsgD, TopB, YegL, GrpE, HslU, Mrr, CheA, MdtA, YicR, and UvrA. The compiled sequences  
2020 from the 10 DDP clones are shown in red and blue (n = 3-10 independent TetR mutants per clone).  
2021 The 69 *cI* mutations sequenced include 3 IS (mobile)-element insertions, and 2 clones without a  
2022 PCR product (both isolated from TopB overproducing cultures; PCR failure is due to large


2023 deletions, see [STAR Methods](#)). Mutations in the vector-only control strain are shown in black (19  
2024 independent mutants). **Red font**, mutations attributable to common errors of the SOS-upregulated  
2025 error-prone DNA polymerases V and IV ([Kobayashi et al., 2002](#); [Maor-Shoshani et al., 2000](#);  
2026 [Wagner and Nohmi, 2000](#)); **blue font**, mutations not attributable to common Pol V or Pol IV errors.  
2027 Capital letters, basepairs that were changed or deleted; carrots, insertion points of bases indicated;  
2028  $\Delta$ s, deletions of the bases indicated. Upper right, diagram of gross chromosomal rearrangements  
2029 (GCRs) found in TopB-overproducing cells, among which, 18% (7/40) of the TetR mutations are  
2030 GCRs, including large deletions (from 200bp-6200bp), an inversion, and a transposon insertion.  
2031



2032 **Figure S2. Specific Protein-Protein Interactions in *E. coli* and Human DDP Networks**

2033 **Figure S2. Specific Protein-Protein Interactions in *E. coli* and Human DDP Networks**  
2034 (A) Specific protein-protein interactions in *E. coli* DDP network. Diagram details are as indicated  
2035 in [Figure 1G](#). Image enlarged to illustrate the specific proteins with interactions. Connectivity in  
2036 random protein networks is discussed in [Supplemental Discussion 1](#).  
2037 (B) Specific protein-protein interactions of human candidate DDP network. Diagram details are  
2038 as indicated in [Figures 1G](#) and [2B](#). Image enlarged to illustrate the specific proteins with  
2039 interactions, similarly to the human candidate DDP network in [Figure 2B](#). Although, the human  
2040 homolog (candidate hDDP) network has DNA-repair and -replication genes at its center, removal  
2041 of these proteins leaves the remainder with still significant connectivity:  $p = 4.1 \times 10^{-215}$   
2042 (hypergeometric test), though less than the whole network ( $p = 1.2 \times 10^{-327}$ , hypergeometric test).  
2043 Random human proteins do not form robust protein-protein association networks and the  
2044 significant protein-protein interactions of well conserved proteins—the human homologs of  
2045 random *E. coli* proteins—are discussed [Supplemental Discussion 1](#).  
2046






2047  
 2048 **Figure S3. Association of Human Homolog Network with Cancers: Copy-number Gain,**  
 2049 **Survival, and Mutation Load, and Controls for Human DNA-Damage Assays and DNMT1**  
 2050 (A to C) Twenty-six cancer types in TCGA data (Gao et al., 2013) are displayed along the x axes.  
 2051 Blue, median % of patient cancers with increased copy number of any gene in their genome; red,

2052 % of patient cancers with increased copy number of the gene indicated. Copy-number-increases  
2053 in human homologs of *E. coli* DDP genes are higher than those of human homologs of random *E.*  
2054 *coli* genes ( $p < 0.05$ , FDR  $< 0.10$ , Wilcoxon test). Examples of the Pan-Cancer copy-number-  
2055 increase analysis (GISTIC threshold copy-number gain  $\geq 1$ ) of the 284 human homologs of *E. coli*  
2056 DDP genes in 26 cancer types are shown here (complete analysis [Table S4](#)). The human genes fell  
2057 into three categories:  
2058 (A) genes with increased copy numbers across cancers (fold change  $> 1.5$ ,  $p < 0.05$ , FDR  $< 0.10$ ,  
2059 Wilcoxon test);  
2060 (B) genes with cancer-specific copy-number-increases ( $p < 0.05$ ); and  
2061 (C) not particularly cancer associated.  
2062 (D) Decreased cancer survival is associated with high DDP-homolog RNA levels in cancers [our  
2063 analyses of data from TCGA ([Gao et al., 2013](#)), [STAR Methods](#)]. BRCA, breast invasive  
2064 carcinoma; LGG+GBM, gliomas (low-grade glioma + glioblastoma multiforme); HNSC, head and  
2065 neck squamous cell carcinoma; UCEC, uterine corpus endometrial carcinoma. \*, \*\*, \*\*\* indicate  
2066 that survival of the cancers with high and low levels of the 284 RNAs differ at  $p \leq 0.05$ ;  $\leq 0.01$ ,  
2067 and  $\leq 0.001$  respectively, log-rank test.  
2068 (E) Decreased cancer survival is not confined to the previously known cancer drivers in the  
2069 network. RNAs of the known ([Forbes et al., 2015](#)) and predicted ([D'Antonio and Ciccarelli, 2013](#))  
2070 cancer-driving genes among the homologs show less association with poor survival than the whole  
2071 homolog network.  
2072 (F) RNAs of the human DDP homologs excluding known ([Forbes et al., 2015](#)) and predicted  
2073 ([D'Antonio and Ciccarelli, 2013](#)) drivers are still associated with decreased patient survival,  
2074 indicating that genes in the homolog network other than and in addition to the previously known  
2075 drivers are also associated with decreased survival.  
2076 (G-I) Human MRC5-SV40 or HEK293T were transfected with human candidate DDP and random  
2077 human genes and random human non-DDP homologs of *E. coli* genes, and DNA-damage markers  
2078 were analyzed by flow cytometry.  
2079 (G) Assay I:  $\gamma$ H2AX in MRC5-SV40 cells.  
2080 (H) Assay II:  $\gamma$ H2AX in MRC5-SV40 cells treated with DNA-PK inhibitor, which inhibits DNA  
2081 break repair by non-homologous end joining and so is a sensitizing DNA-damage screen.  
2082 (I) Assay III: phosphorylated p53 in HEK293T cells. Data represent mean  $\pm$  range,  $n \geq 2$ . The  
2083 candidate hDDP genes differ from the 20 random human genes,  $p < 0.0001$ , Fisher exact test.  
2084 (J and K) Linear response of both human-cell DNA-damage-detection assays with exogenous  
2085 ionizing radiation treatment indicates quantitative validity of these assays. Percent of MRC5-SV40  
2086 cells that are positive for (J)  $\gamma$ H2AX, and (K) phosphorylated p53 (p53-S15p), in flow-cytometric  
2087 assays. MRC5-SV40 cells were treated with IR with the indicated dose and analyzed by flow  
2088 cytometry.  
2089 (L) DNMT1 wild-type (WT) but not  $\Delta$ PBD interacts with replisome sliding clamp, PCNA. The  
2090 tubulin negative control also does not interact with PCNA. GFP-trap immunoprecipitation was  
2091 performed in flipIn stable inducible HEK293T cells expressing GFP-tubulin, GFP-DNMT1-WT  
2092 or GFP-DNMT1- $\Delta$ PBD. Interactions were determined in immunoprecipitation samples by western  
2093 blotting with anti-GFP and -PCNA antibodies.  
2094 (M) Overproduction of wild-type DNMT1, but not the DNMT1-PBD-defective mutant protein,  
2095 enhances RAD18-mediated ubiquitylation of replisome clamp, PCNA. Knockdown of *RAD18*  
2096 reduced the level of ubiquitylated PCNA in DNMT1-WT overexpressing cells. Western analyses

2097 of PCNA ubiquitylation in MRC5-SV40 cells transfected with the plasmids indicated in  
2098 combination with non-targeting (NT) or *RADI8* siRNA.  
2099



2100 **Figure S4. DSBs, Reversed Forks, Reactive Oxygen, and DNA Loss in DDP Clones**

2101 **Figure S4. DSBs, Reversed Forks, Reactive Oxygen, and DNA Loss in DDP Clones**

2102 (A) Increased GamGFP foci indicate DSBs caused by overproduction of 87 of the 208 *E. coli*  
2103 DDPs. DSBs in all 208 *E. coli* DDP-overproducing clones were visualized and quantified as  
2104 GamGFP foci (Shee et al., 2013) using automated microscopy. 87 of the 208 clones, were  
2105 significantly different from the vector-only control at  $p < 0.05$ ,  $q < 0.10$  (unpaired two-tailed  $t$ -test  
2106 with FDR adjustment). Each bar represents a DDP clone (mean  $\pm$  range,  $n=2$  experiments of  
2107  $>1000$  cells per strain, STAR Methods). DDP-overproducing clones are grouped by the fold  
2108 change of GamGFP focus levels compared with the vector-only strain. Blue, vector only; grey,  $<$   
2109 2-fold increase; brown, 2-5-fold increase; green, 5-10-fold increase; magenta,  $>$  10-fold increase,  
2110 per Table S1 (data summary). Representative images are shown above and to the right of the bar  
2111 graphs. None of 25 non-DDP overproducers had increased GamGFP foci, showing that clones  
2112 with high levels of GamGFP foci are enriched in the DDP-overproducing clones ( $p = 3.6 \times 10^{-6}$ ,  
2113 one-way Fisher's exact test).

2114 (B) Stalled reversed replication forks in most DDP-overproducing strains. Significantly increased  
2115 reversed forks (RFs), visualized as RDG foci in  $\Delta recA$  cells (Xia et al., 2016) via automated  
2116 microscopy, occur in 106 of the 208 (51% of) *E. coli* DDP-overproducing clones. The 106 were  
2117 significantly different from the vector-only control,  $p < 0.05$ ,  $q < 0.10$  unpaired two-tailed  $t$ -test  
2118 with FDR adjustment. Each bar represents a DDP clone (mean  $\pm$  range,  $n=2$  experiments of  $>1000$   
2119 cells per strain). Blue, vector only; grey,  $<$  2-fold increase; brown, 2-5-fold increase; green, 5-10-  
2120 fold increase; magenta,  $>$ 10-fold increase, per Table S1 (complete data summary). Representative  
2121 images shown above and on the right side of the bar graphs. None of the 30 non-DDP  
2122 overproducers had increased RDG foci; so, DDP overproducers with high RDG-focus (RF) loads  
2123 are enriched in the DDP-overproducing strains ( $p = 4.0 \times 10^{-9}$ , one-way Fisher's exact test).


2124 (C-D) Increased intracellular ROS levels in 56 *E. coli* DDP-overproducing clones identified by a  
2125 flow-cytometric assay after di-hydrorhodamine (DHR) staining. Intracellular ROS levels in all 208  
2126 *E. coli* DDP-overproducing clones were measured with the peroxide-specific dye DHR (Gutierrez  
2127 et al., 2013) and fluorescence was measured by flow cytometry. We found that 56 of the 208 (27%)  
2128 were significantly different from the vector-only control,  $p < 0.05$ ,  $q < 0.10$  unpaired two-tail  $t$ -test  
2129 with FDR adjustment. Each bar represents a DDP clone (mean  $\pm$  range, of two experiments). Blue,  
2130 vector only; green, DDP overproducers with increased ROS levels, per Table S1. Representative  
2131 flow cytometry histograms are shown above the bar graphs. None of 17 non-DDP overproducers  
2132 had increased ROS, such that high-ROS clones are enriched in the DDP-overproducing clones at  
2133  $p = 0.006$  (one-way Fisher's exact test).

2134 (E-F) DNA loss in 67 *E. coli* DDP-overproducing clones identified by flow-cytometric  
2135 quantification of anucleate cells.

2136 (E) Increased anucleate cells can be detected in a *parCTS* mutant, which has a severe chromosome-  
2137 segregation defect at non-permissive temperature. Live cells were stained with FM464 membrane-  
2138 staining dye, and then fixed and stained with DAPI for DNA staining. Cells with positive  
2139 membrane but negative DAPI staining are anucleate cells (lower right quadrant).

2140 (F) We found that 67 (32%) were significantly different from the vector-only control,  $p < 0.05$ ,  $q$   
2141  $< 0.10$  unpaired two-tail  $t$ -test with FDR adjustment. Each bar represents a DDP-overproducing  
2142 clone (mean  $\pm$  range,  $n=2$ ). DDP overproducers are grouped by the fold change of anucleate cells  
2143 levels compared with the vector only strain. Blue, vector only; grey,  $<$  2-fold increase; brown, 2-  
2144 5-fold increase; green, 5-10-fold increase; magenta,  $>$ 10-fold increase in anucleate cells, per Table

2145 S1. Representative flow cytometric histograms are shown above and to the right of the bar graphs.  
2146 Only 1 of 16 non-DDP-overproducing clones had increased anucleate cells, such that clones with  
2147 high-levels of anucleate cells are enriched in the DDP-overproducing strains at  $p = 0.02$  (one-way  
2148 Fisher's exact test).  
2149



## 2151 **Figure S5. Sensitivities to DNA-Damaging Agents**

2152 (A) Phleomycin sensitivity detected by growth inhibition in known mutants with reduced  
2153 homologous recombinational (HR) repair efficiency. *recF*: defective in single-strand gap HR-  
2154 repair; *recG*: reduced ability to branch migrate Holliday junctions; *recB*: defective in DSB repair  
2155 by HR (Kuzminov, 2011).

2156 (B) 106 *E. coli* DDP overproducers are sensitive to phleomycin. Phleomycin sensitivities of the  
2157 DDP-overproducing clones are shown as normalized to sensitivity of vector-only controls:  
2158 (treated/untreated DDP overproducer) / (treated/untreated vector-only) so that values < 1 indicate  
2159 sensitivity. Among the 106 sensitive DDP clones, 11 are more sensitive than a *recB* mutant; 72 are  
2160 within the range of *recB* and *recF* mutants; 23 are more sensitive than the vector-only control but  
2161 less than *recF* mutant. One of the 16 non-DDP-overproducing strains has phleomycin sensitivity,  
2162 such that overproducing clones with phleomycin sensitivity are enriched in the DDP-  
2163 overproducing clones at  $p = 0.0003$  (one-way Fisher's exact test).

2164 (C) Sensitivity of 75 *E. coli* DDP-overproducing clones to oxidative-damage-inducing agent H<sub>2</sub>O<sub>2</sub>.  
2165 H<sub>2</sub>O<sub>2</sub> sensitivity was detected by reduced viability, measured by colony forming units in known  
2166 mutants with reduced base excision repair (BER) efficiency. *xthA* (inset) encodes exonuclease III;  
2167 *nfo* encodes endonuclease IV. *xthA nfo* (green) double mutants are reported and confirmed by us  
2168 to be more sensitive to H<sub>2</sub>O<sub>2</sub> than each single mutant (Galhardo et al., 2000). *nth* encodes  
2169 endonuclease III; *nei* encodes endonuclease VIII. The *nth nei* (purple) double mutant has almost  
2170 no AP lyase activity, and so has extreme sensitivity to H<sub>2</sub>O<sub>2</sub> (Saito et al., 1997), consistent with  
2171 our observation. In our assay, H<sub>2</sub>O<sub>2</sub> sensitivities of the DDP-overproducing clones are shown as  
2172 normalized to sensitivity of vector-only controls: (treated/untreated DDP overproducer) /  
2173 (treated/untreated vector-only) so that values < 1 indicate sensitivity. Among the 75 H<sub>2</sub>O<sub>2</sub>-sensitive  
2174 DDP overproducers, 36 were more sensitive than the *xthA nfo* mutant; 39 were more sensitive than  
2175 the vector-only control but less sensitive than the *xthA nfo* mutant. None of the 15 non-DDP-  
2176 overproducers had H<sub>2</sub>O<sub>2</sub> sensitivity, such that overproducing clones with H<sub>2</sub>O<sub>2</sub> sensitivity are  
2177 enriched in the DDP-overproducing clones at  $p = 0.002$  (one-way Fisher's exact test).

2178 (D and E) Sensitivity of 10 *E. coli* DDP-overproducing clones to interstrand-crosslinking agent  
2179 Mitomycin C (MMC). (D) MMC sensitivity was detected by growth inhibition in known mutants  
2180 with defective HR repair or nucleotide excision repair (NER): *recA*, defective in HR-repair and  
2181 SOS response; and *uvrC*, defective in NER (shown in E, cyan). (E) Ten *E. coli* DDP-overproducing  
2182 clones were sensitive to MMC. Sensitivities of the DDP-overproducing clones are normalized to  
2183 sensitivity of vector-only controls: (treated/untreated DDP overproducer) / (treated/untreated  
2184 vector-only) so that values < 1 indicate sensitivity. None of the 16 non-DDP overproducers was  
2185 MMC sensitive. Overproduction clones with MMC sensitivity are not enriched among the DDP-  
2186 overproducing clones at  $p = 0.47$  (one-way Fisher's exact test).

2187 (F) Representative DDPs do not downregulate RNAs of DNA-repair genes upon overproduction.  
2188 We chose 7 DDPs that confer DNA-damage sensitivity on overproduction representative of the  
2189 six DDP function clusters (Figure 4N; Table S1). We assayed RNA levels of a panel of 32 DNA-  
2190 repair genes by RNA-seq with and without overproduction of each of 7 DDPs that confer  
2191 sensitivity to the following agents: TopA and BamC (H<sub>2</sub>O<sub>2</sub>); CusR, HemX, AroP, YicR, and YqjD  
2192 (phleomycin). Log<sub>2</sub> ratio (DDP overproducer / vector) for each DNA-repair gene in each of the  
2193 seven DDP-overproducing strains was calculated and clustered by hierarchy clustering (Johnson,  
2194 1967). Most of the DNA-repair genes are up-regulated during DDP overproduction, with the




2195 exception of *mutM* RNA, which is downregulated in the TopA-overproducing strain. However,  
2196 *mutM* downregulation is unlikely to account for the H<sub>2</sub>O<sub>2</sub> sensitivity of the TopA-overproducing  
2197 strain because even *mutM* null mutants are not sensitive to H<sub>2</sub>O<sub>2</sub> (Asad et al., 2004).

2198 (G) Cluster analysis of quantitative data on DNA-damaging-agent sensitivities in the *E. coli* DDP  
2199 network. Each bar represents a quantitative phenotype of each strain producing each of the 208 *E.*  
2200 *coli* DDPs, arrayed along the x axis. Assays indicated to right of the heatmap: H<sub>2</sub>O<sub>2</sub>, hydrogen-  
2201 peroxide sensitivity (reduced base excision repair); PHLEO, phleomycin sensitivity (reduced  
2202 DSB-repair); MMC, mitomycin-C sensitivity (reduced NER and/or HR repair). Red bar: high Z  
2203 score, increased DNA-damage sensitivity of DDP-overproducing clones compared with the  
2204 vector-only negative control.


2205 (H) Heritable mutations do not account for DNA-damage sensitivities of seven highly DNA-  
2206 damage-sensitive DDP-overproducing strains. DDP-overproducing strains with robust sensitivity  
2207 to each of the three DNA-damaging agents were tested for sensitivity with overproduction of the  
2208 DDP (red, “before”), then again after the drug treatment, with the DDP-gene repressed (blue,  
2209 “after”) to determine whether their sensitivity resulted from induction of mutations in genes needed  
2210 for resistance. After drug treatment, three colonies were recovered on plates with no DDP-gene  
2211 inducing IPTG, and then tested for DNA-damaging-agent sensitivity again. In all cases, the  
2212 recovered colonies not induced for DDP overproduction showed no sensitivity to DNA-damaging  
2213 agents (blue, after). Thus, their DNA-damage sensitivities did not result from heritable mutations.  
2214

2215

**A**



**B**




2216 **Figure S6. Examples of DNA-binding Transcription Factor Induction of and Co-localization**  
2217 **with Replication-Stall (RDG) Foci**


2218 (A) DNA-binding ability of DNA-binding transcription factors is required for their promotion of  
2219 increased RDG (reversed-fork) foci upon overproduction.  $\Delta$ DBD, in-frame deletion of the DNA-  
2220 binding domain; CsgDD59N, D59E: single amino-acid changes that reduce CsgD DNA binding  
2221 (Ogasawara et al., 2011). Three wild-type transcription factors and the corresponding mutants with  
2222 reduced DNA-binding ability were overproduced in  $\Delta$ recA cells, RDG (reversed-fork) foci  
2223 quantified (Figure 4C; Table S1), and representative images are shown here.

2224 (B) Foci of transcription factors CsgD-mCherry and HcaR-mCherry co-localize with RDG  
2225 (reversed-fork) foci. Representative examples. Most of the CsgD-mCherry and HcaR-mCherry  
2226 foci were co-localized with RDG (reversed-fork) foci. Showing weak co-localization, about 5% of  
2227 the YahB-mCherry transcription-factor foci were co-localized with RDG (reversed-fork) foci. By  
2228 contrast, mCherry alone rarely forms foci.  
2229





**A** RDG ChIP-seq peaks at CsgD binding site(s)



**B** RDG ChIP-seq peaks near CsgD binding site(s): towards replication origin



**C** RDG ChIP-seq peaks near CsgD binding site(s): away from replication origin



2231 **Figure S7. RDG ChIP-seq Detects Stalled-Fork Enrichment Near CsgD-Binding Sites and**  
2232 **Controls for Pol IV**

2233 Nine of the 10 known, validated CsgD-binding sites (Brombacher et al., 2003; Dudin et al., 2014;  
2234 Keseler et al., 2017; Ogasawara et al., 2011) showed a CsgD-DNA-binding-domain (DBD)-  
2235 dependent RDG peak nearby: within 10kb (median 2.8kb), which differs from random simulations  
2236 of the genomic distribution of the total number of CsgD-DBD-dependent RDG peaks ( $p = 0.01$   
2237 two-tailed z test, see [Supplemental Discussion 12](#)). Isogenic cells overproducing—CsgD, red;  
2238 CsgD  $\Delta$ DBD (deletion of the DNA-binding domain), blue; vector only green. Green boxes, CsgD  
2239 binding site(s).

2240 (A) CsgD-DBD-dependent RDG ChIP-seq peaks overlap with three known CsgD-binding sites.

2241 (B) CsgD-DBD-dependent RDG ChIP-seq peaks near three known CsgD-binding sites, upstream  
2242 in the replication path. Increased negative supercoiling between the oncoming fork and the CsgD-  
2243 bound site may stall replication and causes fork reversal, illustrated [Figure 5J](#).

2244 (C) CsgD-DBD-dependent RDG ChIP-seq peaks located near three known CsgD binding sites,  
2245 downstream in the replication path. Because the upstream peaks (B) are more significantly  
2246 associated with the known CsgD-binding sites relative to simulation of random genomic  
2247 distributions ([Supplemental Discussion 12](#)), it is possible that the downstream CsgD-DBD-  
2248 dependent RDG peaks could result from either CsgD binding to sites not yet known, or from  
2249 indirect consequences of CsgD DNA binding, such as effects of CsgD-regulated gene products  
2250 interacting with other sites in DNA ([Supplemental Discussion 12](#)). Alternatively, some of the  
2251 downstream CsgD-DBD-dependent RDG peaks could be a direct result of CsgD binding its known  
2252 site, slowing replication, then encountering an otherwise surmountable obstacle downstream, per  
2253 [Figure 5J](#).

2254 (D) The Pol IV R49F catalytic-mutant (Pol IV cat<sup>-</sup>) and  $\Delta$ BBD-mutant proteins do not display  
2255 reduced protein levels in western blots, in agreement with previous studies ([Uchida et al., 2008](#);  
2256 [Wagner et al., 1999](#)).

2257 (E) Model: Pol IV overproduction induces DNA damage by binding the beta replisome sliding  
2258 clamp. Excess Pol IV interaction with the replisome could potentially slow the replisome causing  
2259 fork breakage or collapse, or displace DNA-repair proteins that interact with the beta clamp, or  
2260 otherwise promote DNA damage.

2261 (F) Model and hypotheses: overproduced DNMT1 provokes DNA damage independently of its  
2262 DNA-methylase activity but dependently on binding PCNA, the mammalian replisome sliding  
2263 clamp and structural homolog of *E. coli* beta. Excess DNMT1 might promote DNA damage by  
2264 stalling DNA replication, interfering with PCNA-coordinated DNA-repair or translesion-synthesis  
2265 processes, or by other PCNA-dependent means.

2266